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Abstract 
 
Establishing the diagnosis of Inflammatory Bowel Disease (IBD) with its two main sub forms 
Crohn‟s Disease (CD) and Ulcerative colitis (UC) are based on medical history, clinical 
evaluation, laboratory tests, endoscopy, radiology and histology. However no gold standard 
exists. The lack of appropriate diagnostic tools leads to delayed and incorrect treatment of 
IBD patients. A substantial amount of patients diagnosed as CD are later reclassified as UC 
and opposite. Also the type of colitis remains unclassified in many patients. In addition, non-
IBD patients presenting with similar symptoms as IBD are unnecessarily investigated with 
invasive tests leading to increased hospitals costs. 
 
The cause of IBD is not yet completely described, but most evidence points to a combination 
of genetic predisposition, immunological factors, environmental triggers, and gastro intestinal 
(GI) microbes. However, neither the types of microbes responsible for the diseases nor 
changes in the microbiota as a result of the diseases have been sufficiently identified. The aim 
of this thesis was to evaluate the potential of using the fecal microbiota for IBD diagnostics. 
This was achieved through a combination of a literature study, lab study and investigations of 
the commercial potential including a patent search. 
 
The literature study revealed conflicting evidence related to the amounts of bacteria in IBD 
patients relative to controls. Nevertheless, a majority of the articles agreed in decreased 
amounts of Clostridia species and increased amounts of Gammaproteobacteria species in the 
GI microbiota of IBD patients.  
 
The lab study comprised an evaluation of a genetic test, GA-map™, commercialized by 
Genetic Analysis AS (GA). By using variable regions in the 16S rRNA gene, simultaneous 
detection and identification of multiple bacteria in a complex mixture of DNA is possible. 
Probes and analytic methods are suitable for several types of diagnostic tests among other 
IBD. A sequence analysis of fecal samples from 152 IBD patients and 105 non-IBD controls 
was performed. Significantly a probe detecting increased relative amounts of Proteobacteria 
and Bacteroidetes species was identified as a new possible diagnostic test for CD patients.  
 
A search in European and American patent databases revealed several patents related to IBD 
diagnostics. Especially important, a patent application from George Mason University 
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comprised claims referring to IBD diagnostics by using the microbial community of the 
digestive tract and lumen. If issued, this application could influence the freedom to operate to 
companies focusing on bacterial markers in IBD diagnostics. Few other patents or patent 
applications from the search query include claims for identification of bacteria in fecal 
samples.  
 
A concluding remark from examining the commercial potential of IBD diagnostics in this 
thesis is to tailor make a diagnostic test separating IBD from irritating bowel syndrome (IBS), 
a common functional disease frequently confused with IBD. Based on estimations of price 
and profit per test, a €7Mill research budget was recommended for the normal case scenario. 
Finally it is concluded that development of a diagnostic test based on fecal microbiota has a 
commercial potential within the proposed framework.  
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1. Glossary and Abbreviations   
1.1 Glossary 
16S rRNA gene The 16S ribosomal RNA gene is a subunit of prokaryotic ribosomes  
frequently used in phylogenetic studies due to its highly difference 
between conserved regions in bacteria and archaea 
(Pei, et al., 2009). 
Appendicectomy The surgical removal of appendix  (History of 
medicine, 2010) 
Colon  The last part of the digestive system   (SEER Training 
Modules, 2010) 
Commensal Symbiotic relationship between two organisms where one organism 
benefits while the other neither benefit nor is harmed  
 (Baker, Love, & 
Ferguson, 2009) 
Cytokine Any of a group of small, short-lived proteins that are released by one 
cell to regulate the function of another cell, thereby serving as 
intercellular chemical messengers 
 
 (Cytokine, 2010) 
Diagnostic sensitivity The percentage of persons who have the disorder of interest correctly 
detected as such by the assay  
 (Saah & Hoover, 
1997) 
Diagnostic specificity The percentage of persons who do not have the condition of interest 
correctly detected as such by the assay 
 (Saah & Hoover, 
1997) 
Dysbiosis The condition of having microbial imbalances on or within the body   (Baker, et al., 2009) 
Etiology The cause, set of causes, or manner of causation of a disease or 
condition 
(Oxford Dictionary 
of English, 2010) 
Fissure Crack-shaped wounds (Engelsk medisinsk 
ordbok, 2010) 
Fistula An abnormal or surgically made passage between a hollow or tubular 
organ and the body surface, or between two hollow or tubular organs 
 
(Oxford Dictionary 
of English, 2010) 
Freedom to operate Used to describe that testing or commercializing of a product, can be 
done without infringing valid intellectual property rights of others 
(Nagori & Mathur, 
2009) 
Functional disease A disease in which there is an abnormal change in the function of an 
organ, but no structural alteration in the tissues involved 
 
 (Functional 
disease, 2010) 
Homeostasis Any self-regulating process by which biological systems tend to 
maintain stability while adjusting to conditions that are optimal for 
survival 
 
 (Homeostasis, 
2010) 
Ileum  The final and longest segment of the small intestine  (Ileum, 2010) 
Incidence The number of new individuals who contract a disease during a 
particular period of time 
  (Engelsk 
medisinsk ordbok, 
2010)   
Infection The detrimental colonization of a host organism by a foreign species. 
The process of infecting or the state of being infected 
 (Engelsk medisinsk 
ordbok, 2010) 
 (Oxford Dictionary 
of English, 2010) 
Inflammation Inflammation is part of the non-specific immune response that occurs in 
reaction to any type of bodily injury 
 (Ferrero-Miliani, 
Nielsen, Andersen, 
& Girardin, 2007) 
Microbiota The micro-organisms of a particular site   (Oxford Dictionary 
of English, 2010) 
Mucosa A thin membrane that cover the inside of e.g. the digestive tract.  (Engelsk medisinsk 
ordbok, 2010) 
Pathogenesis The manner of development of a disease  (Oxford Dictionary 
of English, 2010) 
Prevalence A measurement of all individuals affected by the disease within a 
particular period of time 
 (Engelsk medisinsk 
ordbok, 2010) 
Proctitis Inflammatory infection of the anus and rectum  (proctitis, 2010) 
Relapse Renewed flare, recurrence  (Medisinsk ordbok, 
2010) 
Remission  A temporary diminution of the severity of disease or pain (Oxford Dictionary 
of English, 2010) 
Toxic megacolon An acute non-obstructive enlargement of the colon, seen in advanced 
UC and CD. 
(Farthing, 2003) 
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1.2 Abbreviations 
 
 
 
16S 16 Svedberg (sedimentation coefficient) 
23S 23 Svedberg (sedimentation coefficient) 
Ahus Akershus University Hospital 
AIEC Adherent invasive E. coli  
ANCA Nuclear anti-neutrophil cytoplasmic antibodies 
ANOVA Analysis of variance 
ASCA Anti-Saccharomyces cerevisiae antibodies 
bp Base pair 
cANCA Classical anti-neutrophil cytoplasmic antibodies 
CARD15 Caspase recruitment domain family, member 15 
CCD Carge-coupled device  
CD Crohns disease 
cDNA complementary DNA 
CRP C-reactive protein 
CT Computed tomography  
CV  Coefficient of variation 
ddNTP dideoxynucleotide 
DGGE Denaturing gradient gel electrophoresis 
DNA Deoxyribonucleic acid 
ECCO European Crohn’s and Colitis Organisation 
EPO European Patent Office 
ESR Erythrocyte sedimentation rate 
EXO I Exonuclease I 
GA Genetic Analysis AS 
GI Gastro intestinal 
HS Healthy subjects 
IBD Inflammatory bowel disease 
IBDU Inflammatory bowel disease unclassified 
IBS Inflammatory bowel syndrome 
IPR Intellectual property rights 
MAP Mycobacterium avium spp. paratuberculosis 
MRI Magnetic resonance imaging 
MWW Mann-Whitney-Wilcoxon-test 
NADPH Nicotinamide adenine dinucleotide phosphate-oxidase 
NASBA Nucleic Acid Sequence Based Amplification 
NCF Neutrophil cytosol factor 4 
NOD2 Nucleotide-binding-oligomerisation-domain2 
OD Opposition division 
pANCA Peri-nuclear anti-neutrophil cytoplasmic antibodies 
PCR Polymerase chain reaction 
PNA Peptide nucleic acid 
RFU Relative fluorescence unit 
RNA Ribonucleic acid 
rRNA Ribosomal ribonucleic acid 
ROI Return on investment 
SAP Shrimp alkaline phosphatase 
SBFT Small bowel follow-through  
SCFA Short-chain fatty acid 
SD Standard deviation 
SNE Single nucleotide extension 
Spp. Species (plural) 
SSU Small subunit 
TLR Toll-like receptor 
TNF-α Tumor necrosis factor-alpha 
T-RFLP Terminal restriction fragment length polymorphism  
TTGE  Temporal temperature gradient electrophoresis 
UC Ulcerative colitis 
USPTO United States Patent and Trademark Office 
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2. Problem description 
 
The adult human gastro intestinal (GI) tract is 9 meters long and refers to the structures from 
the mouth to the anus. It plays an important role in human health where the main functions are 
digestion of food ensuring nutrition to the body, absorption of water and excretion of waste 
material (Dahl & Rinvik, 2010). Several diseases and conditions can affect the GI tract, one of 
these are Inflammatory Bowel Disease (IBD).  
 
Consisting of Crohn‟s Disease (CD) and Ulcerative Colitis (UC), IBD are relapsing and 
chronic inflammation of the gastro intestinal tract. The symptoms can be diarrhea, rectal 
bleeding, abdominal pain, weight loss, fever, fatigue, and/or anemia. No cure exists (D. C. 
Baumgart & Sandborn, 2007). The cause of IBD has not been found, but most evidence points 
to a combination of genetic predisposition, immunological factors, environmental triggers and 
conditions, and GI microbes (Sartor, 2006). 
 
Diagnostics of IBD is comprehensive. The current IBD diagnostics are mainly based on 
medical history, clinical evaluation, laboratory tests, endoscopy, radiology and histology (E F 
Stange, et al., 2006; E. F. Stange, et al., 2008)  
 
Several conditions can be confused with IBD. Patients having diffuse symptoms as abdominal 
pain and/or diarrhea represent a common diagnostic challenge for primary doctors (Dubinsky, 
Johanson, Seidman, & Ofman, 2002). As many as 20% of the population in the western world 
have these symptoms (Suleiman & Sonnenberg, 2001). Most patients suspected to have IBD 
and undergo standard invasive tests (e.g. endoscopy) have a functional disease, and the 
majority of these have Irritable Bowel Syndrome (IBS) (Dubinsky, et al., 2002). Up to 40% of 
patients undergoing endoscopy have IBS, and this accounts for 0,5% of the yearly total health 
care cost in the US (Camilleri & Williams, 2000). In addition, it is difficult to distinguish CD 
from UC. Approximately 10% of the IBD patients are misclassified (Reese, et al., 2006). 
Furthermore, in 10-15% of the IBD patients the type of colitis remains unclassified (Nikolaus 
& Schreiber, 2007). The development of a noninvasive test that can screen for IBD and 
separate CD from UC is of high value. By recognizing the patients in whom invasive 
diagnostic testing can be avoided, it would both gain the patients health and reduce the 
unnecessary resource use and costs (Dubinsky, et al., 2002). Despite of this there is no such 
test existing today. 
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Increasing amounts of evidence show disturbed GI microbiota in IBD patients. A 
comprehensive culture-independent study revealed significant differences between microbiota 
of small intestine from CD, UC and non-IBD samples (Frank, et al., 2007). Studies using 
fecal samples indicate differences in the microbial communities between IBD patients and 
controls, but the relevance of fecal bacteria in IBD pathogenesis and diagnostics remains 
unclear (Swidsinski, et al., 2002; Swidsinski, Weber, Loening-Baucke, Hale, & Lochs, 2005). 
If a dysbiotic pattern in feces could be identified in IBD patients, it can be utilized as a non-
invasive diagnostic test. But controversy exists nevertheless, whether mucosal or fecal 
microbiota are suitable for IBD diagnostics (Bibiloni, et al., 2008; Swidsinski, et al., 2002; 
Swidsinski, et al., 2005; Tannock, 2008). 
 
A major challenge in microbial diagnostics is the simultaneous detection and identification of 
multiple bacteria in a complex mixture. Utilizing DNA based methods for this purpose has 
been a solution, but still many challenges exist. Genetic Analysis AS (GA) is a Norwegian 
company which is trying to solve this problem. A new method for parallel detection of huge 
amounts of different bacteria is being commercialized. The method, called GA-map™ is 
principally based on the detection of nucleic acid sequences in the 16S rRNA gene. The gene 
consists of conserved universal regions and variable regions. Microbiota DNA is isolated 
from stool samples. Using primers to the universal regions of 16S rRNA the sequence is 
amplified by PCR followed by binding of oligo nucleotide probes to the variable regions of 
the sequence. Next bound probe is selectively labeled. Subsequently the probes are hybridized 
to a known sequence on a microarray and finally detected. So far neither bacteria nor probes 
for an IBD test have been identified.  
 
GA is now evaluating the possibilities of commercializing an IBD test using the GA-map™ 
technology. Prior starting research and development of a diagnostic test, investigating the 
commercial potential is important, especially to companies. Challenges with the current 
diagnostics and more general evaluations toward whether it is a product which is needed has 
to be identified. An indication whether a good return on investment (ROI) can be expected 
has to be calculated. This can be achieved through identification of the number of patients, 
expected market share, estimated profits and a proposal of research budget.  
In biotechnology patenting is important. Ahead of commercializing a diagnostic test, search 
for other inventive tests is important. Freedom to operate and possibilities for strong 
intellectual property rights (IPR) have to be assessed. 
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3. Purpose and aim 
 
The purpose of this master thesis was to find the diagnostic and commercial potential of using 
fecal microbiota in IBD diagnostics.  
 
The specific aims and ways to achieve these were:  
 
-Reveal challenges in the current diagnostics of IBD. 
This was done through identification of ways to diagnose IBD and related issues, assisted by 
the literature currently available on the subject.  
 
-Identify gastro intestinal bacteria suitable for IBD diagnostics.  
This was accomplished by a literature study classifying amounts of fecal and mucosa 
associated bacteria as increased, equal or decreased relative to controls. 
 
-Evaluate whether selected bacterial probes can be used for IBD diagnostics on fecal samples. 
The probes were selected based on the literature study. A lab study was then performed, 
analyzing sequences from 152 IBD patients and 105 non-IBD controls. 
 
-Reveal the commercial potential of improved IBD diagnostics.  
A calculation method for a research budget in order to assure a reasonable ROI was 
established. This included identifying the number of possible tests sold yearly, and 
estimations of market share and profit.  
 
-Identify European and American patent documents relevant to IBD diagnostics.  
This was accomplished by initially finding an optimal search profile by performing an 
iterative search processes. Next the search query was submitted in the Esp@cenet and the 
United States Patent and Trademark Office (USPTO) patent databases respectively.  
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4. Inflammatory bowel diseases  
 
IBD is a chronic disease that affects the GI tract. Two major types are CD and UC. CD and 
UC have several clinical and pathological differences, but many similarities exist (Bouma & 
Strober, 2003). As previously described sufferers might experience several GI symptoms, 
including diarrhea, rectal bleeding, abdominal pain, weight loss, fever, fatigue, and/or anemia. 
Extra intestinal manifestation such as joint, skin and eye disorders might also be present (E F 
Stange, et al., 2006).  
IBD can cause lethal conditions such as perforation, rectal bleeding not responding to 
treatment and toxic megacolon. Increased mortality has been shown in CD, but not in UC. 
Patients also have an increased risk of colon cancer after 8-10 years of diagnosis. But the 
overall survival has improved. In the 1950s only 80% of the patients survived a 10 year 
period, today the patients have a normal life expectancy (D. C. Baumgart & Sandborn, 2007; 
Shanahan & Bernstein, 2009).  
The conditions consist of periods of remission and relapse. The time between flare-ups can be 
weeks or years, but some patients have persistent symptoms (E F Stange, et al., 2006; E. F. 
Stange, et al., 2008). 
CD affects the whole thickness of the bowel wall. It can involve any part of the GI tract from 
the mouth to the anus, particularly the most distal part of the small intestine (ileum) as well as 
the proximal part of the large intestine (colon) (Figure 1). Unlike UC, there may be unaffected 
bowel between areas of active disease called skip lesions. Severe complications may include 
narrowing of parts of the intestine (strictures), abnormal tunnels that connect organs (fistulas) 
and cracks in the anal skin (fissures) (Figure 2) (D. C. Baumgart & Sandborn, 2007).   
UC is characterized by diffuse inflammation of the colonic mucosa, the innermost layer that is 
in direct contact with the fecal flow. The disease always starts in the rectum (Figure 1 and 
Figure 3) and can extend as a continuous inflammation to the whole length of the colon 
(Tannock, 2008). However, some patients develop inflammation in the ileum and in 10-15% 
of the cases CD or UC cannot be distinguished (Nikolaus & Schreiber, 2007). 
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Although microbial pathogens have been postulated to cause CD and UC since their original 
descriptions (Sartor, 2008), it is now generally accepted that human IBD pathogenesis arises 
from, and is perpetuated by, interactions between host genetic and immune factors, 
environmental triggers, and GI microbes as previously described (Frank, et al., 2007; Sartor, 
2008; Underhill & Braun, 2008). 
 
 
Figure 1 Anatomy of the gastro intestinal tract. 
 
4.1 Epidemiology 
 
IBD typically occurs between the ages of 15 and 35, but diagnosis can be made at any age. 
Men and women are equally affected (E F Stange, et al., 2006; E. F. Stange, et al., 2008). The 
disease is basically found in developed countries with increasing incidence rates in 
developing countries. As many as 1.4 million persons in the United States and 2.2 million 
persons in Europe suffer from these diseases (D. C. Baumgart & Sandborn, 2007; Loftus, 
2004). Interestingly race seems to play an important role in risk for IBD. For example 
prevalence for CD among Hispanics living in North America is ten times less than those for 
white individuals. Nonetheless, lifestyle and environmental effects are suggested to contribute 
Cecum 
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to disease development as prevalence of IBD rises over time after migration e.g. Chinese 
people living in Hong Kong compared with Chinese living in mainland China (D. C. 
Baumgart & Carding, 2007).  
 
4.2 Host genetic factors 
 
A positive family history is currently the single largest risk factor for the diseases. Studies 
with monozygotic twins show a concordance rate for CD as high as 58% and 6-17% for UC, 
indicating an important role of genetic factors on the pathogenesis of IBD (Bouma & Strober, 
2003). Several genes seem to have an impact on the pathogenesis. So far twelve chromosomal 
regions have been identified and some of them named IBD1-9. CD and UC share several of 
these loci (Gaya, Russell, Nimmo, & Satsangi, 2006). The nucleotide-binding-
oligomerisation-domain 2 (NOD2) is thought to be involved in the recognition of bacteria 
(Bouma & Strober, 2003). Mutations in the Caspase recruitment domain family, member 15 
(CARD15) gene, which encodes NOD2, is present in 10-15% of CD patients. These mutations 
are thought to result in disturbance in immunologic responses to commensal intestinal 
microbiota (Baumgart & Carding, 2007).  
 
Figure 2 Anatomy of Crohn’s disease affecting ileum and cecum (left), colon and ileum (in the midle) 
and fistulising Crohn’s disease (right) (D. C. Baumgart & Sandborn, 2007). 
 
Mutations or polymorphisms in IBD-associated genes can molecularly lead to, down-
regulating of tight junction components, up-regulating of pore-forming components or 
increased epithelial apoptosis which finally contribute to increased mucosal permeability and 
possibly inflammation. Yet it is unclear whether inflammation or increased mucosal 
permeability comes first in the IBD pathogenesis (Packey & Sartor, 2008). 
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4.3 Immunobiology   
 
The normal human colon contains 10
11
 to 10
12
 bacteria per gram of material (Sartor, 2008). 
The reported number of individual species in the GI tracts varies from 500 to more than 
40 000. (Neish, 2009; Sartor, 2008; Sears, 2005) Despite these circumstances, the normal 
intestine remains healthy. This is due to several immunological factors primarily those of the 
mucosa. Epithelial barrier is the first line of defense. It consists of a complex network of 
lymphoid and non-lymphoid cell populations and humoral factors. Dentritic cells express 
NODs and toll-like-reseptors (TLR) which plays an important role in distinguishing 
commensals and pathogens and in activating or silencing T-cell response (Baumgart & 
Carding, 2007).  
 
In IBD the well balanced immune system is disturbed at all levels. Antigens from the 
intestinal lumen are allowed to pass the mucosa to underlying tissue where they trigger and 
maintain inflammation. Commensal antigens are falsely detected as pathogens.  Numerous 
leucocytes enter from the mucosal blood vessels and released chemokines attract more 
inflammatory cells which amplify and perpetuate the inflammation. Tissue damage results 
from the release of numerous injurious mediators (Baumgart & Carding, 2007). Which of the 
antigen being responsible for this are so far unknown, but likely this arises from bacteria in 
the GI tract (Frank, et al., 2007). 
 
  
4.4 Environmental and lifestyle risk factors  
4.4.1 Improved hygiene 
Improved hygiene has been hypothesized to contribute to IBD. Low exposure to bacteria 
during childhood particularly, could lead to inappropriate immunologic responses later in life. 
The hypothesis comes from the observation of the striking increased number of IBD patients 
appearing simultaneously as improvement of the hygiene in the western world over the last 
century. Also, the number of IBD cases in poor countries rises as they develop. Exposure to 
microorganisms seems to be necessary for programming the immune system to respond 
properly to allergens, microbial and other antigens in the GI tract. The exposure appears to be 
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especially important in the early childhood to create the accurate balance between pro-
inflammatory and tolerance-inducing immune cells (Koloski, Bret, & Radford-Smith, 2008).  
 
Hot tap water, pet ownership, use of refrigerator, smaller family size, day care attendance and 
high socioeconomic status have all been suspected as risk factors for developing IBD. 
However the most promising protective factors so far have been Helminthic infection, 
Helicobacter pylori exposure, breastfeeding, lack of antibiotic use, and sibship. All 
representing exposure to bacteria or factors altering which bacteria will thrive in the gut. As 
an example lactoferrin found in human milk is an iron-binding protein with direct antibiotic 
effect on Escherichia coli and Staphylococcuss spp. (D. C. Baumgart & Carding, 2007; 
Koloski, et al., 2008). But conflicting evidence exists and these needs further investigation. It 
is hypothesized that having older siblings represent an increased risk for UC while having 
younger siblings is associated with decreased risk of CD. This is due to a higher risk of 
getting an infection from an older sibling at an early age and re- exposure of protective micro-
organisms from younger siblings respectively (Montgomery, Lambe, Wakefield, Pounder, & 
Ekbom, 2002). The hypothesis that childhood vaccinations increase the risk of IBD by 
altering the maturation of the intestinal and systemic immune system has later been 
discredited (D. C. Baumgart & Carding, 2007; Koloski, et al., 2008).  
 
4.4.2 Commensal colonization 
Other states that it is not the absence of pathogens, but the lack of commensal colonization in 
the gut which needs consideration (Bernstein & Shanahan, 2008). From the moment we are 
born the colonizing of the sterile baby gut begins. Hence vaginal or cesarean delivery 
influences the timing and composition of the microbial progression. During the first 2-3 years 
of life the symbiotic relation is established (D. C. Baumgart & Carding, 2007). How this 
affect the pathogenesis of IBD is not fully understood.  
 
Diet has a huge impact on the human gut microbiota. The diet over the last century has 
changed dramatically compared to earlier times in the western world. Higher amounts of 
vegetables, fruits, fish, dietary fiber and long-chain omega-3 fatty acids have been reported to 
significantly protect from CD, but further investigation is needed (Bernstein & Shanahan, 
2008). 
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4.4.3 Smoking and appendectomy 
While smoking complicates the course of the disease in CD, nicotine surprisingly seems to 
have a protective effect on UC. It is associated with less aggressive course of the UC disease. 
Some of the reasons are suggested to be increased mucus production and improved intestinal 
barrier function. CD smokers on the other hand, probably get an increased amount of 
neutrophils into the intestinal mucosa. Additionally appendectomy might be protective against 
UC while the opposite is true for CD where it is associated with raised risk of strictures (D. C. 
Baumgart & Carding, 2007).  
 
4.5 Management 
 
IBD patients are urged to have close contact with a medical doctor and specialist. The medical 
treatment is not curative thus the goal is to maintain remission and stop flare ups. In addition 
IBD patients must be treated for anemia and nutritional deficiencies (Baumgart & Sandborn, 
2007). 
 
Medical management for UC are quite comprehensive and includes medical treatments which 
provide anti inflammatory effect (5-aminosalicylic acid (5-ASA)), stop acute flare ups 
(glukocorticoides), reduce the lymphocyte count and maintain remission (immune modifying 
cytostatica, Azathioprin/6-mercaptopurine), and monoclonal antibodies which causes 
programmed cell death of certain lymphocytes and is used in maintenance and acute treatment 
(anti-tumor necrosis factor α (anti-TNFα) agent, Infliximab) (Norsk legemiddelhåndbok, 
2009).  
 
UC is typically classified as mild, moderate or severe and treated based on this. The extent of 
the disease determines delivery way of therapy oral or topical (suppositories). Severe colitis 
requires close interaction between gastroenterologists and surgeons to indicate surgery if the 
complications gets life threatening. UC can be cured by surgical removal of the colon 
(colectomy). Depending on the age, overall health state and disease stage of the patient a 
surgical procedure are being choose. The whole colon and rectum can be removed and an 
opening on the abdomen through which feces is emptied into a pouch (ileostomy). Other 
common surgery for UC patients are a comprehensive procedure, ileo-pouch anal 
anastomosis, in which the small intestine is attached to the anal sphincter muscle. This 
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surgery allows the passage of the feces through the anus to be reestablished (Baumgart & 
Sandborn, 2007). 
 
Contrarily, surgery is not curative in patients with CD. Nevertheless surgery is required in 
nearly half of the patients after 5-10 years. Indications for surgery include part or complete 
bowel obstruction, fistulas, abscess, bleeding and/or non-function medical treatment. In the 
simplest surgery, short segment of the intestine with active disease or narrowing is removed 
and the remaining bowel is joined together.  
 
The medical treatment of CD has similarities with UC treatment, but in addition antibiotics 
(metronidazole) might be used for a short period of time. Patients might also be asked to 
follow a dietary treatment low on fat and high on fiber. Probe nutrition can be necessary for 
some CD patients (Norsklegemiddelhåndbok, 2009). 
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5. Relationship between IBD and microorganisms  
 
Few studies have so far enlightened the important role of microbiota in human health. A study 
showed that obese people had a decreased portion of Bacteroidetes in the gut, compared to 
lean people (Ley, Turnbaugh, Klein, & Gordon, 2006). Some research results also presents 
disturbed microbiota in asthmatic airways (Hilty, et al.).  
 
The highest cell densities in any ecosystem are represented by the intestinal microbiota 
(Sokol, et al., 2009). It is dominated by microorganisms as bacteria, but fungi, and archaea are 
also present (Sokol, Lay, Seksik, & Tannock, 2008). The relationship between the microbiota 
and humans are believed to have coevolved over millennia. Complex immune mechanisms 
have been optimized so the host intestine remains healthy. The microbe benefits from stable 
nutrient supply, while the host benefit from metabolic ability and exclusion of less benign 
microbes (Neish, 2009). In the human intestine, bacteria constitute ten times greater numbers 
than human cells. Totally the intestinal microbiota contains at least 100 times as many genes 
as the human genome (Sartor, 2008). Therefore the integrated microorganisms have been 
called the forgotten organ due to their role in the GI tract where they synthesize essential 
amino acids and vitamins, and process components of otherwise indigestible contributions to 
human diet such as plant polysaccharides (Neish, 2009).  
 
Further the intestinal commensal bacteria are essential in protection and homeostasis. 
Protection of the mucosa involves bacteria-bacteria interactions comprising physical 
exclusion, nutrient competition with less benign bacteria and a crosstalk between the 
microbiota and specialized epithelial cells (Sokol, et al., 2009). Disturbance of the normally 
stable GI microbiota are therefore predicted to adversely affect the health of the host (Frank, 
et al., 2007). Studies of experimental animal models of IBD reveal that germ-free animals 
show few signs of inflammation; experimental colitis is exhibited only when the animal is 
exposed to natural microbial communities. Likewise human studies have shown a response of 
IBD patients to antibiotic and probiotic treatment (Hecht, 2008). In CD patients inflammation 
most commonly appears in the gut locations where bacterial concentrations are high. 
Furthermore diversion of the fecal stream from the lumen is associated with improvement of 
the inflammation, indicating a role for bacteria in the IBD pathogenesis (Baker, Love, & 
Ferguson, 2009).  
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Albeit the types of GI microbes which influence IBD pathogenesis not yet have been 
adequately described, some bacterial species have been proposed to have a role. The 
discovery of H. pylori and its role in gastritis and peptic ulcer disease, awarded with The 
Nobel Prize in 2005, has stimulated the search for microbes as possible causes of other 
chronic inflammatory conditions like IBD (Peterson, Frank, Pace, & Gordon, 2008, 
(Inflammatory Bowel Disease, 2009). 
 
5.1 Spesific miroorganisms in IBD 
 
Relatively few studies reports single organisms to be responsible for IBD, especially few for 
UC. Additionally, conflicting results are reported, complicating the picture. Whether it is 
reasonable to expect a single organism to be able on its own to produce the myriad of signs 
and symptoms associated with IBD, should be considered. It has been speculated that the 
difficulty of finding one organism responsible for IBD is that more than one organism is 
involved (Lowe, Yansouni, & Behr, 2008). However, some organisms have been proposed to 
have a role in IBD pathogenesis. 
 
 
5.1.1 Mycobacterium avium spp. paratuberculosis  
Johne‟s disease, a wasting disease in cattle, has histopathological similarities with CD in 
humans. When Mycobacterium avium spp. paratuberculosis (MAP) was found to be the 
etiological agent of Johne‟s disease, huge effort was done to culture MAP from CD tissue. 
The investigations were considerably intensified when MAP was found in tap water and milk. 
But associations found between MAP and the etiology of CD was later contradicted in several 
studies (Sartor, 2008). Yet it is possible that MAP selectively colonize ulcers in the intestines 
of CD patients, especially patients with gene defects e.g. NOD2 (Packey & Sartor, 2008).  
 
5.1.2 Escherichia coli 
Functional alterations of commensal bacteria include enhanced epithelial adherence, invasion, 
and resistance to killing by the immune system or obtaining virulence factors. This can result 
in increased stimulation of innate and adaptive immune responses and subsequently create an 
inflammation. E. coli is a predominant bacterial species in the normal human intestinal flora 
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where it plays an important role in the intestinal homeostasis. In CD higher concentrations 
and antibody titres of E. coli has been found in the intestinal lumen and serum respectively.  
In 80% of microdissected granulomas of CD patients E. coli DNA was found (Packey & 
Sartor, 2008). Some E. coli strains can acquire virulence factors via horizontal transfer of 
DNA and cause a broad spectrum of diseases. Adherent invasive E. coli (AIEC) are 
abnormally predominant in CD. It can adhere and invade to the intestinal epithelium, 
Furthermore AIEC can replicate inside vacuoles in macrophages without killing the host cell 
and induce the release of TNF-α, a cytokine causing among other apoptosis and induction of 
inflammation (Darfeuille-Michaud & Colombel, 2008). The functional changes of AIEC 
might be one of the reasons why there are increased amounts of Enterobacteriae (including E. 
coli) associated with the mucosa in CD (Sartor, 2008). Whether AIEC represents a primary 
insult or rather a secondary contributor, remains to be established (Lowe, Yansouni, & Behr, 
2008).  
 
5.1.3 Faecalibacterium prausnitzii 
Faecalibacterium prausnitzii is producing butyrate, an anti-inflammatory agent (Manichanh, 
et al., 2006). A reduction of F.prausnitzii is associated with a higher risk of postoperative 
recurrence of ileal CD, a study revealed. Interestingly F.prausnitzii was found to exhibit anti-
inflammatory effects in both cellular and mice models. It even tended to reduce the intestinal 
dysbiosis in the mice model. Nonetheless the study showed that the strong anti-inflammatory 
effect of F.prausnitzii not was due to butyrate (Sokol, Pigneur, et al., 2008).  
 
5.1.4 Fungi 
Although most available results indicate a connection between bacteria and IBD pathogenesis, 
fungi microflora might also add valuable information. Anti-Saccharomyces cerevisiae 
antibodies (ASCA) are directed against common fungal cell wall epitope (Underhill & Braun, 
2008). ASCA are mainly present in CD but might also be found in UC (E F Stange, et al., 
2006; E. F. Stange, et al., 2008). Among other S. cerevisiae and Candida albicans are said to 
stimuli the development of ASCA, but the exact way this is done is unknown (Underhill & 
Braun, 2008).  
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5.2 Gastro intestinal microbiota in IBD  
 
In contrast to the interpretation of IBD pathogenesis by a single microorganism, the other 
approach is to find compositional shifts in bowel bacterial communities. A change in the 
composition of the intestinal microbiota has been proposed to have a role in IBD 
pathogenesis. But changes in the composition of microbiota could also be a result of the 
disease. Nonetheless discrepancies between IBD and control GI microbiota could be used in a 
diagnostic test. Before one can state a GI microbiota to be disturbed one need to know what is 
normal. Large studies are now trying to enlighten the human core microbiota, and more 
information will be revealed in the years to come (Tap, et al., 2009).  
 
Bacterial diversity within the human colon and feces is greater than previously described, and 
most of it is novel. Differences between individuals are significantly greater than intrasubject 
differences, with the exception of variation between stool and adherent mucosal communities. 
Variation associated with time, diet and health status have not been adequately described. 
(Eckburg, et al., 2005). 
 
All bacteria are divided in taxonomic ranks from phylum to species via class, order, family, 
and genus. Metagenomic studies reports that most bacteria in human GI tract are represented 
by only four phyla regardless of disease state: Firmicutes, Bacteroidetes, Proteobacteria and 
Actinobacteria (Eckburg, et al., 2005; Frank, et al., 2007; Ley, Turnbaugh, Klein, & Gordon, 
2006). Nearly half of the sequences have been shown to belong to just two subgroups: The 
order Bacteroidales and the family Lachnospiraceae (Frank, et al., 2007).  
 
Neither UC nor CD is characterized by a uniform, stereotypical microbiota (Frank, et al., 
2007). Hence it is unclear whether microbiota of the human intestine alone can be used to 
diagnose IBD, or whether human genetic, serologic and immunologic factors have to be 
included. 
 
5.2.1 Temporal variation of the gastro intestinal microbiota  
Healthy humans have relatively stable temporal compositions of GI microbiota; but the 
microbial content between persons differs considerably (Sokol, et al., 2008). In the case of 
CD patients in remission, the stability of the fecal microbiota varies greatly over time 
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(Scanlan, et al., 2006). Even though microﬂora have a high degree of diversity in both 
situations, dominant microflora varies markedly between remission and flare (Scanlan, 
Shanahan, O'Mahony, & Marchesi, 2006; Seksik, et al., 2003). Additionally IBD patients 
have shown higher concentrations of bacteria in mucosal and fecal samples (Sokol, et al., 
2008). 
 
In contrast, a notably decrease in operational taxonomic units (OTU) in IBD fecal and 
mucosal microbiota, mainly reflected by fewer types of bacteria in the Firmicutes phylum 
have been reported. While Fusobacteria and Verrucomicrobia phyla are associated with 
healthy subjects, increased number of Bacteroidetes is associated with IBD (Eckburg, et al., 
2005). 
 
5.2.2 Composition of gastro intestinal microbiota and bacterial 
metabolism 
Despite differences in GI microbes between persons, the same metabolic functions can be 
accomplished by several bacterial species (Sokol, et al., 2008). Butyrate is a short-chain fatty 
acid (SCFA) which is metabolized by mainly Firmicutes and Bacteroides species. SCFA 
accounts for up to 10% of calories in a Western diet each day. Butyrate also functions as anti-
inflammatory agent by inhibition of NF-κB activation. Loss of butyrate producers might 
therefore interfere with the balance between host epithelial cells and resident microorganisms, 
leading to the development of CD associated ulcerations. Other known butyrate producers are 
microorganisms in Clostridium leptum and Clostridium coccoides groups (Manichanh, et al., 
2006). Loss of butyrate producers in IBD patients are observed in several studies (Gophna, 
Sommerfeld, Gophna, Doolittle, & Veldhuyzen van Zanten, 2006; Manichanh, et al., 2006; 
Sokol, et al., 2009) 
 
Bacteria which produce hydrogen sulfide can inhibit butyrate oxidation and hence cause 
colonic lesions. Higher concentrations of hydrogen sulfide producing bacteria have been 
reported in the microbiota of active UC patients compared to those in remission (Sokol, et al., 
2008).  
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6. IBD Diagnostics 
 
As there is no single pathogenic marker of IBD found, no gold standard for making the 
diagnosis exists. Rather the recommended diagnosis of CD and UC is based on clinical 
evaluation, laboratory findings and medical history and is confirmed by negative 
microbiological test, endoscopy and histological findings. Several diseases presenting similar 
symptoms, needs to be ruled out. Most patients suspected to have IBD and undergo standard 
invasive tests have a functional disease and the majority of these have irritable bowel 
syndrome (IBS)  (Dubinsky, et al., 2002). IBS differ from IBD in that it does not cause 
inflammation, ulcers or organic damage to the GI tract. IBS diagnostics are based on 
symptoms and evaluation of organic abnormality (Grundmann & Yoon). Treatment of IBD 
includes diet, psychotherapy, and medications like antidiarrheal agents, anti spasmodics and 
antidepressants (Kennedy, et al., 2006; Villanueva, Dominguez-Munoz, & Mearin, 2001). 
 
6.1 Medical history and clinical evaluation 
Because the symptoms of IBD are mixed, depending on the localization and severity of the 
disease, diagnostic problems often occur. Diarrhea, abdominal pain and/or weight loss are the 
main symptoms of CD. In UC bloody diarrhea is the primary symptom, but it might also be 
present in CD. Patients with UC might also have symptoms as rectal bleeding and rectal 
urgency. Passage of mucus and pus are more common in UC than CD. Additionally 
symptoms of malaise, loss of appetite and/or fever are common in CD but could be a sign of 
severe attack in UC. Fistulae are common in CD and may occur in UC. Furthermore, several 
symptoms associated with constipation are described by UC patients. Common extraintestinal 
manifestations in IBD are abnormalities of the musculoskeletal system (E F Stange, et al., 
2006; E. F. Stange, et al., 2008).  
 
Conditions that produce similar symptoms need to be ruled out. Recent antibiotic use may 
indicate pseudomembranous colitis, travel abroad might cause infectious colitis and 
abdominal pain relived with bowel movements could represent IBS (Langan, Gotsch, 
Krafczyk, & Skillinge, 2007). Loose stools for more than six weeks normally differentiate 
IBD from infectious diseases. Patients are questioned carefully about medication, recent 
travel, the onset of symptoms, nocturnal diarrhea, incontinence, food intolerances, contact 
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with enteric illnesses, sexual practice, smoking, family history of IBD, and history of 
appendicectomy. Also a general examination is preformed (E F Stange, et al., 2006; E. F. 
Stange, et al., 2008).  
 
 
Figure 3 Anatomy of Ulcerative Colitis affecting the whole colon (left) and partially affected colon 
(right) (D. C. Baumgart & Sandborn, 2007). 
 
6.2 Laboratory Tests 
6.2.1 Blood Tests 
Initially, several blood samples are investigated comprising a full blood count, serum urea, 
creatinine, electrolytes, liver enzymes, iron studies, and C-reactive protein (CRP). (E F 
Stange, et al., 2006; E. F. Stange, et al., 2008). In IBD the blood count might show anemia 
from long term rectal bleeding, thromocytosis as a result of chronic inflammatory response. 
CRP might be elevated as a result of chronic inflammation. A basic metabolic profile may 
demonstrate electrolyte abnormalities from persistent diarrhea (Langan, et al., 2007; E F 
Stange, et al., 2006; E. F. Stange, et al., 2008). Nevertheless no sign of chronic inflammation 
might be found in UC (Nikolaus & Schreiber, 2007) 
 
The single most robust serological biomarker of CD is anti-Saccharomyces cerevisiae 
antibodies (ASCA). Another marker is peri-nuclear anti-neutrophil cytoplasmic antibodies 
(pANCAs). The markers have insufficient sensitivity to serve as a screening tool for 
populations with low prevalence of disease. However, used in combination it is utilized as a 
Extensive Ulcerative Colitis 
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confirmation test when IBD is assigned, to differentiate CD from UC. pANCA is found in 
half of the UC patients (E. F. Stange, et al., 2008). Likewise ASCA can be detected in 35-
50% in the CD patients and less than 1% of the UC patients (Nikolaus & Schreiber, 2007). 
The specificity of ASCA for CD and pANCA for UC is rather high with 89-97%  and 89% 
reported respectively (Nikolaus & Schreiber, 2007).  
 
Studies report that CRP has a diagnostic sensitivity of 70-100% for CD and 50-60% for UC 
(Vermeire, Van Assche, & Rutgeerts, 2006).  
 
6.2.2 Stool Examination  
Microbiological testing is recommended to exclude infectious diarrhea caused by common 
pathogens including specific assays for Clostridium difficile toxin, Campylobacter spp and E. 
coli 0157:H7. In addition other stool test may be tailored for patients who recently have 
traveled abroad (E F Stange, et al., 2006; E. F. Stange, et al., 2008). 
 
Calprotectin is a fecal marker and represents migration of leukocytes to the GI tract. It is a 
sensitive marker for inflammation in the GI tract. Further it can differentiate IBS from IBD 
and it has been suggested to skip endoscopies in patients with normal calprotectin levels and 
IBS symptoms. It can be used to measure disease activity and predict relapse in CD. It has 
been proponed that the marker could replace colonoscopy in follow-up of CD (Jahnsen, 
Røseth, & Aadland, 2009). Nevertheless several other conditions as cancer, infections and 
polyps can give a positive calprotectin test (Vermeire, et al., 2006).  
 
6.2.3 Genotyping 
Genotyping is not recommended in UC since it is a complex disease and mutations in 
identified disease associated genes not guarantee disease development. Nor absence of these 
mutations is sufficient for remaining healthy (E. F. Stange, et al., 2008). CARD15 mutations 
have been associated with CD, but low predictive value and missing preventive treatment 
have led to the absence of routine genetic testing (E F Stange, et al., 2006). 
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6.3 Endoscopy 
 
Endoscopy is used to establish the diagnosis and extent of UC and CD. Some types of 
endoscopy are proctosigmoidoscopy for rectum, colonoscopy for the large bowel and the 
lower colon and ileoscopy for the colon up to the ileum. Patients with upper GI symptoms 
might need to perform an upper endoscopy, oesopagogastroduodenoscopy, but this is not 
recommended as a screening procedure (Nikolaus & Schreiber, 2007). The endoscope is 
passed through the rectum or mouth. It has a small camera attached to a flexible tube and 
tissue samples can be taken with a biopsy forceps inserted through the tube (Endoscopy. 
(2010). In Encyclopædia Britannica.  Retrieved February 19). Biopsies from several sites in 
the colon, rectum and ileum are obtained (E. F. Stange, et al., 2008). The procedure time is 
about 20 minutes (Terheggen, et al., 2008).  
 
A colonoscopy or ileoscopy with biopsy are recommended for the examination of patient 
suspected to have IBD. Endoscopic appearance as distribution and shape of lesions 
differentiate CD from UC in most cases (Nikolaus & Schreiber, 2007). If the condition of an 
IBD patient is severe, there is a danger for perforation and fast medical management might be 
crucial. In this situation it is advised to postpone the examination, alternatively perform 
sigmoidoscopy (E F Stange, et al., 2006). In IBD patients severe complications as bleeding 
and perforation occurs in 0,7% while minor complications as intense flatulence , tachycardia, 
allercic raction etc. occurs in 3,9% of the endoscopic procedures (Terheggen, et al., 2008). 
The need for surgery as a result of endoscopy is 0,42% (Froehlich, Gonvers, Vader, Dubois, 
& Burnand, 1999). Other shortcomings of endoscopy are the invasive nature of the method, 
the discomfort of the patient and the expenses. Additionally it is not an objective test.  
 
Wireless capsule endoscopy might be preformed for the diagnosis of CD after ileoscopy. It is 
swallowed and images are being recorded as the capsule pass the upper GI tract and small 
bowel (Bourreille, et al., 2009). Further studies are needed to confirm the diagnostic 
relevance. 
 
6.3.1 Endoscopic Features 
UC causes continuous inflammation from rectum and a variable length of the colon. The 
inflammation has a clear macroscopically boundary to healthy tissue. Typical features are 
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ulcerations, loss of the vascular pattern, exudates, and granularity (Figure 4). Severity is 
reflected by the presence of spontaneous bleeding, deep ulcerations and mucosal bleeding to 
light touch. But no endoscopic feature is specific for UC (E. F. Stange, et al., 2008). UC are 
restricted to the colon except of rare occasions when the whole colon is affected “back-wash 
ileitis” can be seen. The distribution of UC is classified according to macroscopic findings 
using endoscopy. In proctitis the inflammation is limited to the rectum. Inflammation from 
rectum to the splenic flexure is characterized as left-sided, while inflammation which passes 
this location is called extensive UC (Figure 3). When the diagnosis is set, the disease activity 
is classified as remission, mild, moderate or severe according to parameters as puls, 
temperature, hemoglobin, erythrocyte sedimentation rate (ESR), CRP and number of bloody 
stools pr day.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Endoscopic features of UC. Left: Transverse colon in a UC 
patient in remission. Typical post-inflammatory changes- i.e., loss of 
fine vascular pattern. Right: Descending colon: Extensive UC with 
irregular surface due to extensive ulcerations, spontaneous 
haemorrhage, and pseudopolys (D. C. Baumgart & Sandborn, 
2007).  
Figure 5 Endoscopic features of CD. Left: Terminal ileum of a CD patient: 
Friability of mucosa with erythema, loss of ramifying vascular pattern, and 
lymphoid hyperplasia. Right: Sigmoid colon of a CD patient: Linear and 
serpinguous ulcerations and patchy inflammation ultimately resulting in 
cobblestone pattern (D. C. Baumgart & Sandborn, 2007).  
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The features of CD are normal mucosa within inflamed areas, anal lesions and deep 
ulcerations with swelling of the surrounding tissue (cobble stoning) (Figure 5). The ulcers can 
vary in depths from the submucosa through the muscle layer (E F Stange, et al., 2006). 
Frequently CD patients have small bowel involvement. But 15-23% of the patients have 
inflammation restricted to the colon and this could confuse the diagnosis with UC (Nikolaus 
& Schreiber, 2007).  
 
6.4 Histology 
 
The presence of granuloma, focal inflammation or architectural abnormalities found in 
biopsies is a main feature of CD. In contrast UC features are diffuse crypt irregularity, 
reduced crypt numbers and general crypt epithelial polymorphs (E F Stange, et al., 2006).  
The microscopic features are dependent upon how early the biopsies were obtained. In early 
biopsies no pathological signs might be found (E. F. Stange, et al., 2008). 
 
6.5 Radiology 
6.5.1 Small bowel follow-through, computed tomography, and 
magnetic resonance imaging 
 
Although it is not a diagnostic test for IBD, abdominal radiography is useful in patients where 
endoscopy is not recommended. Small bowel follow-through (SBFT) and small bowel enema 
has been the standard for detection of small bowel involvement in CD or to confirm a normal 
upper GI tract in UC patients. SBFT requires an experienced radiologist and main findings are 
often only observed during fluoroscopy. In addition the radiation dose is relative high and 
should preferably not be used in children (Nikolaus & Schreiber, 2007; E F Stange, et al., 
2006). 
 
Several other techniques exists for small bowel investigations including among other 
ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) (E F Stange, 
et al., 2006). MRI can differentiate active inflammation from fibrosis. As SBFT, MRI can be 
used to detect stenosis, anorectal fistulae and abscesses in IBD. MRI have higher costs than 
SBFT, but because of non-ionizing radiation and increasing higher diagnostic precision MRI 
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can become the method of choice for detection of small bowel involvement in CD (Nikolaus 
& Schreiber, 2007). CT gives additional information especially in patients where the disease 
is severe such as thickening of the bowel wall. CT includes radiation and other method should 
be considered in young patients (E F Stange, et al., 2006).  
 
6.5.2 Ultrasound 
Sonography can detect inflamed areas in both small bowel and colon with high diagnostic 
precision based on bowel wall diameter and blood flow. Based on this, quiescent disease can 
be separated from moderate to severe disease. Pathological findings like enlarged lymph 
nodes, abscesses, stenoses, and fistulae can be detected. It is a quick and inexpensive 
screening method for IBD and can also be used to evaluate complications. The sensitivity for 
primary detection of CD with sonographic techniques is 75-95% with a specificity of 67-
100%, depending on the operator (Nikolaus & Schreiber, 2007). 
 
6.6 Innovative diagnostic procedures identifying intestinal 
microbial populations using the 16S rRNA gene 
 
Several methods exist for the identification of bacteria in a certain microbiota. Previously, 
phenotypic determination of bacterial species by cultivation was the only way. Through the 
evolution intestinal bacteria has adapted to the metabolism of the host and other bacteria in 
the ecosystem, hence they are almost impossible to cultivate in pure culture. Only 10-50% of 
bacteria in the gut can be identified by this method (Zoetendal, Rajilic-Stojanovic, & de Vos, 
2008). Thanks to new culture-independent tools, huge amounts of new data can be revealed. 
Especially technologies based on 16S rRNA sequence information have been a solution.  
 
6.6.1 Identification of bacteria by 16S rRNA 
Ribosomes comprise two rRNA subunits, called small and large subunit, which work together 
during protein synthesis (Schluenzen, et al., 2000). In prokaryotes these consist of, among 
other, 16S and 23S rRNA respectively (Pei, et al., 2009). While 23S rRNA catalyzes peptide 
bonds, 16S rRNA initiates contact with mRNA, decode mRNA via tRNA and control the 
interaction between codon and anticodon (Schluenzen, et al., 2000). Throughout the 
evolution, the gene functions and sequence of rRNA genes have remained relatively 
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conserved with the exception of some variable regions. The variable regions of 16S and 23S 
rRNA are used to identify and differentiate species. PCR primers are designed for the 
universal regions surrounding the variable regions of the gene. In this way sequence and 
species differences can be detected (Zoetendal, et al., 2008). The nature of the gene allows 
simultaneously detection of many species. Primers and probes can be designed to detect 
species, genra, family or even order. 
 
Small subunit (SSU) rRNA genes are found in all organisms. Because of these properties, the 
gene was used in the construction of the "tree of life" where the Archaea was discovered as 
the third "domain of life” in addition to Bacteria and Eucarya. So far more than 400 000 SSU 
rRNA sequences are available in databases (Zoetendal, et al., 2008). The two prokaryotic 
rRNA genes have a length of 1542 (16S) and 2904bp (23S) (Srikanta & Simpson, 2005) 
which is sufficient length for comparative sequence analysis (Zoetendal, et al., 2008). Due to 
the short sequence, the 16S rRNA gene is used more frequently in the identification of 
prokaryotes than 23S rRNA. The properties of the gene make it suitable for detection of 
microbiota in different types of samples. Samples from the intestines as fecal and mucosal 
samples can be utilized to detect bacteria in i.e. IBD diagnosis. 
 
6.6.2 Challenges with the simultaneously detection of a complex 
mixture of DNA from different organisms 
Methods such as flow cytometry, Real-Time PCR and mass spectrometry, can utilize the 
rRNA gene, but is limited to a low number of tests carried out simultaneously. The two first 
because of limited number of fluorochromes (Rudi & Jakobsen, 2003). Denaturing gradient 
gel electrophoresis (DGGE) is another option, but because of low throughput, hetero-duplex 
formation and the difficult comparison of gels, this method has also been causing problems. 
Terminal restriction fragment length polymorphism (T-RFLP) is widely used, but is imprecise 
and has low solubility. Standard microarray for 16S rRNA has been shown to provide a high 
number of cross hybridization. Non-specific labeling of samples with DNA array 
hybridization has been tested, however it do not identify many bacteria at a time (Rudi & 
Jakobsen, 2003; Rudi, Skulberg, Skulberg, & Jakobsen, 2000). For this purpose next 
generation sequencing can become an option, but so far many challenges exist. Short reads 
and base calling errors makes it difficult to assemble the sequences. Furthermore, an 
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unnecessary, large volume of data is generated and needs to be handled. Additionally the 
costs are high (Chistoserdova, 2010). 
 
6.6.3 Fecal and mucosal samples in the detection of gastro intestinal 
microbiota 
Materials used for testing the microflora of the human intestine are heavily discussed. 
Conflicting evidence exists whether fecal microbiota differs substantially from that of the GI 
mucosa. High similarity profiles of biopsy-, aspirate- and faeces associated bacteria have been 
presented (Bibiloni, et al., 2008; Tannock, 2008) while other report that some microbes are 
associated with the gut wall and these are likely a more critical factor than fecal microbes in 
promoting IBD pathogenesis (Frank, et al., 2007) The existence of a so called biofilm more 
adherent to the intestinal mucosa in patients with IBD than healthy humans further suggests 
the relevance of biopsy (Swidsinski, Weber, Loening-Baucke, Hale, & Lochs, 2005). 
Biofilms, with their inherent resistance to antibiotics and host immune attack, have 
increasingly been identified as sources of many recalcitrant bacterial infections (e.a 
periodontal disease, endocarditis)(Swidsinski, et al., 2005). Patients usually undergo bowel 
cleansing before endoscopy and residuals pools in the large bowel. This aspirate 
contaminates, in all likelihood, the endoscope and the collected tissue (Tannock, 2008). 
Further, a study found no clear bacterial infiltration of the mucosa in IBD patients. Even in 
patients with severe inflammation, bacteria were not found below the epithelial layer. 
Biofilms were also found in regions without signs of inflammation. Crossing of the mucus 
and bacterial adherence is therefore considered taking place before mucosal destruction. The 
diversity of mucosal bacteria was additionally found to be low compared to the fecal bacteria 
(Swidsinski, et al., 2005).  
 
Absolute numbers of microbial species vary greatly a long the gut, ranging from 10
2-3
 cell/g 
content in the proximal ileum and jejunum to 10
7-8
 in the distal ileum and 10
11
-10
12 
in the 
ascending colon (Neish, 2009, Sartor, 2008). Results from several studies on GI mucosa 
reveal that the same bacterial phyla dominate in the stomach, small intestine, and colon, 
although their relative abundance and details of the component species vary as a function of 
position along the gut (Peterson, et al., 2008). Mucosal biopsies, unlike stool, provide samples 
collected from regions of the intestinal tract where inflammation occurs (Tannock, 2008). In 
contrast, the fecal microbiota is thought to represent the microbiology of the distal large 
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bowel and it has been stated that it do not reflect neither the colon nor the terminal ileum 
(Sokol, et al., 2008). Knowing that CD can occur anywhere in the digestive tract from mouth 
to anus (Tannock, 2008) revealing where in the GI tract the microbiota of stool samples 
reflect is important. Anyway, as previously described, differences in the fecal microbiota 
between IBD patients and controls have been reported. Fecal samples with their easily 
availability are preferred instead of biopsies. But so far no such test is commercially available. 
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7. GA-map™ - technology description 
 
The Norwegian company Genetic Analysis AS (GA) is commercializing a patented 
technology, named GA-map™. To diagnose IBD, GA is seeking to identify an IBD specific 
bacteria composition in fecal samples. Generally, GA-map™ involves detection of sequences 
in the 16S rRNA gene by binding of oligonucleotide probes and selective labeling of the 
bound probe. Subsequently, the probes are hybridized to a known sequence followed by 
detection, see Figure 6 (Rudi & Jakobsen, 2003).  
 
The method can be used in a complex mixture of DNA from different organisms. Microbiotas 
in fields such as water, soil, buildings, health, veterinary and food products can be explored 
using this method. In health, GA wants to survey the human intestinal flora in terms of 
stomach ulcers, allergies, obesity, bowel cancer, energy capture and IBD. 
 
The method described in the patent, US6617138 "Nucleic acid detection method", has a 
general profile and multiple customizations to the invention are possible. Different 
approaches are being optimized. 
 
7.1.1 Target sequences, primers and probes  
The target sequences for detection may be of numerous types: DNA, PCR amplified DNA, 
native DNA, reverse transcribed DNA (cDNA), single-or double stranded DNA, linear or 
circular. Moreover, the target sequence might be RNA such as mRNA, or rRNA. (Rudi & 
Jakobsen, 2003) 
 
Primary, a method using PCR amplified rRNA gene sequences, have been developed. Other 
possible amplification methods are; in vivo cloning, Nucleic Acid Sequence Based 
Amplification (NASBA) for amplification of RNA and ligase chain reaction. The main focus 
is the 16S rRNA gene, but the method might also be compatible with other genes.   
 
The Cover-all™ universal 16S rRNA primers pair developed by GA, can be used to amplify 
most bacteria in the human gut. Further the company has developed a computer program, the 
GA-map ProbeTool™, for the identification of specific areas within the 16S rRNA gene 
suitable for probes. The probes used are complementary to the variable regions of 16S rRNA. 
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The length of the oligonucleotide probes are approximately 20 nucleotides. The lengths of the 
probes are optimized to be sufficiently long for specific binding, and reasonably short to 
avoid unnecessary chemical synthesis. Amounts of probe are optimized in terms of qualitative 
and quantitative detection (Rudi & Jakobsen, 2003). 
 
7.1.2 Single nucleotide extension (SNE)  
DNA is extracted from the fecal samples and the 16S rRNA gene is amplified using primers 
targeting universal regions in the gene. Excess primers and unincorporated nucleotides are 
removed by Exonuclease I (EXO I) and Shrimp Alkaline Phosphatase (SAP) treatment 
respectively. Subsequently, the oligonucleotide probe binds to the target sequence in the 
sample with normal base pairing and forms a complex (probe-sequence) (Kostić T & L., 
2007). 
     
Labeling of the probe is template dependent. Extension with fluorescently labeled nucleotide 
will only occur in the presence of target sequence. A dideoxynucleotide (ddNTP) is 
incorporated to the bound probe by the polymerase. Further polymerization is prohibited 
because of  the nature of ddNTPs having a 3'hydroxyl group which is modified or missing 
(Kostić T & L., 2007). The method can be performed using one dideoxynukleotid, or a mix of 
ddGTP, ddCTP, ddTTP and ddATP. If only one ddNTP is present it may be a higher risk of 
misincorporation despite the usual base pairing rules. Several different ddNTP'er in the 
reaction reduces the likelihood of misincorporation and thus the background signal and noise 
on the array. 
 
Several types of labeling or reporter molecules of the probe are possible. Examples of 
labeling are chemiluminescent, radioactivity, chromogenic, enzymatic, antibody, and 
fluorescence. The use of fluorescently labeled ddNTP are under development (Rudi & 
Jakobsen, 2003). 
   
7.1.3 Specificity and sensitivity  
Compared to other DNA based methods, GA-map ™ can perform with higher specificity, 
lower noise and lower background signal. The main reason is the specific binding of the probe 
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followed by the incorporation of fluorescent labeled ddNTP with specific polymerase. 
Methods where the probe is marked in advance will result in lower specificity. In the case of  
 
Figure 6  The GA-map
TM
 technology. DNA is isolated from the fecal sample (A). Variable regions of 
the 16S rRNA gene are amplified by Cover-all
TM 
16S rRNA universal PCR primers (B). Specific probes 
are bound to a complementary sequence and extended with a single fluorescence labeled nucleotide. 
Subsequently the probe is separated from the sequence by denaturation (C). The specific probes are 
hybridized to complementary probes spotted on a microarray (D). Step C and D are patent protected 
and licensed by GA (Rudi & Jakobsen, 2003). 
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normal base pairing the corresponding nucleotide is preferred and specificity increased. The 
sensitivity can be improved by increasing the number of cycles in the labeling step and the 
use of a thermal stable polymerase is presupposed. The optimal number of cycles is 
approximately 10. Additional cycles may be used even in quantitative detection, using a 
competitive PCR, where a competing sequence is added in specific amounts to the reaction 
containing the same primer-template sequence (Rudi & Jakobsen, 2003). 
 
7.1.4 Hybridization 
The SNE reaction is followed by the hybridization reaction. First the complex (probe-PCR 
product) is separated by denaturation. This can be e.g. high pH or high temperature (Rudi & 
Jakobsen, 2003). High temperature denaturation is used in the method now being developed. 
Subsequently, the oligonucleotide is hybridized to a complementary sequence on a 
microarray. The microarray allows simultaneous detection of a high number (thousands) of 
different oligonucleotide attached to a glass or silicon chip (Passarge, 2001). Other options of 
solid surfaces are particles, gels, filters, membranes, fibers, capillaries, microtitre strips, tubes,  
plates or wells. The probe sequences on the microarray can be designed with areas not 
completely complementary to the probe, it can e.g. be truncated or contain a longer sequence.  
But the sequence must be sufficiently complementary to allow binding of the probe. 
The complementary sequence can be DNA or PNA (Peptide Nucleic Acid) (GeneticAnalysis, 
2010; Rudi & Jakobsen, 2003).  
 
7.1.5 Detection 
The detection can be quantitative, qualitative or semi-quantitative. The signals are detected 
according to what form of labeling used. Fluorescent labeling is detected by a 
laser scanner. Monochrome light emits, and fluorescent signal are detected by a charge-
coupled device (CCD) camera. The image created is analyzed and each spot is quantified. The 
signals can be treated with a variety of statistical applications for qualitative and quantitative 
measurements. Finally, the signals will reflect the relative content of target sequences, the 
bacteria it contains, and the number of bacteria in a sample (GeneticAnalysis, 2010; Kostić T 
& L., 2007; Rudi & Jakobsen, 2003). 
 
  
 
40 
8. Potential bacterial target for the GA-map™ 
 
A literature study was performed to reveal what is known about the relationship between IBD 
and a change in the GI microbiota. Articles presenting results from bacterial markers of IBD 
in feces and mucosal samples were studied. A complete overview of the findings is presented 
in Appendix A and Appendix B and a summary is presented in Table 1. 
 
8.1.1 Variation in the gastro intestinal microbiota of IBD patients 
Conflicting evidence is presented in the literature. The most uniform results reports reduced 
amounts of C. coccoides in stools from CD patients (Mangin, et al., 2004; Seksik, et al., 2003; 
Sokol, et al., 2009) Additionally a study reported reduced amounts in UC versus controls 
(Sokol, et al., 2006). Further, consistent results have also reported reduced amounts of another 
Clostridium species, namely C. leptum (Mangin, et al. 2004; Manichanh, et al., 2006; 
Prindiville, Cantrell, & Wilson, 2004; Scanlan, et al., 2006; Sokol et al., 2006). While reduced 
amounts in active-IBD were found, this was not true for patients in remission, a study showed 
(Sokol et al., 2009). Furthermore, Clostridium cluster IV and XI and subcluster XIVa are 
decreased in CD versus healthy subjects (Andoh, et al., 2009). 
 
Using fecal samples Bacteroidetes vulgatus was the only species shared by all 4 patients in a 
study. Especially it was high in the two patients with CARD15 mutation and disease located in 
the ileum (Mangin, et al. 2004). Also in mice B. vulgatus was found to be positive associated 
(Ye, et al., 2008). 
 
Enterobacteria were detected in feces from all patients but none of the controls (Seksik, et al., 
2003). Similarly the order Enterobacteriales has also been reported in increased amounts in 
fecal samples from IBD patients (Andoh, et al., 2009). 
 
Faecalibacterium prausnitzii was found to be reduced in active IBD in a study using 
quantitative real-time PCR on fecal samples (Sokol, et al,. 2009). While the opposite was 
reported in a study using mucosal samples (Swidsinski, et al., 2005).  
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Firmicutes phylum was reduced in both biopsy and fecal samples of CD and active IBD 
patients (Gophna, Sommerfeld, Gophna, Doolittle, & Veldhuyzen van Zanten, 2006; 
Manichanh, et al., 2006; Sokol, et al., 2009). Interestingly the Firmicutes/Bacteroidetes ratio 
has been presented as reduced in active IBD (Sokol, et al., 2009). 
 
Confunding results have been reported from numerous studies of species in the Bacteroidetes 
phylum and Bacteroides genus. Increased, equal and similar amounts have been presented 
(Appendix A and Appendix B).  
 
Table 1 Bacteria status reported in IBD patients relative to controls  
Class Feces Mucosa 
 Increased Decreased Equal Increased Decreased Equal 
Actinobacteria  3 5 5   
Alphaproteobacteria    3   
Bacilli 5 2 5 3   
Bacteroida 4 2 4 8 8 1 
Clostridia  17 3 5 10  
Gammaproteobacteria 3  5 6  4 
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9. Evaluation of selected GA-map™ probes for IBD 
diagnostics 
 
In order to search for bacterial probe candidates for the GA-map™ IBD array, a laboratory 
study were performed. Samples from 257 individuals were hybridized with five probes in 
separate reactions. The probes were extended by a fluorescence labeled ddNTP and detection 
was performed by capillary gel electrophoresis as described below. Hence, the following are a 
simplified version of the GA- map™ previously described. 
 
This is the first study to use the GA developed protocols and probes on adult patient samples. 
The study shows the potential of diagnosing IBD by using 16S rRNA probes in fecal samples. 
Most previous IBD studies utilizing 16S rRNA in fecal samples, include few number of 
patients (<50). These previous studies include patients which have initiated their medical 
treatment, although most exclude patients who have taken relevant medication for a period of 
time (month) before collection of sample. The present study includes 152 patients and 105 
controls.  
 
 
9.1 Materials and methods 
 
9.1.1 Patients and samples 
The patient samples used in this study were a cohort from the Norwegian IBSEN study and 
were kindly distributed by Akershus University Hospital (Ahus). The samples comprise 
newly diagnosed untreated IBD patients and non-IBD patients. In total 257 patients were 
included in the study (Table 2). The inclusion criteria for the IBD cohort were abdominal 
symptoms including diarrhea and/or blood in the stools for more than 10 days, endoscopic or 
radiological signs of inflammation as well as histological signs of chronic inflammation. 
Exclusion criteria were infection of pathogenic gut bacteria (excluding mycobacterium 
avium), findings of parasites, cysts and eggs. In addition patients with cancer, hematological 
or hepatological disorders, significant cardiovascular, neurological, or repiratory comorbidity, 
and other chronic inflammation than IBD were excluded from the study (cases and controls).  
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9.1.2 Classification of patients 
The IBD patients were further classified as CD, UC or IBD unclassified (IBDU). 
Patients were diagnosed as CD based on the presence of two or more of the following criteria: 
 Clinical features including abdominal pain, diarrhoea and weight loss. 
 Macroscopic appearance at operation or endoscopy: Segmental, discontinuous, and/or 
patchy lesions with or without rectal involvement, discrete or apthous ulcerations, 
fissuring or penetrating lesions, cobblestone or strictures. 
 Radiological evidence of stenosis in the small bowel, segmental colitis or findings of 
fistulae. 
 Histologic evidence of transmural inflammation or epithelial granulomas with giant 
cells. 
 
The diagnosis of UC was based on the presence of three or more of the following criteria: 
 A history of diarrhoea and or blood/pus in stool 
 Macroscopic appearance at endoscopy, with continuous mucosal inflammation 
affecting the rectum in continuity with some or the entire colon. 
 Microscopic features on biopsy compatible with UC. 
 No suspicion of CD on small bowel roentgenography, ileocolonoscopy, or biopsy. 
 
Patients with inconclusive or divergent endoscopy and histopathology according to CD or UC 
criteria were classified as IBDU. 
 
The non-IBD cohort was derived from patients referred to colonoscopy, not suffering from 
IBD.  
 
Table 2 Characteristics of patients 
 Children Adults Total number 
of patients 
UC 13 50 63 
CD 29 36 65 
IBDU 3 21 24 
Non-IBD 25 80 105 
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9.1.3 Universal polymerase chain reaction 
Collection of stool samples, DNA extraction and PCR products from the 257 fecal samples 
had previously been derived at Ahus. The samples were stored at -80ºC. DNA had been 
extracted using QIAamp DNA Stool Mini Kit (Qiagen, Hilden, Germany). Using the GA 
universal 16S rRNA primers, PCR conditions were as follows: HotFirePol 1.25U, B2 buffer 
1x, MgCl2 2.5mM, dNTP 200µM (Solis BioDyne, Tartu, Estonia), GA Cover -all™ 16S 
rRNA forward primer 0,2µM, GA Cover -all™ 16S rRNA reverse primer 0,2µM  (Genetic 
Analysis, Aas, Norway), DNA template 10-100ng. Each reaction was done in a final volume 
of 25µL. The reactions were performed using a standard PCR machine and the conditions 
were as follows: 95°C for 15 min, followed by 30 cycles at 95°C for 30s, 55°C for 30s, 72°C 
for 1min 20s, followed by a final elongation at 72°C for 7 min. 
 
The PCR products were treated with Exonuclease (EXOI ) 3U and Shrimp Alkaline 
Phosphatase (SAP) 8U in order to remove excess primers and unincorporated nucleotides 
respectively. Subsequently the samples were incubated at 37°C for 2h followed by 80°C for 
15 min. 
 
9.1.4 Probes 
Four probes previously generated by the GA-map ProbeTool™ were chosen on the basis of 
the literature study (AppendixA, Appendix B). The hybridization of the probes had previously 
been tested against target species among 262 bacterial strains. Bacterial hits are described in 
Table 3. Additionally a universal probe was used. 
 
9.1.5 Endlabeling 
A bacterial strain specific probe was hybridized to complimentary sequences in the sample 
and extended with one base pair using fluorescent ddCTP (Tamra) in an end-labeling reaction 
(Single Nucleotide Extention, SNE). All samples were hybridized with five probes (Table 3) 
in separate reactions. The reaction was performed with a final volume of 10µL. The 
conditions were as follows: HOT Termpiol DNA polymerase 0,25U,  HOT Termipol 
Reaction Buffer C 1x, MgCl2 4mM (Solis BioDyne, Tartu, Estonia), ddCTP Tamra 0,4µM 
(Jena Bioscience, Jena, Germany), GA probe 0,1 µM (Genetic Analysis, Aas, Norway), 
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EXOI-SAP treated template 2 µL. The samples were loaded on a thermal cycler: 95°C for 12 
min, followed by 10 cycles at 95°C for 20s and 60°C 35s.  
 
Residual nucleotides and phosphate groups from the 5‟end were removed by SAP, 1U per 10 
µL end-label product. Further the samples were incubated in a thermal cycler at 37°C for 1h 
followed by 80°C for 15min. 
 
9.1.6 Capillary gel electrophoresis 
 Next, 1µL of each SAP treated end-labeling product was transferred to a MicroAmp™  
Optical 96-Well Reaction Plate and mixed with 9 µL Hi-Di™ formamide and 0,5 µL 
GeneScan™ 120 LIZ™ Size Standard (Applied Biosystems, Foster City, CA, USA) 
Subsequently, the samples were denaturated at 95°C for 5min. Capillary gel electrophoresis 
were performed using an AB 3130xl Genetic Analyzer (Applied Biosystems, Foster City, CA, 
USA). Fluorescent signals were measured and represent semi-quantitative signal of 
previously bound probe. The samples were analyzed using GeneMapper ® Software v4.1 
(Applied Biosystems, Foster City, CA, USA). Default settings were used including a cut off 
value of 100 relative fluorescent units (RFU).   
 
9.1.7 Quantification of PCR products 
Quantification of the PCR products was performed using Quant-iT PicoGreen ds DNA 
Reagent and Kits as previously described (Invitrogen, 2008) (Invitrogen, Carlsbad, CA, 
USA).  In order to make a standard curve, Lambda DNA standard was diluted in 1x TE and 
Quant-iT PicoGreen Reagent to the following final concentrations: (1,0 ng/µl, 0,1 ng/µl, 0,01 
ng/µl, 0,001 ng/µl and 0 ng/µl).  
 
Furthermore, 2 µl of each sample was diluted in 100 µl Quant-iT PicoGreen Reagent and 98 
1xTE. A control sample (Lambda DNA standard) with known concentration was measured on 
each run. Each standard, control and sample was analyzed in triplicate. Fluorescent signal 
were detected using FluoStar Optima (BMG Labtecth, Offenburg, Germany). The 
quantification of PCR product was done by the Mars Data Analysis software version 1.10 
(BMG Labtecth, Offenburg, Germany). Standard deviation (SD) and Coefficient of variation 
(CV) was calculated of the RFU. Standards and controls was accepted at <10% CV and 
samples at<33% CV. Additionally the control was accepted at <3SD from the standard curve. 
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The RFU of the blank was subtracted from the average RFU signal of each sample. Further 
the concentration of the sample PCR product was determined by the standard curve 
(y=53897x+27,082). 
 
9.1.8 Statistical Methods 
The patient samples was randomly distributed in three 96 well plates according to patient 
status. To further normalize potentially plate to plate variation, sample RFU values were 
transformed to percent value of mean RFU values per plate. Further, normalization of variable 
concentration of PCR product was done. The sample value was divided by the concentration 
of PCR product as measured by Quant-iT PicoGreen. Mean, median and SD of normalized 
signals from UC, CD, IBDU and control individuals are presented in  
Table 5. 
 
For probe signal between patient groups comparisons, 1-way analysis of variance (ANOVA) 
was performed. Non-parametric distributed data significances were confirmed using the 
Mann-Whitney-Wilcoxon-test (MWW). Further, Tukey‟s Honestly Significant Differences 
(HSD) Test was done for pairwise comparisons of the patient groups. The calculations were 
done using PASW Statistics 18 (SPSS Inc . Chicago, Illinois, USA). Statistical significance 
was accepted at P< 0,05. 
 
Percent sensitivity (True positive / (true positive + false negative) and specificity (true 
negative/(true negative + false positives) was calculated for significant probe in patients 
versus controls. True positives being patients correctly identified as such, and false negative 
being patients diagnosed as non-IBD. Similarly true negative is non-IBD patients diagnosed 
as such, and false positives are non-IBD patients diagnosed as IBD.  
 
9.2 Results 
 
The probes hybridized to sequences in all cohorts. The signal intensity between probes varied 
greatly. While the IG0028 probe had a mean fluorescent intensity of 289 the Universal probe 
had a mean intensity of 4116. Due to among other weak fluorescent signal, samples were 
removed from the study (Table 4).  
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Table 3 Phylogenetic distribution of the probes. Probes are assumed to cover all species within a 
given family 
GAprobe phylum class order family 
IG0005 Proteobacteria Gammaproteobacteria Enterobacteriales Enterobacteriaceae 
      Aeromondales Aeromonadaceae 
      Pseudomonadales   Pseudomonadaceae 
    Epsilonproteobacteria Camylocacterales Helicobacteraceae 
    Deltaproteobacteria Desulfovibrionales Desulfovibrionaceae 
  Bacteroidetes Flavobacteria Flavobacteriales Flavobacteriaceae 
IG0028 Actinobacteria Actinobacteria  Actinomycetales Actinomycetaceae 
        Corynebacteriaceae 
        Micrococcaceae 
        Streptomycetaceae 
      Bifidobacteriales Bifidobacteriaceae 
AG0006 Actinobacteria Actinobacteria Actinomycetales Actinomycetaceae 
        Corynebacteriaceae 
        Micrococcaceae 
        Streptomycetaceae 
      Bifidobacteriales Bifidobacteriaceae 
    Coriobacteridae Coriobacteriales Coriobacteriaceae 
  Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae 
        Porphyromonadaceae 
        Prevotellaceae 
    Flavobacteria Flavobacteriales Flavobacteriaceae 
    Sphingobacteria Sphingobacteriales Sphingobacteriaceae 
  Firmicutes Bacilli Bacillales Staphylococcus 
      Lactobacillales Lactobacillaceae 
    Clostridia Clostridiales Blautia 
        Clostridiaceae 
        
Clostridiales Family XI. 
Incertae Sedis 
        Eubacteriaceae 
        Lachnospiraceae 
        Peptostreptococcaceae 
        Ruminococcaceae 
    Erysipelotrichi Erysipelotrichales Erysipelotrichaceae 
  Verrucomicrobia Lentisphaerae Victivallales Victivallaceae 
AG0012 Actinobacteria Actinobacteridae Actinomycetales Corynebacteriaceae 
        Streptomycetaceae 
    Coriobacteridae Coriobacteriales Coriobacteriaceae 
  Bacteroidetes Sphingobacteria Sphingobacteriales Sphingobacteriaceae 
  Firmicutes Clostridia Clostridiales Veillonellaceae 
    Bacilli Lactobacillales Lactobacillaceae 
  Fusobacteria Fusobacteria (class) Fusobacterales Fusobacteriaceae 
  Proteobacteria Epsilonproteobacteria Campylobacterales Campylobacteraceae 
    Gammaproteobacteria Pseudomonadales Pseudomonadales 
 
 
9.2.1 Probe quantification 
Mean signal between group variance of the probes is presented in Table 6. In particular a 
significant P-value in probe IG0005 was observed. No significant differences were predicted 
using the Universal, IG0028, AG0006, or AG0012 probe. The MWW test showed similar 
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significance for the IG0005 probe (Asymp Sig. (2-tailed) <0,0005). The Tukey HSD test 
(Table 7) further showed a significant increase in the IG0005 probe in CD patients compared 
to the control group (P=3,56E-4). Although not significant, low P-values was observed 
between CD-UC (P=0,089) and between CD-IBDU (P=0,065). No significant values among 
other patient cohorts were found in IG0028, AG0006 and AG0012 probes (data not shown).  
 
The distribution of IG0005 positive bacteria indicates two distinct peaks (Figure 7). Overall, 
no significant difference in RFU was found between adult and child (ANOVA). However, 
when analyzing the IG0005 probe signals separately (HSD), adult samples showed significant 
difference between CD and controls (p=0,003) while no significant value was found in the 
child cohort relative to controls (p=0,274). Accuracy data for the IG0005 probe was 
calculated (Table 8). According to this sample set the IG0005 used as a diagnostic marker in 
feces, could detect 58,3% of the CD patients. 
Table 4 Valid and removed number of samples 
 Universalprobe  IG0028  IG0005  AG0006  AG0012  
 Valid 218 65 250 253 252 
Removed 39 192 7 4 5 
 
Table 5 Profiling of fecal samples from UC, CD, IBDU and control individuals. Normalized signals. 
 
Universal  IG0028  IG0005  AG0006  AG0012  
UC Mean 10.572 11.452 10.085 9.916 10.953 
 Median 6.393 8.438 7.685 9.168 8.743 
  Std. Deviation 10.5529 8.3777 8.3404 4.0916 6.0368 
CD Mean 11.235 11.540 13.645 11.162 9.961 
 Median 9.960 10.269 15.231 10.212 9.193 
 Std. Deviation 7.1232 6.5789 8.8931 5.3880 4.0141 
IBDU Mean 9.643 10.621 8.651 10.373 10.191 
 Median 7.472 9.555 4.857 8.570 9.310 
  Std. Deviation 7.9973 5.7026 8.1694 6.7009 4.4649 
Control Mean 10.421 13.613 8.153 10.102 10.772 
 Median 9.398 11.176 4.371 9.163 9.909 
  Std. Deviation 7.6171 8.6919 8.0041 3.9719 5.2750 
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 Table 6 The 1-way ANOVA between patient group comparisons. Normalized signals. 
GA probe P = 
Universal 0.884 
IG0028 0,773 
IG0005 0,001 
AG0006 0,444 
AG0012 0,680 
 
 
Table 7 Par wise comparisons of cohorts. Tukey HSD Test for the GA developed probe IG0005 sig. 
values. 
 UC CD IBDU Control 
UC -    
CD 0,089 -   
IBDU 0,891 0,065 -  
Control 0,474 3.56E-4 0,994 - 
 
Table 8 Accuracy data for differentiating Crohn’s disease from controls using the IG0005 probe with a 
cut off value of 12 of normalized values.  
 CD patients Control patients 
Diagnosed as CD 35 28 
Diagnosed as non-
CD 
25 77 
Total number of 
patients 
60 105 
 Sensitivity Specificity 
 58,3% 73,3% 
 
 
9.3 Discussion 
 
The IG0005 probe was found to be significantly increased in CD samples compared to 
controls. The IG0005 probe hybridizes to species in the Enterobacteriaceae, Aeromonadaceae, 
Pseudomonadaceae, Helicobacteraceae, Desulfovibrionaceae, and Flavobacteriaceae family 
(Table 3). The result is supported by previous studies demonstrating increased numbers of 
Gammaproteobacteria in fecal samples from CD patients compared to controls. Significantly, 
increased levels (P<0,05) of Enterobacteriales was observed in a study using digested 16S 
rRNA genes determined by T-RFLP (Andoh, et al., 2009). In a semi –quantitative 
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microbiological study, a significant increase in total score of E. coli in active CD compared to 
UC, inactive CD, and controls was reported (Giaffer, Holdsworth, & Duerden, 1991). Further 
signals from Enterobacteria were detected in all CD fecal samples (17) but none in the healthy 
controls (16) using dot blot hybridization. Further no significant difference in Enterobacteria 
between CD patients in remission and flare was found (Seksik, et al., 2003).  
 
An increased level of Enterobacteriales is also reported by several studies on the IBD mucosa 
(M. Baumgart, et al., 2007; Frank, et al., 2007; Gophna, et al., 2006; Swidsinski, et al., 2002)  
Interestingly the number of E.coli in situ correlated with severity of CD according to a study 
by Baumgart et al. (M. Baumgart, et al., 2007). 
 
Two distinct peaks in the IG0005 histogram (Figure 7) were observed. It might indicate the 
existence of two sub groups of CD patients. One group containing increased amounts of 
IG0005 positive bacteria, the other group with similar amounts as controls. Higher quantities 
of mucosa-associated E. coli have previously been shown in subgroups of Crohn‟s iletis 
(Darfeuille-Michaud, et al., 2004; Martinez-Medina, et al., 2009). It could be hypothesized 
that the CD patients with increased amounts of the IG0005 in the fecal sample, reflect AIEC 
associated with ileal CD. 
 
Diagnostic accuracy for the IG0005 probe was calculated (Table 8). Serologic markers 
(pANCA, ASCA) currently used in diagnosing IBD, have similar sensitivity values. A 
combination of ASCA(+) with pANCA(-) test in CD have been observed with 54,6%, 92,8% 
for sensitivity and specificity, respectively (Reese, et al., 2006).   
 
To be used as a diagnostic marker the specificity should be enhanced. This could be done by 
modifying the IG0005 probe sequence in order to exclude non disease specific bacteria hits. A 
combination of probes on the GA-map
TM
 array could also enhance the diagnostic accuracy for 
CD. The predictive values of the test depend critically on the prevalence of CD in the patients 
being tested (Altman & Bland, 1994). Hence, in a diagnostic setting, the use of certain criteria 
for offering the test to a patient is crucial. 
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Figure 7 Distribution of RFU in the IG0005 probe in CD, UC, IBDU, and control patients 
 
Actinobacteria have previously been found in decreased levels in fecal samples from CD 
patients (Table 1). This was not confirmed in this study. The IG0028, AG0006 and AG0012 
probe which comprise complementarities to Actinobacteria was not observed with 
significantly decreased levels. Only 25% of the samples hybridized with IG0028 probe had 
fluorescent signal intensity above the cut off value. A reevaluation of this probe should be 
performed with optimized probe conditions. In IBD, species within the Firmicutes and 
Bacteroidetes phyla has been observed in decreased and increased levels respectively.  
Especially Clostridia and Bacteroida species have been observed with respectively decreased 
and increased levels in CD.  The AG0006 and AG0012 probe both comprise sequences 
 IBDU  
CD 
Control 
UC 
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complementary to species including Actinobacteria, Bacteroidetes, and Firmicutes phyla 
(Table 3). It could be hypnotized that these probes covers too many bacterial species to reveal 
diagnostic relevant information. 
 
Finally, IG0005 was identified as a candidate probe for the GAmap™ array separating CD 
patients from controls. Nevertheless the results should be confirmed in three parallels as the 
samples in this study were performed once. If confirmed, the probe could add valuable 
information to current diagnostic markers in IBD.  
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10. Examination of commercial potential and patent 
situation of IBD diagnostics 
 
10.1 Commercial potential of improving IBD diagnostics 
10.1.1 Direct and indirect cost in IBD 
Cost of disease studies often includes direct and indirect costs. The indirect health costs 
comprise decreased work productivity and disability while the direct health costs comprise the 
expenditures incurred by the health care system in managing a disease (Camilleri & Williams, 
2000). IBD afflicts young adults during higher education, in their economical productive 
years and careers. Lifelong medication is required and often surgery is necessary leading to 
costs for the society. Direct health care costs are increasing and affects the national health 
care resources (Odes, 2008). 
 
Varying costs are being reported for IBD in different countries and studies, primarily because 
of the high prices in private medical practice. Studies report a total economical burden of CD 
to be $10-15 billion in the US and € 2-16 billion in Europe (Yu, Cabanilla, Wu, Mulani, & 
Chao, 2008). In Germany cost diaries reports a mean 4-week cost per patient of €1425 for CD 
and €1015 for UC. The indirect cost accounted for 64% and 54% for CD and UC respectively 
(Stark, Konig, & Leidl, 2006). Annually CD patients cost ~$18 500 in the United States and 
€2800-6900 in other Western countries. Indirect costs accounted for 28 and 64-69% in the US 
and Europe respectively (Yu, et al., 2008).  
 
10.1.2 Costs of IBD diagnostics 
Each year a high number of patients with functional diseases are suspected to have IBD and 
unnecessarily undergo invasive testing (Suleiman & Sonnenberg, 2001).  
Few studies have investigated the clinical and economical effect on different IBD diagnostic 
strategies. A European cost study with 10 years follow-up, found mean (median) costs of IBD 
diagnostics of €257 (€95) per patient-year. The expenditures were highest in the first patient 
year at €734 per patient. CD diagnostics were significantly more expensive than UC 
diagnostics (Odes, et al., 2006). Similarly a study from the US showed that laboratory 
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procedures accounted for 3.6% ($470) of total health care costs in 12 months after the index 
diagnosis in UC patients (Bickston, Waters, Dabbous, Tang, & Rahman, 2008). 
 
A way to reduce the number of patients who unnecessarily underwent invasive testing 
including colonoscopy and biopsies with histological examination, UGI and SBFT, has been 
indicated in a study by Dubinsky et al. The criteria were a sequential serodiagnostic screening 
of ANCA, ASCA followed by a confirmatory assay comprising pANCA and classical anti-
neutrophil cytoplasmic antibodies (cANCA). In fact the study showed a reduction of 39% of 
invasive testing and similarly a reduction of $550 per patient and an increase of diagnostic 
accuracy of 2%. Additionally the saved costs might be higher as indirect costs and other direct 
costs was not considered (Dubinsky, et al., 2002).  
 
This may also suggest a potential cost-effective role for other IBD diagnosing methods 
depending on the overall cost and accuracy of the test. Initially the price per GA-map ™ test 
is assumed to be in the range between 1 000 and 2 000 NOK ($160-$330) by GA. The 
threshold, in the mentioned study, for a cost-effective role of an initial test before invasive 
testing was $650 and $1205 with base case costs of $53.67 and $146.49 for the existing 
primary and confirmatory assays respectively. Hence the estimated price for the GA-map™ 
test is within the threshold for cost effectiveness of testing before initiating invasive testing. 
Yet, this depends on the prevalence of IBD patients with suggestive symptoms and final 
sensitivity and specificity of the test. The same study found that a 80% reduction of the costs 
of invasive testing or a prevalence of IBD of at least 83%, were the threshold where a 
serodiagnostic strategy no longer was cost-effective (Dubinsky, et al., 2002). Nevertheless 
one should keep in mind that this study is using a price list from year 2000, hence the costs 
probably differ ten years later. Interestingly the primary assay had a sensitivity of 80% and a 
specificity of 50%. Contrary the confirmatory assay had a sensitivity of 65% and a specificity 
of 95% (Dubinsky, et al., 2002).   
 
New non-invasive procedures and inventive ways to distinguish IBS from IBD could also 
lower the overall costs of diagnostics. In fact IBS can be ruled out by a diagnostic probability 
of more than 80% without invasive tests, a study showed. Also, simply by questioning patient 
about symptoms and history in addition to the physical examination a sensitivity and 
specificity of 65% and 100%  respectively of IBS was achieved (Suleiman & Sonnenberg, 
2001).  
  
 
55 
10.2 Specifications in IBD diagnostics 
 
There has been a search for laboratory markers of IBD for the last decades without great 
success (Vermeire, et al., 2006). An ideal marker should have many qualities. In terms of 
performance it should be fast and easy to perform, not invasive, cheap, and reproducible 
between labs and individuals. Beside diagnose IBD it should also assess disease activity and 
severity, and determine the prognosis and therapy response.  
 
Since the symptoms often are subjective the test should objectively assess disease activity and 
severity. It needs to separate non-IBD from IBD (specificity) and correctly identify IBD 
patients as having the disease (sensitivity). If possible it should identify persons with risks of 
IBD.   
 
10.3 Calculated number of patients tested for IBD without having the 
disease  
 
Abdominal pain and diarrhea is a common cause for contacting a physician. Several diseases 
can cause these symptoms, both functional and organic. IBS is a functional GI disorder 
commonly confused with CD and UC. In the western world it is assumed that 10-20% of the 
adults have irritable bowel syndrome (IBS) in which 30% seek medical assistance (Maxion-
Bergemann, Thielecke, Abel, & Bergemann, 2006; Suleiman & Sonnenberg, 2001). 
Nonetheless up to 50% who have IBS undergo examination of the colon to exclude cancer 
and IBD (Gunnarsson & Simren, 2008).  
 
Number of patient tested for IBD without having the disease is not easily available. Rather it 
can be assumed that the number of patients is several times higher than new patients 
diagnosed with IBD annually. The European mean incidence rates per 100 000 was 5.6 for 
CD and 10.4 for UC in patients aged 15-64 (Binder, 2004). Roughly calculated this means 
more than 115 000 persons are diagnosed with IBD in Europe annually, (assuming a 
European population of 731 000 000 ) (Europe, 2010).  Moreover, 22-43 million Europeans 
with IBS seek medical assistance each year. Likewise US with its 308 million inhabitants 
have similar incidence rates meaning 50,000 new IBD patients each year. Similarly it can be 
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calculated that 9-18 million persons in the US suffering from IBS seeks medical assistance 
each year.  
 
10.3.1 Symptoms and final diagnosis after endoscopy in children 
A study comprising children showed correlations between main symptom before examination 
and final diagnosis after endoscopy. Of the children with blood in the stool as the main 
symptom, 49% did not have a GI disease, 28% had IBD, while the resuming had other 
diseases. Of the children presenting with chronically diarrhea as the main symptom 30% did 
not have a GI disease, 21% had IBD, 16% had celiac disease and the remaining had other 
diseases. Of the children with abdominal pain as main symptom 19% was diagnosed with 
unspecific abdominal pain as their final diagnosis, 9,5 % had IBD, 5,4% had IBS, 19% had 
celiac disease (Perminow, Rydning, Jacobsen, & Frigessi, 2000). 
 
10.4 The usability of new diagnostic tools in different settings of IBD 
 
In IBD, mainly four goals for initiation of a diagnostic procedure exist. These comprise 
establishing of the disease (IBD), assigning of CD or UC, guiding therapeutic decisions, and 
detect complications that require treatment (Nikolaus & Schreiber, 2007). Challenges on all 
these stages exist. The diagnostic accuracy of a test decides on which level of the diagnostic 
course it can be used. If the diagnostic sensitivity is high it might be used as a primary test. If 
the diagnostic specificity is high it could be used confirmatory.  
 
10.4.1 Establishing of the disease  
As previously described, research results indicate a difference in stool microbiota of IBD 
patients relatively to those of healthy persons. The biggest market for an IBD test is as a 
screening test. Though, even if the test is as good as or even better than endoscopy in 
diagnosing IBD, an invasive procedure might be necessary in some cases, in order of 
excluding other diseases like GI cancer and celiac disease. A positive IBD test might have to 
be confirmed by an invasive test to reveal the extent of the disease. But if the test could 
separate a substantial number of IBS patient from IBD, the test could be useful. Further 
investigation is needed to find indications for performing such a screening test. 
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10.4.2 Assigning of CD or UC 
Proper treatment of IBD is important. Knowing that 10% of patients first diagnosed as UC 
five years later are rediagnosed as CD or discounted (Packey & Sartor, 2008) there is a need 
for a new method. Contrary 10-15% of the CD patients are being reclassified as UC during 
the first year (E F Stange, et al., 2006). Further, 10-15% of the IBD patients remain 
unclassified (Nikolaus & Schreiber, 2007). Additionally, about 5-10% of patients undergoing 
ileo-pouch anal anastomosis surgery with a diagnosis of UC at the time of surgery are 
subsequently diagnosed with CD (Fleshner, Vasiliauskas, Melmed, & Targan, 2008). Some 
results indicate different microbiota in stools of IBD patients especially CD patients (Chapter 
8). 
 
10.4.3 Guiding therapeutic decisions 
A test using microbiota might also be useful in guiding of therapeutic decisions. Mesalamine 
(5-ASA) lowers sulfide concentrations (Packey & Sartor, 2008). Higher concentrations of 
hydrogen sulfide producing bacteria have been reported in the microbiota of active UC 
patients compared to those in remission (Sokol, et al., 2008). UC patients are warranted to 
take follow-up endoscopies to find the time to stop taking mesalamine and start maintenance 
therapy or as a outcome parameter for biological therapy (Nikolaus & Schreiber, 2007). If the 
GI microbiota is proved to respond to different therapy, a GA-map
TM
 array could be costume 
made to guide therapeutic decisions.  
 
A US study showed that medical expenditures (sum of inpatient, outpatient, emergency room, 
and prescription drug spending) accounted for $18,963 and $15,020 for CD and UC 
respectively.  Infliximab entered the arena for treating severely affected CD patients in 1998. 
UC patients now also receive Infliximab. There are an increasingly trend to introduce 
Infliximab earlier in the therapeutic regimen as it reduces hospitalization and surgery. 
Infliximab is very expensive. It can cost $19,000 to $22,000 a year per patient (Gibson, et al., 
2008). Thus a test guiding the physician in which patients who should receive biologic 
therapy, when to start, predicting response, when to end therapy and when to change to other 
types of therapy, is desirable. 
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10.4.4 Detect complications that require treatment 
Charges for hospitalization, surgery and biological therapy comprises a large percentage of 
the health care costs in IBD. Keeping a patient in remission therefore means more than 
increased quality of life to the patients, it also reduces the costs related to medical and 
surgical hospitalization (Odes, 2008). Indeed a study showed that patients with severe CD had 
3-9 fold higher costs than patients in remission (Yu, et al., 2008). A test improving 
therapeutic guiding and detection of complications would enhance health related quality of 
life for IBD patients and reduce the health care costs.  
 
 
10.5 Profits and research budget 
 
When developing a commercial diagnostic test, it is important to have an economic 
framework for research and development. Estimated profits for a patent period can be used as 
an indication of commercial potential and what should be invested in research and 
development. The following presentation of possible scenarios includes estimates, risks and 
uncertainties. In order to estimate the profit of the GA-map
TM 
test, a business plan must be 
developed. However, this was out of the scope of this thesis, so a simplified method for 
budget estimates is presented.  
 
 
Figure 8 Method for estimating research budget and ROI. *50% of profit in  
the normal case scenario for the R&D period is calculated as a research budget 
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To estimate the profit, research budget and ROI for a diagnostic test, a calculation method 
was developed (Figure 8). 
 
10.5.1 Market  
Forecasting the market share of a future product is a challenge and depends on several factors 
such as how much funding will be spent on marketing. What market share can GA expect? As 
an example, a Norwegian company, NorDiag ASA, is selling a genetic test for early diagnosis 
of GI cancer based on human DNA in fecal samples (Genefec
TM
). The test was launched in 
2002 and four years later the market share was 11% in Norway, 2 % in the Nordic countries 
and 0,09% in Europe (Nordiag, 2010). Another comparison is an American company Myriad 
Genetics Inc. with their breast cancer diagnostic test, BRACAnalysis. The test is used by 10% 
of the American obstetrician/gynecologist (Seekingalpha, 2010). The market share depends 
on the performance of the diagnostic test. In this calculation it is assumed that the test perform 
as good as or better than endoscopy. Further an assumption was that it can be sold as a kit for 
screening IBD by differentiate between IBD and IBS and be used to avoid endoscopies 
especially in IBS patients. The potential market for GA-map
TM
 is presented in Table 9 and 
three different scenarios based on different market share are presented in Table 11. 
 
 
Table 9 Market for an IBD screening test 
 
Number of 
patients yearly 
Number of 
patients in a 20 
year period* 
Patients diagnosed with IBD in USA and Europe¤ 165 000 3 300 000 
Endoscopies performed on IBS patients in USA and 
Europe§ 
15 500 000 
310 000 000 
Sum market 15 665 000 313 300 000 
¤ Based on chapter 10.3 
§ Assuming 50% of the calculated IBS patients (10.3) undergo an endoscopy examination (Gunnarsson & 
Simren, 2008) 
*Period of a patent 
 
10.5.2 Price 
A recommended way to determine the price for a new inventive product is 10% of the 
expenditures of the existing alternatives (Monrad-Krohn, Personal communication). But 
factors like the degree of reimbursement from European national health authorities or 
American insurance companies, can affect the price. The recommended price in Table 10 does 
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not include labor costs. Even though additional costs as hospitalization may be saved as a 
result of new diagnostics, such cost was not included in the calculation of the price. Price and 
calculated profits are presented in Table 10. 
 
 
Table 10 Calculated profits pr GA-map
TM
 test sold 
Recommended price for GA-map
TM 
kit*  €70 
Estimated marginal costs of a GA-map
TM
 kit ** €20 
Gross margin§ €50 
Estimated share of fixed cost (30%)  €15 
Profits per GA-map
TM 
kit €35 
*Assuming the existing diagnostic alternative corresponds to expenditures the first patient year, €734 (Odes, et 
al., 2006) Labor is not included 
**Cost of producing one GA-map test is assumed to cost €10 by GA, but in this calculation €20 is used 
§Gross margin: Price – marginal costs 
 
 
10.5.3 Profit estimates 
The margin depends on a number of factors e.g. competition, volume, turnover rate and 
business talent of the entrepreneurs (Utgård & Refsum, 2007). The competition further 
heavily depends on the patent situation. Additionally, the marginal costs depend on the 
complexity of the test. Few probes in e.g. GA-map
TM,
 result in lower marginal costs.  
Price, margin and there by profit will be highest in the first years, but might decrease as 
competing diagnostic tools become available.  
 
Table 11 Scenarios for a patent period 
 
Worst case scenario 
0,01% market share in 
Europe and USA 
Normal case scenario 
0,5% market share in 
Europe and USA 
Best case scenario 
10% market share in 
Europe and USA 
Tests sold to IBD patients 20 years§ 330 16 500 330 000 
Tests sold to IBS patients 20 years§ 31 000 1 550 000 31 000 000 
Sum tests sold next 20 years§ 31 330 1 566 500 31 330 000 
    
Yearly profit *  €55 000 €2,7 Mill €55 Mill 
Sum profit the next 20 years*  1,1 Mill €55 Mill €1 100 Mill 
 
§Number of tests is based on Table 9 
*Profits are based on Table 10 
 
10.5.4 Investing in research 
In order to assure reasonable ROI a calculation of the threshold for research budget should be 
performed. The period of development is assumed to be three years for the diagnostic test. 
Additionally 2-3 years are necessary for an approval from Food and Drug Administration 
(FDA). In most situations a long period must be calculated to penetrate the market, but in this 
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calculation a simplified model was used. If one further assumes that 50% of the profits for 
five years are budgeted on research and development, this totally accounts for €7 Mill. in the 
normal case scenario (Table 11). In return this leads to a 38% ROI of research (grossly 
simplified calculations for guidance only). This is considered as acceptable numbers to 
recommend commercialization.  
 
10.6 Examination patent situation in IBD diagnostics 
 
 
In biotechnology patents plays an important role. Particularly it is important for the 
advancement of innovation. Investors can get a security for their funds and may be 
compensated for high development costs.  
 
The US is traditionally one of the main markets for biotechnology and therefore all 
development within the US patent law, are of interest to the biotechnology industry 
worldwide. Europe has also become an important biotech market. Since 1977 it has been 
possible to apply for a joint patent in Europe (EPO, 2010b). Biotechnology is a field of 
constant development, and patenting of some parts of it is controversial. Especially the 
patenting of genes and genetic diagnostics has been publicly discussed. Some of these patents 
have resulted in litigations. Modification of the patent law or how it is interpreted may be a 
result. Biotechnology companies may benefit from following this development. A description 
of the European and American patent system is presented in Appendix C. 
 
The nature of the patent system allows others to learn what has already been invented. 
Resources can be saved and competitors or potential business partners might be found by 
searching for patents and patent application in patent databases. An indication whether a 
diagnostic test for IBD based on fecal microbiota has a commercial potential may be found by 
search in patent databases.  
 
To find new inventive IBD diagnostic methods, search in European and American patent 
databases were performed.  
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10.5.5 Issued US patents 
To find an optimal search profile an iterative search process was performed (Appendix D). 
The query comprised words in the title and abstract of the documents in the database. In 
addition application date was set to the last ten years. The following search was performed in 
the United States Patent and Trademark Office (USPTO) Patent full-text and image database 
(http://patft.uspto.gov/netahtml/PTO/search-adv.htm): ((((ABST/"inflammatory bowel 
disease" OR ABST/Crohn) OR ABST/"Ulcerative colitis") AND ABST/diagn$ OR 
ABST/analy$ OR ABST/detect$ AND APD/20000101->20100803).  54 patents were found ( 
 
Appendix H), in which 36 were referring to IBD diagnostics. The remaining patents were 
primarily related to treatment of IBD or treatment and diagnostics of non-IBD diseases.  
 
Even though most patents do not specify a certain biologic material for detecting IBD, a 
majority of the found patents might utilize blood samples. In a few patents the use of fecal 
samples in the diagnosis of IBD patients is claimed. The claimed fecal samples are primarily 
used for lactoferrin detection. Lactoferrin is a detection marker for leukocytes in fecal 
samples, and elevated levels are associated with IBD in contrast to IBS (James Hunter Boone, 
David Maxwell Lyerly, Tracy Dale Wilkins, & Richard Littleton Guerrant, 2009; Boone, 
2007). Interestingly exhaled gas after digestion of a controlled amount of radio labeled sugars 
is also used in some of the patents (Lin & Pimentel, 2004; Lin & Pimentel, 2006). Another 
patent use sera for the detection of antibodies for Fusobacteria varium to diagnose UC 
patients, (Sato, Okusa, & Okayasu, 2010). Other patents comprise detection of sequences 
from an unknown microbial organism from the human gut (Braun & Sutton, 2001, 2004). 
None of these patents used 16S rRNA in diagnostics; in fact few of the patents were related to 
detection of bacteria (Table 12). 
 
Nevertheless, human gene and protein sequences and antibodies like ASCA, ANCA, anti-
outer membrane protein C (anti-OmpC) and anti-I2 antibody, accounted for most of the 
relevant US patents (Table 12). The gene patents comprising presence or absence of 
haplotypes, mutations and gene expression. 
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10.5.6 US patent application 
The same search profile as previously described was used for the USPTO patent application 
full text and image database (http://appft.uspto.gov/netahtml/PTO/search-adv.html) with the 
exception of application date, APD/20050101->20100803. The query resulted in 101 hits 
(Appendix F). Of the 101 patent applications 74 were considered relevant.  
 
The vast majority of the applications use serum and blood for IBD diagnostics, but colon 
biopsy, urine, and stool samples are also used. Among the most represented patent 
applications found are human gene or polypeptide and antibodies to ASCA, pANCA, outer 
membrane protein C (OmpC), anti I-2 polypeptide, anti-CBir1. Among the gene expression 
applications are methods predicting responsiveness of infliximab treatment in UC patients 
(US20090054253, US20080293582). Another inventive application was prostaglandin in 
urine which can be measured to separate pre-remission from the remission state of UC 
(Fujiwara, Isao, & Hayashi, 2009). 
 
A US patent application claiming the use of rRNA sequences in order of detecting bacteria 
was found, “Composition and methods for diagnosing colon disorders, US 20090197249”. 
The invention relates to diagnosing, prognosticating, or monitoring disease progression of 
IBD by detecting bacterial rRNA genes in mucosal tissue or lumen samples. Among the 
species are Acinetobacter sp. of Pseudomonas group, Bacteroides sp. of the Bacteroides 
Group, Ruminoccocus sp. of the C. Coccoides Group, Clostridium sp. of the Clostridium 
botulinum Group and Enterococus sp. of the Enterococcus Group. Among other E. coli is 
used in the diagnosis of pouchitis (Gillevet, 2009). If issued, this patent application, filed by 
the US George Mason University November 1, 2005, could reduce the freedom to operate in 
IBD diagnostics using fecal microbiota. 
 
Another application comprised an assay for nucleic acids of two bacteria genes namely serine 
protease autotransporter (SPATE) family and antigen 43 (Ag43). Ag43 is a surface adhesin 
promoting bacterial biofilm formation due to cell-to-cell aggregation. SPATEs are potentially 
important in IBD because they exhibit functions like degradation of the barrier function of the 
gut, and cleavage of proteins in the enterocyte, which are phenotypes associated with IBD. 
Conserved and specific regions to virulent enteric strains of E.coli can be detected in fecal 
samples as a biomarker of IBD (Krause & Bernstein, 2009).  
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10.5.7 European patent documents 
Relevant patents and patent applications in Europe were found by search in the EPO‟s patent 
database Esp@cenet (http://ep.espacenet.com/advancedSearch?locale=en_EP). The database 
has some limitations compared to the USPTO database. Only one member of each patent 
family is shown and a smaller number of words are allowed in the search query. As a result, a 
limited number of European patent documents have identified in this study. The worldwide 
database was chosen for the following query (Appendix E ): "inflammatory bowel disease?" 
or crohn* or "ulcerative colitis" (diagnos* or analys* or detect* or determin*) in the title or 
abstract AND EP as the publication number AND 2005:2010 as the publication date. Twenty 
applications were found in which two were written in a foreign language and was not 
considered (Appendix G).  
Table 12 Number of patents using various markers 
 Esp@cenet US application US patent 
Antibody 7 29 9 
Cytokine 1 4 1 
Human gene** and/or 
polypeptide 
7 31 12 
Human protein 2 6 8 
Bacterial protein  1  
Metabolite 1 1  
Gas 1 2 2 
Cell*  3 1 
Glycans§ 1 2  
Bacterial gene** and/or 
polypeptide 
1 3 4 
Other 1 2 2 
The number of markers do not sum up to number of patents due to multiple markers used in several of the patent 
documents. 
** “Gene” also comprising nucleic acid sequences, alleles, gene expression etc. 
* Cells e.g: antigen presenting cell that expresses polypeptides or T cells that are specific for cells expressing 
such polypeptides. 
§ Glycans e.g.: oligosaccharide in immunoglobulin G (IgG), O-linked glycans etc. 
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Several ways of diagnosing IBD are presented in the considered applications (Table 12). 
Antibodies, gene expression, gene variants and genotypes are represented in most documents. 
 
The expression of anti-CBir, an antibody against flagellin, is associated with Crohn disease 
but not UC and is found in about 40% of patients with Crohn disease who are ASCA-
negative. In addition the detection of inflammation markers in biopsy, prostaglandin 
metabolite in urine, glycans and oligo saccharide in blood are claimed ways to diagnose IBD.  
Interestingly lactoferrin measured in fecal samples obtained at two different times, are 
claimed to improve the detection of IBD compared to one measurement (J. H.. Boone, D. M. 
Lyerly, T. D.  Wilkins, & R.L. Guerrant, 2009). 
 
10.5.8 Current focus in patenting of IBD diagnostics 
Few patents related to bacterial genes or polypeptides (Table 12) were found. Rather the 
current focus in IBD diagnostics seems to be human genes or polypeptides/polynucleotides, 
and antibodies. A trend seems to be an increase of applications claiming methods with the use 
of gene expression and human DNA variations which are more represented than among the 
found issued patents. Also an increased interest of antibodies is indicated by number of found 
patent applications. 
 
10.5.9 Patent assignees in IBD diagnostics 
Two American assignees, Cedars-Sinai Medical Center and Prometheus Laboratories Inc, 
have in particular numerous patents and applications covering both treatment and diagnostics. 
Cedars-Sinai Medical Center have a broad field of diagnostics and have patents comprising 
the detection of the CARD15 gene, interleukins, small intestinal bacterial overgrowth by 
measuring exhaled gas, antibodies like ASCA, pANCA, IgA anti-OmpC. The focus on 
antibodies and other interest concerning IBD diagnostics and therapy is shared by 
Prometheus. Their patent documents were found in all three databases (Appendix F, 
Appendix G,  
 
Appendix H). Especially interesting are their invention using an algorithm based on the 
levels of IBD markers like ANCA, ASCA-IgA, ASCA-IgG, anti-OmpC antibody, anti-I2 
antibody, and pANCA in serum in IBD diagnostics. With low sensitivity and specificity one 
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by one these antibodies gives a complex picture of IBD. But calculated simultaneously they 
may add valuable information in the diagnostics of IBD. It is stated that the algorithm also 
can be trained to detect complications and the efficacy of therapeutic treatment. 
The autumn 2010 Prometheus and Tarrot Laboratories, a business unit of Cedars-Sinai 
Medical Center, announced exclusive agreement for CD treatment, to focus on identifying 
genetic or serologic markers associated with clinical responses to anti-TNF (Prometheuslabs). 
 
Another company with several patents is Techlab Inc. which uses lactoferrin, ASCA and 
ANCA in feces. Lately the company Exagen diagnostics Inc. have filed several applications 
on distinguishing IBD and IBS by gene expression. Of all the relevant US patents nine have 
universities as assignees and six of the relevant US patent applications had a university as 
assignee. Patents from such an institution might be easier to license compared to that of 
corporations.  
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11. Recommendations for future development in IBD 
diagnostics based on the GA-mapTM technology 
 
11.1 Future development of IBD tests 
 
11.1.1 Recommended sample sets 
To find suitable fecal markers, comprehensive and well designed studies needs to be 
accomplished. Today most culture independent studies on fecal microbiota as markers of IBD 
include few patients and controls. The reproducibility of relative amounts of bacteria in IBD 
is also poor between articles. This might be due to different sample set used as well as 
methods. Patient samples are often from long term patients on medications. These are 
circumstances which can lead to modification of the fecal microbiota. Hence samples from 
these patients are probably not ideal for studies with the goal of early detection of IBD or 
assigning CD or UC. Compared to these studies, the sample set used in the present study are 
unique in quantity and quality. Access to these samples and sample data should be secured by 
an agreement with Ahus. But other sample sets should also be considered. Since microbiota 
stability is low in CD, revealing the temporal differences in fecal samples from such patients 
would be interesting.  
 
11.1.2 Target selection 
In this thesis, the CD patients could be detected with sensitivity and specificity of 58,3% and 
73,3 % respectively, using one single probe. Adding more probes could enhance these values 
to match or even be better than those of existing non-invasive tests. Research should be done 
to reveal a potential etiologic effect of organisms detected by IG0005. Further the effect of 
serologic status, disease activity, disease location, and CARD15 genotype should be analyzed 
in the relation to increased IG0005 levels. 
 
The IG0005 probe was designed to many species. Probes designed to lower phylogenetic 
levels within this probe should be tested. Similarly the other probes tested in this thesis should 
also be redesigned to species at lower phylogenetic levels. 
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Furthermore, other possible targets uniformly reported (presented in chapter 8, Appendix A 
and Appendix B) should be tested on a patient material. 
 
11.1.3 Type of test to be developed 
Based on the high numbers of IBS patients compared to IBD patients, a diagnostic test should 
focus on differentiating IBD from IBS, in order to exclude IBS patients from having 
endoscopy unnecessarily. The need for performing other laboratory tests in advance of an 
IBD test based on fecal microbiota should be investigated. Further the level of the tests 
sensitivity and specificity is crucial for its use. If GA-map™ should be used as a screening 
test the specificity have to be high. The prevalence of IBD in the patient population (IBD and 
e.g. IBS patients) tested has to be limited to avoid false positive. 
 
The fecal microbiota of children differs substantially from that of the adults (Palmer, Bik, 
DiGiulio, Relman, & Brown, 2007). Hence different tests to children and adult have to be 
developed.  
 
11.1.4 Challenges of GA-mapTM  
Number of probes 
Using the GA-map™ technology, multiple probes can be detected at once. If only a few 
probes are necessary to diagnose IBD, cheaper and more efficient technologies than GA-
map™ should be utilized. The threshold of the number of probes in which GA-map™ no 
longer is reasonable should be investigated.  
 
Bacterial virulence 
The 16s rRNA PCR do not differentiate between strains or identify functional alterations. 
Therefore, virulence factors, toxin production and the reciprocal regulation of bacterial and 
host epithelial genes must be investigated by other methods (Packey & Sartor, 2008). An 
opportunity is to measure 16S rRNA genes followed by virulence genes.  
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Price and performance 
The preliminary price for a test is set to €110-€230 ($160-$330) by GA. This is within the 
range for what is acceptable before an endoscopy procedure, but considerably more expensive 
than the recommended price per test (€70) presented in this thesis. The price per test should 
therefore be reconsidered. 
 
Estimated time of GA-map
TM
 is in the range 24 to 48 hours and experienced personnel are 
required. Reproducibility of the test remains to be established. To achieve high reproducibility 
GA may use only a few centers which specialize in doing the analysis. 
 
It is questionable whether a test solely based on microbiota totally can replace the use of 
endoscopy in IBD. To give a proper therapeutic management it is required to find to which 
extend the inflammation of the intestine is. 
 
Challenges using the 16S rRNA gene 
One of the advantages of using the 16S rRNA gene for identification of bacteria is that 
cultivation is not necessary. Nonetheless, it has been stated that only concentrations above 10
3
 
cfu/uL can be reliably detected techniques by using universal 16S rRNA PCR (Swidsinski, et 
al., 2002). Another challenge with the 16S rRNA gene is that multiple copies of this gene are 
often present in a bacterium. These copies can differ in sequence, leading to identification of 
multiple ribotypes for a single organism (Case, et al., 2007). 
 
Furthermore it has been stated that it might be more useful to identify bacterial antigens 
against which the immune cells of CD and UC patients react, rather than to determine shifts in 
community composition (Tannock, 2008).  
 
 
11.2 Commercial remarks  
 
According to EPO, significant commercial potential depends on a number of factors (Table 
13) (EPO, 2008). Beside, products are categorized as exceptional, good or unexceptional. The 
author of this thesis has the opinion that a diagnostic test for IBD based on fecal microbiota 
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represents an exceptional product which can set new diagnostic standards and possibly 
dominate the market.  
 
 
Table 13 Significant commercial potential  
Most companies look for 
(EPO, 2008): 
The thesis author‟s comment related to GA-mapTM IBD test 
Strong IP or monopoly 
situation 
 
GA should secure strong IP comprising patents, trademarks, 
copyright, secrecy and non-disclosure agreements. Additionally 
monitoring patent infringements is important. Several patents 
related to improved IBD diagnostics have been identified in this 
thesis. However, few of the patents were related to IBD 
diagnostics using fecal microbiota.  
Good return on 
investment 
 
In the normal case scenario a yearly profit of €2,7 Mill. was 
calculated. The return of investment is estimated to be €1,35Mill. 
yearly the first five years followed by €2,7Mill. the subsequent 
years. This result in 38% ROI which is reasonable. 
A clear, low-risk route 
to market 
 
Intensive research is needed in most diagnostic industries, 
representing a higher risk route to market.  
Something consumers 
will want in preference 
to competing products 
 
Depending on analytic sensitivity and specificity, it is assumed 
that patients, doctors and health authorities prefer a diagnostic test 
based on fecal microbiota as an alternative to invasive tests such 
as endoscopy. If a diagnostic alternative utilizing markers in 
blood is launched, it will probably outperform a fecal test. People 
prefer not to work with feces (Ingrid Alfheim, BMI, Personal 
communication). 
 
 
All methods diagnosing IBD are potential competitors of a GA-map
TM
 IBD test. Search in 
patent databases should be done frequently. One reason is the possibility to file a complaining 
against applications (see Appendix C). The US patent application filed by US George Mason 
University is an example. A complain against this application should be considered. 
Otherwise, licenses can usually be bought to affordable prices, especially from universities. 
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11.2.1 Patent strategy 
Different patent strategies exist. A company may be taken more seriously financially and get 
a higher credibility by patenting even small inventions. This type of patenting might function 
as a warning to small companies speculating in starting IBD diagnostics. Larger companies 
may buy a license from the patentee. Patent applications on single probe sequences for the 
identification of intestinal bacteria in IBD diagnostics, might be a challenge to be issued 
because of previously publicized literature. As an alternative GA might patent a combination 
of probes to the IBD GA-map
TM 
test, even though infringement of this type of patent are 
easily avoided. Based on the results of this thesis it is recommended to consider applying for a 
patent comprising the IG0005 probe. 
 
Patents have many assets other than just being a protective measure. Based on renewal data 
the general mean value of a patent have been estimated to $78 000 in the US. Further patents 
issued to small patentees are much less valuable than those issued to large corporations. The 
cause is probably because economical force is needed to litigate. Litigated patents are more 
valuable, as are highly cited patents (Bessen, 2008). 
 
11.2.2 Additional search in patent databases to be performed 
Search for international applications filed under the PCT of the World Intellectual Property 
Organization (WIPO) was not performed in the master thesis. Search in WIPO‟s patent 
database, Patentscope, could add valuable information.  
 
The European patent database, esp@cenet, is not meant for detailed search. As only one 
member of each patent family is displayed, more thorough search for European issued patents 
should be done. Access to more complex databases is commercially available. 
 
This thesis did not include patent search for specific technologies which could replace the 
GA-map
TM 
technology. Hence such search should be performed to further identify the 
freedom to operate. 
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12. Conclusion 
 
 
This thesis presents an overview of GI bacteria as potential biologic markers in diagnostics of 
IBD. Results from the lab study revealed a significantly increased level of the IG0005 probe 
in CD patients relative to controls. The probe was increased in 58,3% of the CD patients 
showing similar sensitivity as the existing serum markers. As a result of this thesis, the 
IG0005 probe, detecting species in the Proteobacteria and Bacteroidetes phyla, is suggested as 
a new diagnostic marker in IBD diagnostics. Applying for a patent protection of the probe is 
recommended. 
 
Supported by the evaluations done in this thesis, it is concluded that a screening test based on 
fecal microbiota separating IBD from IBS, has a commercial potential. However, if the test 
shall dominate the market it needs to show similar or better diagnostic accuracy as endoscopy.  
 
Several patent documents related to IBD diagnostics was found in European and American 
patent databases. Hardly any patents or patent applications claimed the use of fecal microbiota 
in order of diagnosing IBD. Nevertheless, a US patent application from the George Mason 
University comprised claims which could affect the freedom to operate to methods using fecal 
microbiota in IBD diagnostics.  
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 Appendix A Variation of bacterial organisms in fecal 
samples from IBD patients vs. controls 
Organism Class 
IBD, CD or 
UC 
compared 
to controls 
Techniques used in the 
article Refferences 
bifidobacteria Actinobacteria decreased 
standard culture, semi-
quantitative method (Giaffer, et al., 1991) 
bifidobacteria Actinobacteria decreased TTGE, dot blot hyb (Seksik, et al., 2003) 
bifidobacteria Actinobacteria decreased 
quantitative real-time 
PCR (Sokol, et al., 2009) 
Lactobacillus Bacilli decreased 
standard culture, semi-
quantitative method (Giaffer, et al., 1991) 
Bacteroides fragilis Bacteroida decreased DGGE (Scanlan, et al., 2006) 
Clostiridium cluster IV Clostridia decreased T-RFLP (16S rRNA) (Andoh, et al., 2009) 
Clostiridium cluster XI Clostridia decreased T-RFLP (16S rRNA) (Andoh, et al., 2009) 
Clostridium family Clostridia decreased T-RFLP (16S rRNA) (Andoh, et al., 2009) 
Clostiridium subcluster XIVa Clostridia decreased T-RFLP (16S rRNA) (Andoh, et al., 2009) 
Clostridium coccoides Clostridia decreased TTGE, dot blot hyb (Seksik, et al., 2003) 
Clostridium leptum group Clostridia decreased 
quantitative real-time 
PCR (Sokol, et al., 2009) 
Clostridium coccoides group Clostridia decreased 
quantitative real-time 
PCR (Sokol, et al., 2009) 
Faecalibacterium prausnitzii Clostridia decreased 
quantitative real-time 
PCR (Sokol, et al., 2009) 
Clostridium coccoides group 
(ClusterXIVa) Clostridia decreased cloning, sequencing (Mangin, et al., 2004) 
Clostridium leptum group Clostridia decreased cloning, sequencing (Mangin, et al., 2004) 
Clostridium coccoides Clostridia decreased DGGE (Scanlan, et al., 2006) 
Clostridium leptum    Clostridia decreased DGGE (Scanlan, et al., 2006) 
Clostridium leptum group Clostridia decreased 
Clone library, macroarray, 
sequencing , FISH (Manichanh, et al., 2006) 
Clostridium coccoides Clostridia decreased FISH + flow cytometry (Sokol, et al., 2006) 
Clostridium leptum Clostridia decreased FISH + flow cytometry (Sokol, et al., 2006) 
Bacteroides   phylum decreased TTGE, dot blot hyb (Seksik, et al., 2003) 
Firmicutes phylum phylum decreased 
quantitative real-time 
PCR (Sokol, et al., 2009) 
Firmicutes/Bacteroidetes ratio phylum decreased 
quantitative real-time 
PCR (Sokol, et al., 2009) 
Firmicutes phylum decreased 
Clone library, macroarray, 
sequencing , FISH (Manichanh, et al., 2006) 
Bacteroides phylum decreased standard culture (Krook, et al., 1981) 
Total bacteria  decreased FISH + flow cytometry (Sokol, et al., 2006) 
Additivity  decreased FISH + flow cytometry (Sokol, et al., 2006) 
Gram-positive  decreased FISH + flow cytometry (Sokol, et al., 2006) 
Bifidobacterium subgroup Actinobacteria equal T-RFLP (16S rRNA) (Andoh, et al., 2009) 
bifidobacteria Actinobacteria equal DGGE (Scanlan, et al., 2006) 
Actinobacteria Actinobacteria equal 
Clone library, macroarray, 
sequencing , FISH (Manichanh, et al., 2006) 
Atopobium group Actinobacteria equal FISH + flow cytometry (Sokol, et al., 2006) 
Bifidobacterium subgroup Actinobacteria equal FISH + flow cytometry (Sokol, et al., 2006) 
Lactobacillales Bacilli equal T-RFLP (16S rRNA) (Andoh, et al., 2009) 
viridans streptococci Bacilli equal 
standard culture, semi-
quantitative method (Giaffer, et al., 1991) 
Lactobacillus Bacilli equal TTGE, dot blot hyb (Seksik, et al., 2003) 
Lactobacillus johnsonii Bacilli equal 
OFRG (Oligonucleotide 
Fingerprinting of rRNA 
Genes) (Ye, et al., 2008) 
Prevotella   Bacteroida equal T-RFLP (16S rRNA) (Andoh, et al., 2009) 
  
Organism Class 
IBD, CD or 
UC 
compared 
to controls 
Techniques used in the 
article Refferences 
Bacteroides fragilis Bacteroida equal 
standard culture, semi-
quantitative method (Giaffer, et al., 1991) 
Bacteroides vulgatus Bacteroida equal 
standard culture, semi-
quantitative method (Giaffer, et al., 1991) 
Bacteroidetes phylum Bacteroida equal 
quantitative real-time 
PCR (Sokol, et al., 2009) 
Clostridia Clostridia equal 
standard culture, semi-
quantitative method (Giaffer, et al., 1991) 
Clostridium leptum Clostridia equal TTGE, dot blot hyb (Seksik, et al., 2003) 
Clostridium coccoides group Clostridia equal 
Clone library, macroarray, 
sequencing , FISH (Manichanh, et al., 2006) 
Klebsiella Gammaproteobacteria equal 
standard culture, semi-
quantitative method (Giaffer, et al., 1991) 
Proteus spp Gammaproteobacteria equal 
standard culture, semi-
quantitative method (Giaffer, et al., 1991) 
E.coli Gammaproteobacteria equal 
quantitative real-time 
PCR (Sokol, et al., 2009) 
E. Coli Gammaproteobacteria equal standard culture (Krook, et al., 1981) 
Enterobacteria Gammaproteobacteria equal FISH + flow cytometry (Sokol, et al., 2006) 
Bacteroides phylum equal 
standard culture, semi-
quantitative method (Giaffer, et al., 1991) 
Bacteroides phylum equal 
Clone library, macroarray, 
sequencing , FISH (Manichanh, et al., 2006) 
Bacteroides phylum equal FISH + flow cytometry (Sokol, et al., 2006) 
anaerobic flora  equal 
standard culture, semi-
quantitative method (Giaffer, et al., 1991) 
yeast  equal 
standard culture, semi-
quantitative method (Giaffer, et al., 1991) 
Total number of bacteriaI  equal 
quantitative real-time 
PCR (Sokol, et al., 2009) 
aerobic bacteria  equal standard culture (Krook, et al., 1981) 
anaerobic bacteria  equal standard culture (Krook, et al., 1981) 
Gram-negative  equal FISH + flow cytometry (Sokol, et al., 2006) 
Enterococcus faecalis Bacilli increased* 
standard culture, semi-
quantitative method (Giaffer, et al., 1991) 
Bacteroides vulgatus (and 
relatives) Bacteroida increased cloning, sequencing (Mangin, et al., 2004) 
Unclassified 
Porphyromonadaceae Bacteroida increased 
Clone library, macroarray, 
sequencing , FISH (Manichanh, et al., 2006) 
Enterobacteriales Gammaproteobacteria increased T-RFLP (16S rRNA) (Andoh, et al., 2009) 
E. coli Gammaproteobacteria increased 
standard culture, semi-
quantitative method (Giaffer, et al., 1991) 
Enterobacteria Gammaproteobacteria increased TTGE, dot blot hyb (Seksik, et al., 2003) 
Bacteroides phylum increased T-RFLP (16S rRNA) (Andoh, et al., 2009) 
total aerobe  increased 
standard culture, semi-
quantitative method (Giaffer, et al., 1991) 
E. faecalis Bacilli 
increased / 
decreased* 
quantitative real-time 
PCR (Sokol, et al., 2009) 
Prevotella subgroup Bacteroida 
Increased 
number of 
ribotypes** 
Clone library, macroarray, 
sequencing , FISH (Manichanh, et al., 2006) 
Atopobium group Actinobacteria 
Reduced 
number of 
ribotypes** 
Clone library, macroarray, 
sequencing , FISH (Manichanh, et al., 2006) 
Bacteroides fragilis subgroup Bacteroida 
Reduced 
number of 
ribotypes** 
Clone library, macroarray, 
sequencing , FISH (Manichanh, et al., 2006) 
"Other Firmicutes groups  
Reduced 
number of 
ribotypes** 
Clone library, macroarray, 
sequencing , FISH (Manichanh, et al., 2006) 
Bifidobacterium subgroup Actinobacteria 
Similar 
number of 
ribotypes** 
Clone library, macroarray, 
sequencing , FISH (Manichanh, et al., 2006) 
Bacteroides distasonis 
subgroup Bacteroida 
Similar 
number of 
ribotypes** 
Clone library, macroarray, 
sequencing , FISH (Manichanh, et al., 2006) 
  
Organism Class 
IBD, CD or 
UC 
compared 
to controls 
Techniques used in the 
article Refferences 
Delta proteobacteria Delta proteobacteria 
Similar 
number of 
ribotypes** 
Clone library, macroarray, 
sequencing , FISH (Manichanh, et al., 2006) 
Gamma proteobacteria Gammaproteobacteria 
Similar 
number of 
ribotypes** 
Clone library, macroarray, 
sequencing , FISH (Manichanh, et al., 2006) 
Proteobacteria phylum 
Similar 
number of 
ribotypes** 
Clone library, macroarray, 
sequencing , FISH (Manichanh, et al., 2006) 
*Isolated from significantly fewer patients with active CD than quiescent CD or UC. 
**Ribotypes:  Organisms whose 16S rRNA sequences are at least 97% identical are commonly considered to be 
the same ribotype (Stackebrandt & Goebel, 1994) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Appendix B Variation of bacterial organisms in mucosal 
samples from IBD patients vs. controls 
Organism Class 
IBD, CD or 
UC 
compared 
to controls 
Techniques used in the 
article Refferences 
Butyrate-producing bacterium 
A2–A165 - decreased 
Library construction, 
sequence analysis, Q-
PCR (Frank, et al., 2007) 
Bacteroidetes Bacteroida decreased 
Library construction, 
sequence analysis, Q-
PCR (Frank, et al., 2007) 
Alistipes sp. WAL 8169 
Bacteroidetes; Bacteroidales Bacteroida decreased 
Library construction, 
sequence analysis, Q-
PCR (Frank, et al., 2007) 
Bacterium mpn-isolate group 5 
Bacteroidetes; Bacteroidales Bacteroida decreased 
Library construction, 
sequence analysis, Q-
PCR (Frank, et al., 2007) 
Bacteroides thetaiotaomicron 
Bacteroidetes; Bacteroidales Bacteroida decreased 
Library construction, 
sequence analysis, Q-
PCR (Frank, et al., 2007) 
Bacteroides acidofaciens Bacteroida decreased cloning, sequencing (Prindiville, et al., 2004) 
Prevotella nigrescens Bacteroida decreased cloning, sequencing (Prindiville, et al., 2004) 
Bacteroides_5 (Bacteroides 
fragilis) Bacteroida decreased cloning, sequencing (Prindiville, et al., 2004) 
Bacterium mpn-isolate group 
18 Firmicutes; 
Lachnospiraceae Clostridia decreased 
Library construction, 
sequence analysis, Q-
PCR (Frank, et al., 2007) 
Bacterium mpn-isolate group 
19 Firmicutes; 
Lachnospiraceae Clostridia decreased 
Library construction, 
sequence analysis, Q-
PCR (Frank, et al., 2007) 
Butyrate-producing bacterium 
L2—L7 Firmicutes; 
Lachnospiraceae Clostridia decreased 
Library construction, 
sequence analysis, Q-
PCR (Frank, et al., 2007) 
Butyrate-producing bacterium 
SR1/1 Firmicutes; 
Lachnospiraceae Clostridia decreased 
Library construction, 
sequence analysis, Q-
PCR (Frank, et al., 2007) 
Butyrate-producing bacterium 
SS2/1 Firmicutes; 
Lachnospiraceae Clostridia decreased 
Library construction, 
sequence analysis, Q-
PCR (Frank, et al., 2007) 
Clostridium nexile Firmicutes; 
Lachnospiraceae Clostridia decreased 
Library construction, 
sequence analysis, Q-
PCR (Frank, et al., 2007) 
Firmicutes; Lachnospiraceae Clostridia decreased 
Library construction, 
sequence analysis, Q-
PCR (Frank, et al., 2007) 
Lachnospiraceae Clostridia decreased 
Library construction, 
sequence analysis, Q-
PCR (Frank, et al., 2007) 
Firmicutes phylum decreased cloning, sequencing (Gophna, et al., 2006) 
total bacteria  decreased 
Library construction, 
sequence analysis, Q-
PCR (Frank, et al., 2007) 
Lachnospiraceae bacterium 
A4 (Gp66) Clostridia decreased 
OFRG (Oligonucleotide 
Fingerprinting of rRNA 
Genes) (Ye, et al., 2008) 
Lachnospiraceae bacterium 
A4 (GpC2) Clostridia decreased 
OFRG (Oligonucleotide 
Fingerprinting of rRNA 
Genes) (Ye, et al., 2008) 
Barnesiella viscericola Bacteroida decreased 
OFRG (Oligonucleotide 
Fingerprinting of rRNA 
Genes) (Ye, et al., 2008) 
Clostridium leptum Clostridia decreased cloning, sequencing (Prindiville, et al., 2004) 
Akkermansia muciniphilia Verrucomicrobiae decreased 
OFRG (Oligonucleotide 
Fingerprinting of rRNA 
Genes) (Ye, et al., 2008) 
Bacteroides phylum dominant 
FISH + in situ 
quantification of mucosal 
bacteria (Swidsinski, et al., 2005) 
  
Organism Class 
IBD, CD or 
UC 
compared 
to controls 
Techniques used in the 
article Refferences 
Bacteroides vulgatus Bacteroida equal cloning, sequencing (Gophna, et al., 2006) 
E.coli Gammaproteobacteria equal cloning, sequencing (Gophna, et al., 2006) 
Gamma proteobacteria Gammaproteobacteria equal cloning, sequencing (Gophna, et al., 2006) 
Enterobacteriaceae Gammaproteobacteria equal 
Library construction, 
sequence analysis, Q-
PCR (Frank, et al., 2007) 
Gamma proteobacteria Gammaproteobacteria equal FISH   (Swidsinski, et al., 2008 
Bacteroides phylum equal FISH   (Swidsinski, et al., 2002 
Total bacteria (universal probe) equal FISH   (Swidsinski, et al., 2013 
Acidimicrobidae Ellin7143 
Actinobacteria Actinobacteria increased 
Library construction, 
sequence analysis, Q-
PCR (Frank, et al., 2007) 
Actinobacteria Actinobacteria increased 
Library construction, 
sequence analysis, Q-
PCR (Frank, et al., 2007) 
Actinobacterium GWS-BW-
H99 Actinobacteria 62.5 Actinobacteria increased 
Library construction, 
sequence analysis, Q-
PCR (Frank, et al., 2007) 
Actinomyces oxydans 
Actinobacteria 48.9 Actinobacteria increased 
Library construction, 
sequence analysis, Q-
PCR (Frank, et al., 2007) 
Nocardioides sp. NS/27 
Actinobacteria 61.8 Actinobacteria increased 
Library construction, 
sequence analysis, Q-
PCR (Frank, et al., 2007) 
Drinking-water bacterium Y7 
Alphaproteobacteria 76.0 Alphaproteobacteria increased 
Library construction, 
sequence analysis, Q-
PCR (Frank, et al., 2007) 
Novosphingobium sp. K39 
Alphaproteobacteria 57.8 Alphaproteobacteria increased 
Library construction, 
sequence analysis, Q-
PCR (Frank, et al., 2007) 
Sphingomonas sp. AO1 
Alphaproteobacteria 49.6 Alphaproteobacteria increased 
Library construction, 
sequence analysis, Q-
PCR (Frank, et al., 2007) 
Bacillus licheniformis 
Firmicutes; Bacilli 49.7 Bacilli increased 
Library construction, 
sequence analysis, Q-
PCR (Frank, et al., 2007) 
Enterococcus faecium Bacilli increased cloning, sequencing (Prindiville, et al., 2004) 
Bacteroides fragilis Bacteroida increased cloning, sequencing (Gophna, et al., 2006) 
Bacteroidetes Bacteroida increased cloning, sequencing (Gophna, et al., 2006) 
Bacteroides distasonis  Bacteroida increased 
FISH + in situ 
quantification of mucosal 
bacteria (Swidsinski, et al., 2005) 
Bacteroides fragilis  Bacteroida increased 
FISH + in situ 
quantification of mucosal 
bacteria (Swidsinski, et al., 2005) 
Bacteroides-Prevotella  Bacteroida increased 
FISH + in situ 
quantification of mucosal 
bacteria (Swidsinski, et al., 2005) 
Bacteroides-Prevotella, 
Bacteroides fragilis Bacteroida increased 
FISH + in situ 
quantification of mucosal 
bacteria (Swidsinski, et al., 2005) 
Ruminococcus gnavus  Clostridia increased cloning, sequencing (Prindiville, et al., 2004) 
Eubacterium rectale  Clostridia increased 
FISH + in situ 
quantification of mucosal 
bacteria (Swidsinski, et al., 2005) 
Fusobacterium prausnitzii  Clostridia increased 
FISH + in situ 
quantification of mucosal 
bacteria (Swidsinski, et al., 2005) 
Clostridium Clostridia increased 
quantitative PCR + 
sequence analysis (Swidsinski, et al., 2005 
Peptostreptococci Clostridia increased 
quantitative PCR + 
sequence analysis (Swidsinski, et al., 2009 
Klebsiella pneumonia Gammaproteobacteria increased cloning, sequencing (Gophna, et al., 2006) 
Acientobacter junii Gammaproteobacteria increased cloning, sequencing (Gophna, et al., 2006) 
Gamma proteobacterium Gammaproteobacteria increased Library construction, (Frank, et al., 2007) 
  
Organism Class 
IBD, CD or 
UC 
compared 
to controls 
Techniques used in the 
article Refferences 
DD103 Gammaproteobacteria 
50.9 
sequence analysis, Q-
PCR 
Pseudomonas straminea 
Betaproteobacteria 53.7 Gammaproteobacteria increased 
Library construction, 
sequence analysis, Q-
PCR (Frank, et al., 2007) 
Enterobacteriaceae Gammaproteobacteria increased Culture (Swidsinski, et al., 2006 
Enterobacteriaceae Gammaproteobacteria increased 
quantitative PCR + 
sequence analysis (Swidsinski, et al., 2007 
Proteobacteria phylum increased cloning, sequencing (Gophna, et al., 2006) 
Proteobacteria phylum increased 
Library construction, 
sequence analysis, Q-
PCR (Frank, et al., 2007) 
Bacteroides acidofaciens Bacteroida increased 
OFRG (Oligonucleotide 
Fingerprinting of rRNA 
Genes) (Ye, et al., 2008) 
Streptococci Bacilli increased 
quantitative PCR + 
sequence analysis (Swidsinski, et al., 2010 
Bacteroides phylum increased Culture (Swidsinski, et al., 2003 
Bacteroides phylum increased 
quantitative PCR + 
sequence analysis (Swidsinski, et al., 2004 
Total aerobes  increased Culture (Swidsinski, et al., 2011 
Total anaerobes increased Culture (Swidsinski, et al., 2012 
Bacteroides vulgatus Bacteroida increased 
OFRG (Oligonucleotide 
Fingerprinting of rRNA 
Genes) (Ye, et al., 2008) 
Ruminococcus schinkii (GpC1) Clostridia increased 
OFRG (Oligonucleotide 
Fingerprinting of rRNA 
Genes) (Ye, et al., 2008) 
Clostridium ramosum Clostridia increased 
OFRG (Oligonucleotide 
Fingerprinting of rRNA 
Genes) (Ye, et al., 2008) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Appendix C American and European patent legislation  
 
Patenting is a way to give inventors exclusive rights for their invention for a limited period of 
time, usually 20 years. The intention of the patent system is to promote advances in science 
and technology and give new and useful products and processes which the citizens can benefit 
from (Elliott, 2007). To achieve this, the patentee needs to disclose a description of the 
invention in the application. In this way inventions are available to the public allowing further 
development. In return the inventor can prevent others from making, using, selling, or 
distributing the patented invention without permission (WIPO, 2010). In addition to the 
disclosed description a patent contains claims, drawings, and abstract. The claims are the most 
essential part of the patent. Only what is set forth in the claims is protected by the patent 
(Elliott, 2007).  
 
C.1  European and US patents 
 
The United States Patent and Trademark Office (USPTO) are issuing patents in the US. In 
Europe it is possible to obtain patent in the thirty seven member countries of the European 
Patent Convention by filing one single application to the European Patent Office (EPO) (EPO, 
2010b). EPO is not an EU institution. 
 
C.1.1 Interpretation of the US and European Patent law 
The key laws for the approval of U.S. patents are 35 USC Section 101, 102, 103, and 112. 
They describe requirement as inventions patentable, novelty, non-obviousness and 
specification respectively. Generally the invention or discovery must be novel, useful and 
non-obvious compared to earlier inventions. But an improvement of an earlier invention is 
also patentable (35 USC section 101).  
 
In the United States so-called "everything under the sun made by man" is patentable. This is 
often cited although it is misleading. The full quote reads “A person may have “invented” a 
machine or a manufacture, which may include anything under the sun made by man but it is 
  
not necessarily patentable under section 101 unless the conditions of the title are fulfilled 
(H.R. Rep. No. 1923, 82d Cong., 2d Sess. 6 (1952). 
 
In 2001 Utility examination guidelines were published by the USPTO. The guidelines were 
made to assist patent examiners and do not have the force and effect of the law. Several tests 
from the Supreme Court were adopted. E.g it requires that the application contains at least one 
specific, substantial and credible use of the invention. Additionally the guidelines stress the 
utility to be credible to a person skilled in the art. The claimed inventions must have a 
practical purpose, a real world use in currently available form. This excludes a utility as non-
specific utilities as e.g. “landfill” or “throw-away”. Further, an object which is only useful of 
further research is not considered to have a substantial utility. Developments occurring after 
the filing date of an application are of no significance regarding what one skilled in the art 
believed as of the filing date (USPTO, 2001). Patent laws in the US have a broad view of 
what is applicable and the judiciary does not require that an invention will be better than 
previous inventions (Baillie, Richards, & Cord, 2009). It is not a requirement in law that the 
inventor may know how or why the invention works (USPTO, 2001).  
 
European Patent Convention (EPC) is a legal system in which European patents are granted. 
The patentable subject must have a technical character, be new, involve an inventive step, be 
susceptible of industrial application, and be sufficiently disclosed to the skilled person. 
Mathematical methods or formulae, computer programs and business methods are some 
innovations which are not patentable under the EPC. Especially discoveries, methods for 
performing mental acts, new plant or animal varieties or inventions contrary to order public or 
morality as cloning of human life are excluded from patentability in Article 52 (2). 
 
C.1.2  The legal basis and differences of the European and US patent 
system 
The European and US patent laws are slightly different. The legal basis of the patent system 
in US is set forth in The Constitution Article 1, Section 8, Clause 8 ”The Congress shall have 
power (...) to promote the Progress of Science and useful Arts, by securing for limited Times 
to Authors and Inventors the exclusive Right to their respective Writings and discoveries”. In 
Europe discoveries are not considered patentable and it is expected an inventive step. 
According to the European Patent Convention (EPC) Article 52 paragraph 1:  ”European 
  
patents shall be granted for any inventions, in all fields of technology, provided that they are 
new, involve an inventive step and are susceptible of industrial application”.  
 
In the US a patent might be granted to the first person who invents while the first to apply for 
an invention can get a patent in Europe (USPTO, 2009). Furthermore, in the US inventors can 
freely publish and sell the invention for one year prior to the application (35 USC 102). 
However, by doing so the invention is not suitable for a patent in Europe (Article-54-EPC, 
2007). The US patent law requires that the best way to practice the invention is described in 
the patent application (35 USC 112). In contrast, the Europe patent law requires a description 
of at least one way of practicing the invention. But it is not required that it is the best way to 
perform the invention (Article-83-EPC, 2007). In this way the patentee can keep some secrets 
of the invention in the European system.  
 
C.1.3   Validity and Opposition opportunities of granted patents 
Patents granted by the EPO automatically become valid in each of the member counties and 
get the same rights as a national patent in those EPC countries. During the first nine months 
after a patent is granted under the EPC it is possible to anyone to start a procedure against the 
patent to get it annulled in all the countries at once. Patent disputes are handled within the 
EPO and not in the courts. The patentee and the opponents can debate by exchanging written 
arguments followed by an oral proceeding. The Opposition Division (OD) of the EPO will 
take a decision based on these arguments. Both parties can appeal the decision. Once again 
written and oral arguments are made before a final decision is made by the Board of Appeal. 
Later, nine months after granting, separate proceedings in each country are necessary to get a 
patent annulled (EPO, 2008).  
 
Because the US patent law is a federal statue a patent granted in the US are valid in all states 
of the USA. Anyone can complain about the validity of a granted patent. Then it is up to the 
patentee to give reasons to the USPTO examiner why the patent should remain valid. The 
opponent is not a part of this discussion. Appeals for patent decisions are made by the Federal 
Circuit Court of Appeals, which is a special court for patent cases. United States Supreme 
Court is the highest federal court in the United States, it has ultimate authority to interpret and 
decide questions of federal laws including the federal constitution (Berg, s.a.). Judge adopted 
  
here will also be important for the interpretation of the patent law. As an example genes have 
been patentable since the case of Diamond v. Chakrabarty in 1980, (Falciola, 2000).  
 
C.1.4  Description 
According to both EPC and US patent law, the application needs to have a description 
disclosed in such a way that an educated and trained person can perform the invention 
(35USC 112, EPC article 83). Nowadays patent specifications are filed with as little as 
possible detailed information about the invention. Contrary, background information about 
possible usage is vast, especially in biotechnology and pharmaceutical industry. This is done 
in order to avoid narrowing of the patent protection by the examiner or the courts. As a result 
claims and applications are complex and huge resulting in a nearly impossible job for 
examiners to find what the inventor has done to advance the technology. Now applicants are 
asked to describe more clearly what is invented. 
 
C.2  Patentability of Genes 
 
The patentability of genes is a controversial topic. It is widely discussed how the genetic 
information should be treated to serve the greater good raising questions touching upon 
innovation policy, social policy, medical ethics, economic policy, and the ownership of what 
some view as our common heritage. When the US Company Celera Genomics managed to 
map the whole human genome and later attempted to patent it, it led to public outrage. The 
US President Clinton and UK Prime Minister Blair jointly condemned it, stating that the 
human genome belongs to no man and that it is a resource that should be freely available to 
all researchers (Palombi, 2009). This is however not yet been adopted by the US and 
European patent law.  
 
C.2.1  Patentability of genes in the US 
Currently USPTO have a practice in which patents on genes are granted as long as the DNA 
is in an isolated form, making it no different from any other chemical compound. However 
many feels that this way to interpret the law is a “lawyer‟s trick”.  On the other hand other 
claims that isolated human DNA constitutes patentable subject matter and fears that banning 
  
this would negatively affect innovation and scientific research of human therapeutics and 
personalized medicine (Barton, 2006).  
 
RNA and DNA sequences can be patented if they meet the statutory requirements for 
patentability. Every patent holder on a diagnostic sequence or marker may block others from 
using the sequence. Licensing of sequences is possible, but it is not required to provide a 
license (Barton, 2006). A DNA sequence itself is not patentable because the sequence only 
describes information about a molecule. An isolated and purified DNA molecule, however, 
may be patentable because it is considered a composition of matter. A patent application on 
genes is granted by the general rules in which the use of the isolated gene must be presented 
in the claims. If other develops new and not obvious ways to use the patented sequence, they 
have opportunity to patent the new method (USPTO, 2001).  
 
Recently the Court of Appeals for the Federal Circuit (CAFC) supported USPTO in the 
decision that expressed sequence tags (EST) are DNA fragments without specific and 
substantial utility (in re Fisher) (Elliott, 2007).  
 
C.2.2 Patentability of genes in EPC countries 
 
In 1998 the European Parliament and Council stated that: the human body, at the various 
stages of its formation and development, and the simple discovery of one of its elements, 
including the sequence or partial sequence of a gene,...‟‟ are not patentable but that „„an 
element isolated from the human body or otherwise produced by means of a technical 
process, including the sequence or partial sequence of a gene may constitute a patentable 
invention, even if the structure of that element is identical to that of a natural element‟‟. This 
directive was taken up in the EPC under Rule 29 of the implementing regulations. Discoveries 
which are non patentable subject matter under article 52 (2) should be interpreted in the light 
of rule 29 (2). 
 
C.2.3 Obviousness of gene sequences 
 
If a claimed DNA molecule is obvious or not, depends on whether a molecule that has the 
given structure of DNA is obvious to an educated and trained person at the time the invention 
  
was made. The amount of work load done to describe the DNA molecule is not significant in 
order for a sequence to be patentable (USPTO, 2001). “Patentability shall not be negatived by 
the manner in which the invention was made” (Section 103 US). In other words patent on 
gene sequences can not be denied because of the method used was of previous art according 
to US law. In contrast EPO requires what is referred to as “an inventive step”. A gene 
discovered by using known methodologies does not provide an inventive step and hence is 
obvious. If the isolated gene possess unexpected or improved features the Board of Appeal 
can accept an inventive step (Nelson, 2004).  
 
The EPO Guidelines state that to ”find a substance freely occurring in nature is also a mere 
discovery and therefore unpatentable. However, if a substance found in nature first has to be 
isolated from its surroundings and a process for obtaining it is developed, that process is 
patentable. Moreover, if the substance can be properly characterized either by its structure, by 
the process by which it is obtained or by other parameters and is ”new” in the sense of having 
no previously recognized existence, then the substance may be patentable (EPO, 2010a).  
 
 
C.2.3 Patentability of Gene Probes 
In the Utility Guide lines of 2001 the USPTO attempts that genes are patentable, but raise the 
need for specific, substantial, and credible utility for gene fragments. Further probes are also 
patentable, but in order to satisfy the utility requirement it needs to be specific, substantial, 
and credible. A nucleic acid fragment claimed a utility as a probe does not pass the specific 
utility test. In order to pass, it is necessary to identify the particular gene. Further it is not 
sufficiently specific to describe a probe as diagnostic- the condition diagnosed also needs to 
be identified.  A substantial utility is one that defines a “real world” use. For example a probe 
is not patentable if it is only useful for further research. But a probe which is used for a 
diagnostic purpose like IBD is defined as substantial useful (USPTO, 2001).  
 
Whether a probe is credible, depends if a person skilled in the art would accept the invention 
as currently available for such use. One of the core questions of the patent examiner is if 
additional knowledge is necessary before invention can be used. A nucleic acid used as a 
probe for the 16S rRNA would likely satisfy the credibility requirement (Duke L. 2001). 
 
  
Appendix D Iterative patent search process in the USPTO Patent 
Full-Text and Image Database and Patent Application Full Text 
and Image Database 
Search query number of hits   Comment 
APD/1/1/2000->8/3/2010 AND ABST/"inflammatory bowel disease" 
AND ABST/diagn$ 15 
Few hits, use additional 
disease expressions 
((((ABST/"inflammatory bowel disease" OR ABST/Crohn) OR 
ABST/"Ulcerative colitis") AND ABST/diagn$) AND APD/20000101-
>20100803): 49 
Try additional expressions 
related to diagnose 
(ABST/"inflammatory bowel disease" OR ABST/Crohn OR 
ABST/"Ulcerative colitis") AND (ABST/diagn$ OR ABST/analy$) AND 
(APD/20000101->20100803) 50 
Try additional expressions 
related to diagnose 
 (ABST/"inflammatory bowel disease" OR ABST/Crohn OR 
ABST/"Ulcerative colitis") AND (ABST/diagn$ OR ABST/analy$ OR 
ABST/detect$) AND (APD/1/1/2000->8/3/2010) 56 OK 
ABST: Abstract, APD:Application date, $:Truncation mark  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Appendix E Iterative patent search process for the EPO’s 
Esp@cnet database  
Search query 
number of hits 
Comment 
"inflammatory bowel disease?" or crohn* or "ulcerative colitis" in the 
title or abstract AND EP as the publication number AND 2005:2010 
as the publication date 192 Too many 
("inflammatory bowel disease?" or crohn* or "ulcerative colitis") AND 
diagnos* in the title or abstract AND EP as the publication number 
AND 2005:2010 as the publication date 14 Too few? 
("inflammatory bowel disease?" or crohn* or "ulcerative colitis") AND 
(diagnos* or analy*) in the title or abstract AND EP as the publication 
number AND 2005:2010 as the publication date 15 Too few? 
("inflammatory bowel disease?" or crohn* or "ulcerative colitis") 
(diagnos* or analy* or detect*) in the title or abstract AND EP as the 
publication number AND 2005:2010 as the publication date 20 Ok 
 
* Truncation; multiple digits,?;Truncation; one digit 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Appendix F Patents found in the USPTO patent application 
database 
PUB. 
APP. 
NO. 
Title Assignee 
 
Description Specimen Type of 
marker 
200901
97249 
COMPOSITIONS AND 
METHODS FOR 
DIAGNOSING COLON 
DISORDERS 
 GEORGE MASON 
UNIVERSITY 
Fairfax 
VA 
*** The invention relates to microbial 
community present in the digestive 
tract and lumen in normal subjects and 
IBD. It also relates to diagnosing, to 
determine a therapeutic regimen, to 
determine the onset of active disease 
and to determine the predisposition to 
the disease. 
Colonic 
mucosal 
tissue, lumen 
sample 
Bacterial 
gene and/or 
polypeptide 
201001
29838 
METHODS FOR 
PREDICTION OF 
INFLAMMATORY BOWEL 
DISEASE (IBD) USING 
SEROLOGIC MARKERS 
 Prometheus 
Laboratories Inc. 
San Diego 
CA 
** Classifying a sample from a pediatric 
individual as an IBD sample using a 
statistical algorithm and/or empirical 
data 
Sample Antibodies 
200902
21007 
DIAGNOSIS, 
PREVENTION AND 
TREATMENT OF 
CROHN'S DISEASE 
USING THE OMPC 
ANTIGEN 
 Cedars-Sinai Medical 
Center 
Los Angeles 
CA 
** Diagnosing CD in a subject by 
determining the presence or absence 
or IgA anti-OmpC antibodies 
Serum Antibodies 
200902
21006 
DIAGNOSIS, 
PREVENTION AND 
TREATMENT OF 
CROHN'S DISEASE 
USING THE OMPC 
ANTIGEN 
Cedars-Sinai Medical 
Los Angeles 
CA 
** Diagnosing CD in a subject by 
determining the presence or absence 
or IgA anti-OmpC antibodies 
Serum Antibodies 
200801
82280 
METHODS OF 
DIAGNOSING 
INFLAMMATORY BOWEL 
DISEASE 
Prometheus 
Laboratories Inc. 
San Diego 
CA 
** Differentiating between a clinical 
subtype of IBD such as CD and UC 
using a statistical algorithm and/or 
empirical data. 
Serum, 
plasma, 
whole blood, 
and stool. 
Antibodies 
200801
31439 
METHODS OF 
DIAGNOSING 
INFLAMMATORY BOWEL 
DISEASE 
 Prometheus 
Laboratories Inc. 
San Diego 
CA 
** Differentiating between a clinical 
subtype of IBD such as CD and UC 
using a statistical algorithm and/or 
empirical data. 
Serum, 
plasma, 
whole blood, 
and stool. 
Antibodies 
200701
96931 
THERAPEUTIC AGENT 
FOR ULCERATIVE 
COLITIS 
 Nobuhiro SATO 
Suginami-Ku 
JP 
** A method for making a diagnosis of 
UC caused by Fusobacterium varium 
in a patient. 
Serum Antibodies 
200701
61065 
DIAGNOSIS, 
PREVENTION AND 
TREATMENT OF 
CROHN'S DISEASE 
USING THE OmpC 
ANTIGEN 
Cedars-Sinai Medical 
Los Angeles 
CA 
** Diagnosing CD in a subject by 
determining the presence or absence 
or IgA anti-OmpC antibodies 
Serum Antibodies 
200602
05014 
Method for diagnosing and 
prognosing inflammatory 
bowel disease and Crohn's 
disease 
 -  ** Diagnosing and prognosing IBD or CD  
by measuring levels of antibodies to 
glycans in a biological sample. 
Sample Antibodies 
200601
54276 
Methods of diagnosing 
inflammatory bowel disease 
 Prometheus 
Laboratories Inc. 
San Diego 
CA 
** Differentiating between a clinical 
subtype of IBD such as CD and UC 
using a statistical algorithm and/or 
empirical data. 
Serum Antibodies 
200600
83686 
Therapeutic agent for 
ulcerative colitis 
 Sato; Nobuhiro 
Suginami-Ku 
JP 
** A method for making a diagnosis of 
UC caused by Fusobacterium varium 
in a patient. 
Serum Antibodies 
200600
03392 
Methods of diagnosing 
inflammatory bowel disease 
 Prometheus 
Laboratories Inc. 
San Diego 
CA 
** Differentiating between a clinical 
subtype of IBD such as CD and UC 
using a statistical algorithm and/or 
empirical data. 
Serum Antibodies 
201000
99124 
Method for Diagnosing 
Diseases Based on Levels 
of Anti-Glycan Antibodies 
 Glycominds, LTD 
Global Park 
IL 
** Diagnosing CD or anti-phospholipid 
syndrome by measuring levels of 
antibodies to glycans in a biological 
sample 
Biological 
sample 
Antibody 
  
PUB. 
APP. 
NO. 
Title Assignee 
 
Description Specimen Type of 
marker 
201000
21455 
METHODS FOR 
DIAGNOSIS AND 
TREATMENT OF 
CROHN'S DISEASE 
CEDARS-SINAI 
MEDICAL CENTER 
Los Angeles 
CA 
** Diagnosis of CD is accomplished by 
determining the presence of the anti-
CBir1 expression or determining the 
presence of anti-CBir1 expression and 
detection of the presence of pANCA. 
Treatment methods include antigen-
directed therapy targeting CBir1 
flagellin and manipulating the bacteria 
in the colon and/or small intestine. 
Sample Antibody 
201000
15600 
METHOD FOR 
DIAGNOSING AND 
TREATING CROHN'S 
DISEASE 
 -  ** Diagnosing or determining 
predisposition to CD by detecting 
overexpression of the CD66c receptor. 
Biological 
sample 
Antibody 
200903
05267 
MICROBIAL MARKERS OF 
INFLAMMATORY BOWEL 
DISEASE  
 UNIVERSITY OF 
MANITOBA 
Winnipeg 
MB 
** Method for diagnosing IBD or 
determining susceptibility to 
developing IBD, comprising the step of 
assaying for serine protease 
autotransporter (SPATE) or antigen 43 
(Ag43) or both, in an enteric bacteria-
containing sample from the subject, 
wherein the presence of SPATE in the 
sample indicates that the subject has 
IBD or is susceptible to developing 
IBD. 
Enteric 
bacteria-
containing 
sample; 
tissue, stool 
sample, or 
intestinal 
wash. 
Bacterial 
gene and/or 
polypeptide 
200901
42778 
COMPOSITIONS AND 
METHODS FOR THE 
THERAPY AND 
DIAGNOSIS OF 
INFLAMMATORY BOWEL 
DISEASE  
 Corixa Corporation 
Seattle 
WA 
** Diagnosis, prevention and/or treatment 
of IBD by bacterial polypeptides, 
immunogenic portions thereof, 
polynucleotides that encode such 
polypeptides, antigen presenting cell 
that expresses such polypeptides, and 
T cells that are specific for cells 
expressing such polypeptides 
Biological 
sample 
Bacterial 
gene and/or 
polypeptide, 
cells, 
antibody 
200903
11694 
Splice variants of human IL-
23 receptor (IL-23R) mRNA 
and use of a delta 9 isoform 
in predicting inflammatory 
bowel diseases 
 Medical Diagnostic 
Laboratoiries, LLC 
Hamilton 
NJ 
** Method of predicting CD by measuring 
.DELTA.9 isoform of IL-23R. 
Biological 
sample, 
blood, colon 
tissue 
Cytokine 
200602
05012 
Diagnostic test  Meso Scale 
Technologies, LLC 
Gaithersburg 
MD 
** Diagnostic tests for the identification of 
the IBDs by the detection of cytokines 
Sample Cytokines 
200903
11707 
O-GLYCANS AS 
DIAGNOSTIC MARKERS 
FOR INFLAMMATORY 
BOWEL DISEASE  
 - ** Diagnostic methods for inflammatory 
bowel disorders comprising assessing 
expression, structure and/or function of 
O-glycans in a sample from a subject, 
as well as antibodies to such 
molecules. 
Colon 
lavage, a 
fecal sample, 
a colorectal 
swab, or a 
colon tissue 
sample. 
Glycans 
200901
86371 
METHOD FOR 
DETERMINATION OF 
INFLAMMATORY BOWEL 
DISEASE  
OSAKA UNIVERSITY 
Suita-shi, Osaka 
JP 
** Differential diagnosis of IBD which 
comprises, determining the relative 
ratio of G0 oligosaccharide 
Serum Glycans 
201001
90162 
METHODS OF USING 
SINGLE NUCLEOTIDE 
POLYMORPHISMS IN THE 
TL1A GENE TO PREDICT 
OR DIAGNOSE 
INFLAMMATORY BOWEL 
DISEASE  
 CEDARS-SINAI 
MEDICAL CENTER 
Los Angeles 
CA 
** Diagnosing or predicting susceptibility 
to IBD by determining the presence or 
absence of genetic variants in the 
TNFSF15 locus. 
Biological 
sample 
Human gene 
and/or 
polypeptide 
201001
84967 
Biomarkers for inflammatory 
bowel disease and Irritable 
Bowel Syndrome 
 EXAGEN 
DIAGNOSTICS, INC. 
Albuquerque 
NM 
** Diagnosing or distinguishing IBD and 
irritable bowel syndrome by expression 
levels of certain genes. 
Blood Human gene 
and/or 
polypeptide 
201001
84625 
Biomarkers for inflammatory 
bowel disease and Irritable 
Bowel Syndrome 
 EXAGEN 
DIAGNOSTICS, INC. 
Albuquerque 
NM 
** Diagnosing and/or distinguishing IBD 
and irritable bowel syndrome by 
expression levels of certain genes 
Blood Human gene 
and/or 
polypeptide 
201001
84050 
DIAGNOSIS AND 
TREATMENT OF 
INFLAMMATORY BOWEL 
DISEASE IN THE PUERTO 
RICAN POPULATION 
 CEDARS-SINAI 
MEDICAL CENTER 
Los Angeles 
CA 
** Diagnosis and treatment of IBD by 
determining the presence or absence 
of a risk variant of different gene loci 
Biological 
sample 
Human gene 
and/or 
polypeptide 
  
PUB. 
APP. 
NO. 
Title Assignee 
 
Description Specimen Type of 
marker 
201001
52062 
Biomarkers for inflammatory 
bowel disease and Irritable 
Bowel Syndrome 
 EXAGEN 
DIAGNOSTICS, INC. 
Albuquerque 
NM 
** Diagnosing and/or distinguishing IBD 
and irritable bowel syndrome by 
expression levels of certain genes 
Blood Human gene 
and/or 
polypeptide 
201000
99083 
CROHN DISEASE 
SUSCEPTIBILITY GENE 
 GENIZON 
BIOSCIENCES INC 
VILLE ST-LAURENT 
CA 
** The ATG1611 gene and 
pharmacogenomics, diagnostics, 
patient therapy and the use of genetic 
haplotype information to predict an 
individual's susceptibility to CD and/or 
their response to a particular drug or 
drugs. 
Biological 
sample 
Human gene 
and/or 
polypeptide 
201000
81129 
Genemap of the human 
genes associated with 
crohn's disease 
 -  ** Pharmacogenomics, diagnostics, 
patient therapy and the use of genetic 
haplotype information to predict an 
individual's susceptibility to CD and 
their response to drugs, so that drugs 
tailored to genetic differences of 
population groups may be developed 
and administered to the appropriate 
population. 
Sample Human gene 
and/or 
polypeptide 
201000
55700 
ROLE OF IL-12, IL-23 AND 
IL-17 RECEPTORS IN 
INFLAMMATORY BOWEL 
DISEASE  
 CEDARS-SINAI 
MEDICAL CENTER 
Los Angeles 
CA 
** Diagnosing or predicting susceptibility 
or protection against IBD in an 
individual by determining the presence 
or absence of genetic variants in the 
genes for IL-12, IL-23, and/or IL-17 
receptors. 
Sample Human gene 
and/or 
polypeptide 
201000
21917 
METHODS OF USING 
GENES AND GENETIC 
VARIANTS TO PREDICT 
OR DIAGNOSE 
INFLAMMATORY BOWEL 
DISEASE  
 CEDARS-SINAI 
MEDICAL CENTER 
Los Angeles 
CA 
** Diagnosing or predicting susceptibility 
to IBD by determining the presence or 
absence of genetic variants. 
Sample Human gene 
and/or 
polypeptide 
200902
33306 
Biomarkers for inflammatory 
bowel disease and Irritable 
Bowel Syndrome 
 EXAGEN 
DIAGNOSTICS, INC. 
Albuquerque 
NM 
** Diagnosing or distinguishing IBD and 
irritable bowel syndrome by expression 
levels of certain genes. 
Blood Human gene 
and/or 
polypeptide 
200902
33305 
Biomarkers for inflammatory 
bowel disease and Irritable 
Bowel Syndrome 
 EXAGEN 
DIAGNOSTICS, INC. 
Albuquerque 
NM 
** Diagnosing or distinguishing IBD and 
irritable bowel syndrome by expression 
levels of certain genes 
Blood Human gene 
and/or 
polypeptide 
200902
33304 
Biomarkers for inflammatory 
bowel disease and Irritable 
Bowel Syndrome 
 EXAGEN 
DIAGNOSTICS, INC. 
Albuquerque 
NM 
** Diagnosing or distinguishing IBD and 
irritable bowel syndrome by expression 
levels of certain genes 
Blood Human gene 
and/or 
polypeptide 
200901
55788 
GENE EXPRESSION 
MARKERS FOR 
INFLAMMATORY BOWEL 
DISEASE  
 -  ** Detecting the presence of IBD in 
gastrointestinal tissues or cells by 
gene expression  
Tissue 
biopsy 
Human gene 
and/or 
polypeptide 
200901
11102 
METHODS FOR 
DETECTING 
INFLAMMATORY BOWEL 
DISEASE  
Genentech, Inc. 
South San Francisco 
CA 
** Detecting the presence of IBD in 
gastrointestinal tissues or cells of a 
mammal by detecting increased 
expression of LY6 genes, relative to a 
control. 
Tissue or 
cells 
Human gene 
and/or 
polypeptide 
200900
81658 
GENEMAP OF THE 
HUMAN GENES 
ASSOCIATED WITH 
CROHN'S DISEASE 
 -  ** Pharmacogenomics, diagnostics, 
patient therapy and the use of genetic 
haplotype information to predict an 
individual's susceptibility to CD or their 
response to a particular drugs, so that 
drugs tailored to genetic differences of 
population groups may be developed 
and administered to the appropriate 
population. 
Sample Human gene 
and/or 
polypeptide 
200900
54253 
Markers and Methods for 
Assessing and Treating 
Ulcerative Colitis and 
Related Disorders Using 66 
Gene Panel 
 ** A method for prognostic or diagnostic 
assessment of a gastrointestinal-
related disorder, such as UC, in a 
subject correlates the presence, 
absence, and/or magnitude of a gene 
in a sample with a reference standard 
to determine the presence or severity 
of the disorder, and the response to 
treatment for the disorder. 
Colon 
biopsy, blood 
Human gene 
and/or 
polypeptide 
  
PUB. 
APP. 
NO. 
Title Assignee 
 
Description Specimen Type of 
marker 
200802
93582 
Markers and Methods for 
Assessing and Treating 
Ulcerative Colitis and 
Related Disorders Using a 
43 Gene Panel 
 -  ** A method for prognostic or diagnostic 
assessment of a gastrointestinal-
related disorder, such as UC, in a 
subject correlates the presence, 
absence, and/or magnitude of a gene 
in a sample with a reference standard 
to determine the presence and/or 
severity of the disorder, and/or the 
response to treatment for the disorder. 
Colon 
biopsy, blood 
Human gene 
and/or 
polypeptide 
200700
42364 
Target genes for 
inflammatory bowel disease 
 - ** The invention pertains to a method to 
identify patients susceptible to IBD by 
testing for single nucleotide 
polymorphisms (SNPs) in two genes, 
FLJ21425 and CSF1R, which were 
shown to be susceptibility genes for 
IBD, especially CD. 
Biological 
sample 
Human gene 
and/or 
polypeptide 
200602
05022 
Method for diagnosing and 
prognosing inflammatory 
bowel disease and crohn's 
disease 
 -  ** Diagnosing and prognosing IBD or CD 
by measuring levels of antibodies to 
glycans in a biological sample. 
Sample Human gene 
and/or 
polypeptide 
and 
antibodies 
201000
15156 
DIAGNOSIS OF 
INFLAMMATORY BOWEL 
DISEASE  IN CHILDREN 
 CEDARS-SINAI 
MEDICAL CENTER 
Los Angeles 
CA 
** Diagnosing and predicting disease 
progression of CD by determining the 
presence or absence of CARD15 
variants and serological markers. 
Biological 
sample 
Human gene 
and/or 
polypeptide, 
antibodies. 
Bacterial 
protein 
201001
29386 
Composotions And Methods 
For The Identification And 
Treatment Of Immune-
Mediated Inflammatory 
Diseases 
 -  ** Therapy and diagnosis of IBD by 
bacterial polypeptides, immunogenic 
portions thereof, polynucleotides that 
encode such polypeptides, antigen 
presenting cell that expresses such 
polypeptides, and T cells that are 
specific for cells expressing such 
polypeptides 
Biological 
sample 
Human gene 
and/or 
polypeptide, 
cells 
201001
44903 
METHODS OF DIAGNOSIS 
AND TREATMENT OF 
CROHN'S DISEASE 
 CEDARS-SINAI 
MEDICAL CENTER 
Los Angeles 
CA 
** Diagnosing and/or predicting 
susceptibility to CD by determining the 
presence or absence of risk 
haplotypes in IL23R, IL17A, IL17RA 
and/or IL12RB1 locus. In another 
embodiment, the invention provides 
methods of diagnosing and/or 
predicting susceptibility to CD in an 
individual by determining the presence 
or absence of risk haplotype at the 
IL12RB2 locus. 
Biological 
sample 
Human gene 
and/or 
polypeptides 
200700
20660 
Expression profiles of 
peripheral blood 
mononuclear cells for 
inflammatory bowel 
diseases 
 -  ** The identification of PBMC- and IBD-
associated biomarkers that may be 
used to diagnose IBD, and optionally, 
distinguish between PBMCs isolated 
from a patient with CD and PBMCs 
isolated from a patient with UC. 
Blood Human gene 
and/or 
polypeptide, 
antibodies 
and proteins 
200902
53155 
Method For Diagnosing 
Irritable Bowel Syndrome 
and Monitoring 
inflammatory bowel disease 
 TECHLAB, INC. 
BLACKSBURG 
VA 
** Differentiating irritable bowel syndrome 
from IBD by determining the level of 
total endogenous human lactoferrin in 
clinical specimens 
Fecal sample Human 
protein 
201001
83521 
METHODS OF 
DETECTING AND 
TREATING COLON 
DISORDERS 
 UNIVERSITY OF 
SOUTH FLORIDA 
Tampa 
FL 
** Determining whether 
Lipopolysaccharide Responsive Beige-
like Anchor (LRBA) is underexpressed 
in the peripheral blood mononuclear 
cells (PBMCs), wherein LRBA 
underexpression is indicative of the 
colon disorder. 
Blood Human 
protein 
200901
76244 
METHODS AND 
COMPOSITIONS FOR THE 
DIAGNOSIS OF CROHN'S 
DISEASE 
 - ** Diagnose, monitor, or determine the 
efficacy of treatment for CD. The 
methods involve determining the 
presence, absence, or level of zonulin 
in a subject sample. 
Blood Human 
protein 
  
PUB. 
APP. 
NO. 
Title Assignee 
 
Description Specimen Type of 
marker 
200901
30775 
METHOD FOR CLINICAL 
STAGING OF 
ULCERATIVE COLITIS OR 
INTERSTITIAL 
PNEUMONIA AND 
REAGENT KIT FOR THE 
SAME 
 OKAYASU; Isao 
Sagamihara-shi 
JP 
HAYASHI; Yuzo 
Sagamihara-shi 
JP 
Mutsunori FUJIWARA 
Minato-ku 
JP 
FUJIREBIO INC. 
Chuo-ku 
JP 
** Measurement of the value of main 
metabolites of prostaglandin E (PGE-
MUM) concentration in urine to 
separate the pre-remission phase from 
the remission phase of UC. 
Urine Metabolite 
200502
60155 
 Compositions and methods 
for treatment of ulcerative 
colitis  
 - ** The identification of TCP-1 gamma as 
a protein whose expression is 
decreased in patients with UC and CD. 
The protein interacts with hTM5, which 
is involved in the pathogenesis of UC.  
Blood Human 
protein 
201002
03042 
RECOMBINANT ANTI-
VLA4 ANTIBODY 
MOLECULES 
 BIOGEN IDEC MA 
INC. 
Cambridge 
MA 
* Humanized recombinant anti-VLA-4 
antibodies disclosed can be useful in 
methods of diagnosing and localizing 
sites of inflammation. 
Sample Antibody 
200702
98447 
Method for diagnosing 
immunologic food sensitivity 
 -  * A method for diagnosing an 
immunologic food sensitivity 
comprising the steps of: collecting a 
fecal sample; screening the fecal 
sample to detect the presence of an 
antibody to a particular food 
substance; and diagnosing an 
immunologic food sensitivity based on 
the presence of the antibody. 
Fecal sample Antibody 
200901
23478 
Human antibody molecules 
for IL-13 
 -  * Diagnosis or treatment of IL-13 related 
disorders 
Sample Antibody 
200802
67959 
Anti-Il13 Human Antibodies Novartis AG * Methods for using anti-IL-13 antibody 
molecules in diagnosis or treatment of 
IL-13 related disorders, such as 
asthma, atopic dermatitis, allergic 
rhinitis, fibrosis, IBD and Hodgkin's 
lymphoma. 
Sample Antibody 
200702
31266 
Diagnosis of macrophage 
mediated disease 
 -  * Treating or monitoring/diagnosing a 
disease state mediated by activated 
macrophages in a myriad of different 
diseases 
Biological 
sample 
Cell 
201000
61987 
High Affinity Antibodies 
Against HMGB1 and 
Methods Of Use Thereof 
 MedImmune, LLC 
Gaithersburg 
MD 
* Inhibiting the release of a 
proinflammatory cytokine from a 
vertebrate cell, and for inhibiting an 
inflammatory cytokine cascade in a 
patient. Also suitable as diagnostic 
antibodies. 
Biological 
sample 
Antibodies 
200901
69546 
HIGH AFFINITY 
ANTIBODIES AGAINST 
HMGB1 AND METHODS 
OF USE THEREOF 
 MedImmune, LLC 
Gaithersburg 
MD 
* Inhibiting the release of a 
proinflammatory cytokine from a 
vertebrate cell, and for inhibiting an 
inflammatory cytokine cascade in a 
patient. Also suitable as diagnostic 
antibodies. 
Biological 
sample 
Antibodies 
200600
99207 
High affinity antibodies 
against HMGB1 and 
methods of use thereof 
 MedImmune, LLC 
Gaithersburg 
MD 
* Inhibiting the release of a 
proinflammatory cytokine from a 
vertebrate cell, and for inhibiting an 
inflammatory cytokine cascade in a 
patient. Also suitable as diagnostic 
antibodies. 
Biological 
sample 
Antibodies 
200901
42806 
INTERLEUKIN-17F 
ANTIBODIES AND OTHER 
IL-17F SIGNALING 
ANTAGONISTS AND USES 
THEREFOR 
 WYETH 
MADISON 
NJ 
* Diagnosing, prognosing, monitoring 
the progress of, and treating and/or 
preventing disorders related to IL-17F 
signaling. 
Sample Cytokines 
200802
41130 
METHODS AND 
COMPOSITIONS FOR 
MODULATING IL-17F/IL-
17A BIOLOGICAL 
ACTIVITY 
 - * The invention is also directed to novel 
methods for diagnosing, prognosing, 
monitoring, preventing, and/or treating 
IL-17F/IL-17A-associated disorders 
Sample Cytokines 
  
PUB. 
APP. 
NO. 
Title Assignee 
 
Description Specimen Type of 
marker 
200802
33134 
Antibodies That Specifically 
Bind to Chemokine Beta-4 
HUMAN GENOME 
SCIENCES, INC. 
Rockville 
MD 
* Antibodies and related molecules that 
specifically bind to chemokine beta-4. 
Such antibodies have uses, for 
example, in wound healing and in the 
diagnosis, prevention, and treatment 
of a number of diseases including IBD. 
The invention also relates to nucleic 
acid molecules encoding anti-
chemokine beta-4 antibodies, vectors 
and host cells containing these nucleic 
acids, and methods for producing the 
same. 
Serum Antibodies 
201002
09507 
METHODS OF 
DIAGNOSING AND 
TREATING SMALL 
INTESTINAL BACTERIAL 
OVERGROWTH (SIBO) 
AND SIBO-RELATED 
CONDITIONS 
 CEDARS-SINAI 
MEDICAL CENTER 
Los Angeles 
CA 
* A method of detecting small intestinal 
bacterial overgrowth (SIBO) in a 
human subject, comprising:detecting 
the relative amounts of methane, 
hydrogen, and at least one sulfur-
containing gas in a gas mixture 
exhaled by said human subject, after 
said human subject has ingested a 
controlled quantity of a substrate, said 
gas mixture being at least partially 
produced by the intestinal microflora of 
said human subject. 
Gas mixture 
exhaled by a 
human, 
serum 
Gas  
200601
47496 
Methods of diagnosing 
small intestinal bacterial 
overgrowth (SIBO) and 
SIBO-related conditions 
 Cedars-Sinai Medical 
Center 
Los Angeles 
CA 
* A method of detecting small intestinal 
bacterial overgrowth (SIBO) in a 
human subject, comprising:detecting 
the relative amounts of methane, 
hydrogen, and at least one sulfur-
containing gas in a gas mixture 
exhaled by said human subject, after 
said human subject has ingested a 
controlled quantity of a substrate, said 
gas mixture being at least partially 
produced by the intestinal microflora of 
said human subject. 
Gas mixture 
exhaled by a 
human, 
serum 
Gas  
200602
51659 
Method for screening 
molecules that restore 
NOD1 activity in cells 
containing an NOD2 
mutation that reduces or 
eliminates NOD1 activity 
 -  * A method for identifying a molecules 
which modulates the activity of Nod 
pattern recognition molecules 
Cell Human gene 
and/or 
polypeptide 
200602
29272 
Human G-protein coupled 
receptor, HGPRBMY11, 
and variants thereof 
 -  * The invention relates to diagnostic and 
therapeutic methods for applying novel 
HGPRBMY11, HGPRBMY11v1, 
and/or HGPRBMY11v2 polypeptides in 
various diseases including CD 
Biological 
sample 
Human gene 
and/or 
polypeptide 
200601
05381 
Polymorphisms of the 
OCTN1 cation transporters 
associated with 
inflammatory bowel 
disorders 
 - * Method for diagnosing IBD, using 
genetic markers that are implicated in 
severe, early-onset CD. 
Biological 
sample, 
tissue 
Human gene 
and/or 
polypeptide 
200901
37783 
CNGH0010 Specific 
Polynucleotides, 
Polypeptides, Antibodies, 
Compositions, Methods and 
Uses 
 -  * Novel polypeptides (CNGH0010), 
antibodies and polynucleotides for 
therapeutic and diagnostic purposes in 
among other IBD 
Biological 
sample 
Human gene 
and/or 
polypeptide 
and 
antibodies 
201001
67285 
METHODS AND AGENTS 
FOR EVALUATING 
INFLAMMATORY BOWEL 
DISEASE,  AND TARGETS 
FOR TREATMENT 
 -  * Diagnostic and therapeutic agents for 
IBD including methods, 
polynucleotides, polypeptides, and 
antibodies relating to variants of, and 
polymorphisms in, the nel-like 1 
precursor (NELL1), as well as the 
5p13.1 locus, and other genes 
associated with IBD. 
Biological 
sample 
Human gene 
and/or 
polypeptides 
201001
30526 
Methods for Disease 
Therapy 
 - * A method of identifying a phenotype-
linked variant genomic sequence in an 
individual to be used for various 
diagnostic, prognostic, and/or 
therapeutic applications. 
Biological 
sample 
Human gene 
and/or 
polypeptides 
  
PUB. 
APP. 
NO. 
Title Assignee 
 
Description Specimen Type of 
marker 
201000
93552 
USE AND 
IDENTIFICATION OF 
BIOMARKERS FOR 
GASTROINTESTINAL 
DISEASES 
 * Identification of biomarkers for 
gastrointestinal diseases and provides 
methods utilizing the biomarkers for in 
drug discovery, monitoring of 
treatment efficacy, and diagnostics.  
Mucosal 
tissue 
Human gene 
and/or 
polypeptides 
200800
44422 
CNGH0010 Specific 
Polynucleotides, 
Polypeptides, Antibodies, 
Compositions, Methods and 
Uses 
 -  * Novel polypeptides (CNGH0010), 
antibodies and polynucleotides for 
therapeutic and diagnostic purposes in 
among other IBD. 
Biological 
sample 
Human gene 
and/or 
polypeptides 
201001
36574 
METHOD FOR 
DETECTING A CHRONIC 
INFLAMMATORY-
ASSOCIATED DISEASE 
 -  * Early detection marker for chronic or 
acute inflammatory-associated 
diseases 
Fluid sample; 
serum, 
plasma, or 
cerebrospinal 
fluid. 
Human 
protein 
200701
66768 
Method for predicting sepsis 
or an acute infectious 
inflammatory response 
 -  * Methods for detecting chronic and 
acute inflammatory-associated 
diseases by detecting CAP37 proteins 
in a body fluid. 
Fluid sample 
comprising 
serum, 
plasma, or 
cerebrospinal 
fluid 
Human 
Protein 
200802
60640 
Use of Precursors Of 
Tachykinins and/or Their 
Fragments in Medical 
Diagnostic 
 SPHINGOTEC 
GMBH 
Borgsdorf 
DE 
* The use of protachykinin and/or 
fragments thereof that can be isolated 
from body fluids, tissues or other 
biological samples and used as a 
marker peptide for medical diagnosis 
of diseases/disorders. 
Body fluids, 
tissues 
and/or other 
biomaterials 
Polypeptides 
antibody 
200901
86022 
Organic Compounds Novartis AG */- Methods for using anti-hTSLP 
antibody molecules in diagnosis or 
treatment of hTSLP related disorders 
 Antibody 
200902
80055 
Use of Fluorine-Containing 
Compounds for Diagnostic 
Purposes Using Imaging 
Methods 
Heinrich-Heine 
Universitat Dusseldorf 
Dusseldorf 
DE 
*/- Administering a fluorine-containing 
compound to a subject and imaging 
the compound for the detection of an 
inflammatory process 
 Imaging 
201001
84728 
MATERIALS AND 
METHODS FOR 
TREATMENT AND 
DIAGNOSIS OF 
DISORDERS 
ASSOCIATED WITH 
OXIDATIVE STRESS 
 THERAPEUTIC 
RESEARCH LLC 
Memphis 
TN 
 -     
201001
05044 
ILEAL POUCH-ANAL 
ANASTOMOSIS (IPAA) 
FACTORS IN THE 
TREATMENT OF 
INFLAMMATORY BOWEL 
DISEASE  
 CEDARS-SINAI 
MEDICAL CENTER 
Los Angeles 
CA 
 -     
200900
54380 
Methods for diagnosing and 
treating a mycobacterium 
avium subspecies 
paratuberculosis infection 
 -  -     
200900
12048 
Methods for diagnosing and 
treating a mycobacterium 
avium subspecies 
paratuberculosis infection 
 -  -     
200803
11122 
Antagonists of Hmgb1 
and/or Rage and Methods 
of Use Thereof 
Medimmune, LLC 
Gaithersburg 
MD 
 -     
200802
88227 
Algorithms to predict clinical 
response, adherence, and 
shunting with thiopuriness 
UNIVERSITY OF 
MICHIGAN, Ann 
Arbor MI 
 -     
200700
32426 
Therapeutic and diagnostic 
methods for ulcerative 
colitis and associated 
disorders 
 -   -     
  
PUB. 
APP. 
NO. 
Title Assignee 
 
Description Specimen Type of 
marker 
201002
22303 
REVERSE-TURN 
MIMETICS AND METHOD 
RELATING THERETO 
 Choongwae Pharma 
Corporation 
Seoul 
KR 
 -    
201001
20758 
REVERSE-TURN 
MIMETICS AND METHOD 
RELATING THERETO 
Choongwae Pharma 
Corporation 
Seoul 
KR 
 -    
201000
81655 
REVERSE-TURN 
MIMETICS AND METHOD 
RELATING THERETO 
Choongwae Pharma 
Corporation 
Seoul 
KR 
 -    
201000
29630 
REVERSE-TURN 
MIMETICS AND METHOD 
RELATING THERETO 
 Chongwae Pharma 
Corporation 
Seoul 
KR 
 -    
200903
25994 
METHODS OF TREATING 
DIARRHEA CAUSED BY 
SMALL INTESTINAL 
BACTERIAL 
OVERGROWTH 
 CEDARS-SINAI 
MEDICAL CENTER 
Los Angeles 
CA 
 -    
200902
91884 
Proteins for use in 
diagnosing and treating 
infection and disease 
 -   -    
200801
38396 
Treatment and diagnosis of 
macrophage mediated 
disease 
 -   -    
200800
14184 
METHODS OF TREATING 
FIBROMYALGIA CAUSED 
BY SMALL INTESTINAL 
BACTERIAL 
OVERGROWTH 
 CEDARS-SINAI 
MEDICAL CENTER 
Los Angeles 
CA 
 -    
200702
48598 
Recombinant anti-VLA4 
antibody molecules 
Biogen Idec MA Inc. 
Cambridge 
MA 
 -    
200700
43052 
Reverse-turn mimetics and 
method relating thereto 
 Choongwae Pharma 
Corporation 
Seoul 
KR 
 -    
200600
84655 
Reverse-turn mimetics and 
method relating thereto 
 Choongwae Pharma 
Corporation 
Seoul 
KR 
 -    
200600
29550 
Methods of treating irritable 
bowel syndrome and other 
disorders caused by small 
intestinal bacterial 
overgrowth 
 CEDARS-SINAI 
MEDICAL CENTER 
Los Angeles 
CA 
 -    
200502
72123 
Novel human G-protein 
coupled receptor 
 Solvay 
Pharmaceuticals B.V. 
CP Weesp 
NL 
 -    
200502
72122 
Novel human G-protein 
coupled receptor 
Solvay 
Pharmaceuticals B.V. 
CP Weesp 
NL 
 -    
200502
66529 
Novel human G-protein 
coupled receptor  
 Solvay 
Pharmaceuticals B.V. 
Weesp 
NL 
 -    
201001
66789 
PROTEINS FOR USE IN 
DIAGNOSING AND 
TREATING INFECTION 
AND DISEASE 
 The Regents of the 
University of Colorado 
Denver 
CO 
-    
200902
53645 
METHODS AND 
MATERIALS FOR 
TREATING AND 
PREVENTING 
INFLAMMATION OF 
 - -    
  
PUB. 
APP. 
NO. 
Title Assignee 
 
Description Specimen Type of 
marker 
MUCOSAL TISSUE 
200802
06251 
Methods and Compositions 
to Treat and Detect 
Misfolded-SOD1 Mediated 
Diseases 
 - -    
200800
14185 
METHODS OF TREATING 
DIARRHEA AND 
BLOATING CAUSED BY 
SMALL INTESTINAL 
BACTERIAL 
OVERGROWTH 
 CEDARS-SINAI 
MEDICAL CENTER 
8700 Beverly 
Boulevard 
Los Angeles 
CA 
90048 
-    
Relevance: -less interesting, *relevant, **interesting, ***very interesting 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Appendix G Patent documents found in the European patent 
database Espacenet 
 
Publica
tion 
number Title Applicant(s)  Description 
Type of 
specimen 
used 
Type of 
marker 
 
EP1955
070 
(A2) 
METHODS OF 
DIAGNOSING 
INFLAMMATORY BOWEL 
DISEASE 
PROMETHEUS LAB 
INC [US] ** 
Diagnosing the presence or severity of 
IBD and for stratifying IBD in an 
individual by determining the level of 
one or more IBD markers in a sample 
from the individual and calculating an 
index value using an algorithm based 
upon the level of the IBD markers. Serum Antibody 
 
EP1554
580 
(A2) 
INFLAMMATORY BOWEL 
DISEASE AND IRRITABLE 
BOWEL SYNDROME IBD-
FIRST CHEK DIAGNOSTIC 
PANEL TECHLAB INC [US] ** 
A method for differentiation of IBS from 
IBD followed by distinguishing UC from 
CD by testing  lactoferrin  anti- 
Saccharomyces cerevisiae antibodies 
(ASCA) and anti-neutrophil 
cytoplasmic antibodies (ANCA) in fecal 
samples Feces 
Antibody, 
human 
protein 
 
EP1819
827 
(A2) 
METHODS FOR 
DIAGNOSIS OF CROHN'S 
DISEASE 
CEDARS SINAI 
MEDICAL CENTER 
[US] ** 
Diagnosis of CD by determining the 
presence of the anti-CBir1 expression 
or presence and detection of the 
pANCA. Sample Antibody 
 
EP1539
791 
(A2) 
METHOD FOR 
DISTINGUISHING 
ULCERATIVE COLITIS 
FROM CROHN S DI 
SEASE BY DETECTING 
THE PRESENCE OF 
FECAL ANTI-NEUTROPHIL 
CYTOPLASMIC 
ANTIBODIES (ANCA) TECHLAB INC [US] ** 
Differentiation of ulcerative colitis from 
Crohn's disease and other 
gastrointestinal illnesses using the 
presence of anti-neutrophil 
cytoplasmic antibodies (ANCA) as a 
marker of ulcerative colitis 
Feces, whole 
blood, 
serum, 
plasma, 
human bodily 
fluid and 
human 
tissue. Antibody 
 
EP1780
215 
(A1) 
CROHN'S DISEASE 
ANTIBODY EPITOPE 
PEPTIDE AND REAGENT 
FOR TESTING CROHN'S 
DISEASE 
TOAGOSEI CO LTD 
[JP];  UNIV KURUME 
[JP] ** 
A peptide characteristic of an epitope 
to a Crohn's disease antibody. Blood 
Antibody 
human 
peptide 
 
EP2034
305 
(A1) 
METHOD FOR 
DETERMINATION OF 
INFLAMMATORY BOWEL 
DISEASE UNIV OSAKA [JP] ** 
A method for the differential diagnosis 
of inflammatory bowel disease by 
determining the relative ratio of G0 
oligosaccharide to G2 oligosaccharide 
in a serum IgG oligosaccharide 
fraction. 
Periferal 
blood Glycan 
 
EP2224
012 
(A1) 
Compositions and methods 
for the therapy and 
diagnosis of inflammatory 
bowel disease CORIXA CORP [US] ** 
Diagnosis, prevention and/or treatment 
of IBD. Comprising one or more 
bacterial polypeptides, immunogenic 
portions, polynucleotides that encode 
such polypeptides, antigen presenting 
cell expressing such polypeptides.  
Biological 
sample 
Bacterial 
gene and/or 
polypeptide 
 
EP1642
135 
(A1) 
METHOD FOR 
DIAGNOSING 
INFLAMMATORY BOWEL 
DISEASE 
ASTRAZENECA AB 
[SE] ** 
A method for the diagnosis of IBD or 
determining susceptibility to develop 
IBD, by detecting variant DLG5.  Sample 
Human gene 
and/or 
polypeptide 
 
EP1534
855 
(A1) 
METHOD AND KIT FOR 
THE DIAGNOSIS OF 
ULCERATIVE COLITIS 
INDEX 
PHARMACEUTICALS 
AB [SE] ** 
Differentiation between ulcerative 
colitis and Crohn's disease by a multi-
gene approach where gene 
expression profiles in biopsy samples 
obtained from inflamed, and optionally 
also non-inflamed, areas in the 
intestines of a patient are studied. Biopsy 
Human gene 
and/or 
polypeptide 
 
EP2132
342 
(A1) 
A METHOD FOR 
DETERMINING THE 
GENOTYPE AT THE 
CROHN'S DISEASE 
LOCUS 
UNIV LIEGE [BE];  
CT HOSPITALIER 
UNIVERSITAIRE D 
[BE];  
COMMISSARIAT 
ENERGIE 
ATOMIQUE [FR] ** 
A method for determining the 
genotype of a human individual at the 
5p13.1 CD risk locus, Sample 
Human gene 
and/or 
polypeptide 
 
  
Publica
tion 
number Title Applicant(s)  Description 
Type of 
specimen 
used 
Type of 
marker 
 
EP2071
332 
(A1) 
Method for monitoring 
persons with IBD using total 
endogeneous lactoferrin as 
a marker TECHLAB INC [US] ** 
Monitioring IBD by meassuring 
lactoferrin in two fecal samples 
obtained at two different times Feces 
Human 
protein 
 
EP2050
761 
(A1) 
Galactosylated peptides, 
their preparation and use in 
autoimmune diseases 
diagnosis 
TOSCANA 
BIOMARKERS S R L 
[IT] * 
The invention refers to galactosylated 
peptides formed of 11-21 amino acids 
capable of identifying autoantibodies in 
several autoimmune diseases 
Sample, 
serum Antibody 
 
EP1811
303 
(A2) 
Methods of diagnosing and 
treating irritable bowel 
syndrome and other 
disorders 
CEDARS SINAI 
MEDICAL CENTER 
[US] * 
Detecting the presence of small 
intestinal bacterial overgrowth (SIBO) 
by measuring exhaled gas mixture 
after ingesting a controlled quantity of 
a labeled substrate 
Exhaled gas, 
cellular, fluid, 
fecal, or 
gaseous 
matter  Gas 
 
EP2140
021 
(A2) 
METHODS FOR 
DETECTING 
INFLAMMATORY BOWEL 
DISEASE 
GENENTECH INC 
[US] * 
Method of detecting the presence of 
inflammatory bowel disease in 
gastrointestinal tissues or cells of a 
mammal by detecting increased 
expression of LY6 genes in the tissues 
or cells relative to a control. 
Tissue or 
cells 
Human gene 
and/or 
polypeptide 
 
EP1557
428 
(A1) 
Antibodies against a human 
stromal derived factor (SDF) 
and pharmaceutical 
composition containing 
them 
ONO 
PHARMACEUTICAL 
CO [JP] * 
Novel polypeptides produced by 
hematopoietic cells and DNAs 
encoding them for the treatment and 
diagnosis of among other UC - 
Human gene 
and/or 
polypeptide 
 
EP2185
936 
(A2) 
DIAGNOSIS, STAGING 
AND MONITORING OF 
INFLAMMATORY BOWEL 
DISEASE 
ISS IMMUNE 
SYSTEM 
STIMULATION [SE] * 
A method of differentiating between 
active and inactive IBD in a patient 
and methods of determining the 
presence of CD and UC in a patient 
using inflammation markers in biopsies Biopsy 
Human gene 
and/or 
polypeptide, 
protein, 
cytokine and 
antibody 
 
EP1870
708 
(A1) 
METHOD FOR CLINICAL 
STAGING OF 
ULCERATIVE COLITIS OR 
INTERSTITIAL 
PNEUMONIA AND 
REAGENT KIT FOR THE 
SAME 
FUJIREBIO KK [JP];  
FUJIWARA 
MUTSUNORI [JP];  
OKAYASU ISAO [JP];  
HAYASHI YUZO [JP] * 
A method that measures the value of 
main metabolites of prostaglandin E 
(PGE-MUM) concentration in urine and 
judges stages between the pre-
remission phase of and the remission 
phase of ulcerative colitis Sample Metabolite 
 
EP1653
231 (A1
) 
MEASURING APPARATUS 
FOR ULCERATIVE 
COLITIS 
DIAGNOSIS/PROGNOSTIC 
TEST AND METHOD OF 
MEASURING  
MATSUSHITA 
ELECTRIC IND CO 
LTD (JP)  
TOKYO UNIVERSITY 
OF PHARMACY A 
(JP)  * 
A measurement apparatus for 
ulcerative colitis diagnosis and 
prognostic test Sample Other 
 
EP1950
222 
(A1) 
Method for detecting 
antibodies in body fluids via 
an immune reaction with 
glycoprotein 2 (GP2) from 
zymogen granula of the 
pancreas for a differential 
diagnosis of inflammatory 
bowel diseases and chronic 
pancreatitis 
GA GENERIC 
ASSAYS GMBH [DE] §    
 
EP1800
134 
(A2) 
METHOD FOR 
DIAGNOSING AND 
TREATING CROHN'S 
DISEASE 
UNIV D AUVERGNE 
CLERMONT 1 [FR] § 
Diagnosing or determining 
predisposition Crohn's disease, by 
detecting an overexpression of the 
CD66c receptor    
 
Relevance: -less interesting, *relevant, **interesting, ***very interesting, § not read, patent document written in foreign language 
 
 
 
  
Appendix H Patents found in the USPTO issued patent database 
PAT. 
NO. 
Title Assignee  Description Type of 
specimen 
used 
Type of 
marker 
 
6,320,0
37  
IBD-associated microbial 
nucleic acid molecules  
The Regents of the 
University of 
California (Oakland, 
CA) 
*** The present invention provides nucleic 
acid and amino acid sequence of the 
novel I-1 and I-2 polypeptides, which 
are associated with human IBD. 
Sample Bacterial 
gene and/or 
polypeptide 
 
6,759,5
30 
IBD-associated microbial 
nucleic acid molecules  
The Regents of the 
University of 
California (Oakland, 
CA) 
*** Diagnosing and treating IBD using the 
IBD-associated I-1 and I-2 antigens 
Whole blood, 
plasma, 
saliva, or 
other bodily 
fluid or 
tissue, 
preferably 
serum 
Bacterial 
gene and/or 
polypeptide 
 
7,759,0
79 
Methods of diagnosing 
inflammatory bowel disease  
Prometheus 
Laboratories Inc. (San 
Diego, CA) 
** Diagnosing the presence or severity of 
inflammatory bowel disease. 
Monitoring the efficacy of IBD therapy, 
monitoring the progression or 
regression of IBD, and optimizing 
therapy in an individual having IBD.  
Biological 
sample 
Antibody  
7,662,5
69 
Methods of assessing 
Crohn's disease patient 
phenotype by I2 serologic 
response  
Cedars-Sinai Medical 
Center (Los Angeles, 
CA) 
** Determining the likelihood of being 
susceptible to a fibrostenotic subtype 
of Crohn's disease by determining the 
presence or absence in the subject of 
IgA anti-I2 antibodies, a NOD2 variant, 
anti-Saccharomyces cerevisiae 
antibodies (ASCA), IgA anti-OmpC 
antibodies, or perinuclear anti-
neutrophil cytoplasmic antibodies 
(pANCA) 
Sample Antibody  
7,608,4
14 
Method for diagnosing and 
prognosing inflammatory 
bowel disease and crohn's 
disease  
Glycominds, Ltd (IL) ** Diagnosing and prognosing IBD or CD 
by measuring levels of antibodies to 
glycans in a biological sample 
Serum Antibody  
7,592,1
50 
Method for diagnosing 
diseases based on levels of 
anti-glycan antibodies  
Glycominds, Ltd (IL) ** Methods for diagnosing CD or anti-
phospholipid syndrome by measuring 
levels of antibodies to glycans in a 
biological sample. 
Biological 
fluid 
Antibody  
7,358,0
58 
Method and agents for the 
diagnosis and therapy of 
chronic inflammatory 
intestinal disease  
B.R.A.H.M.S 
Aktiengesellschaft 
(Henningsdorf, DE) 
** Diagnosis, early diagnosis, differential 
diagnosis, assessment of the severity 
and therapy-accompanying monitoring 
and prognosis of chronically 
inflammatory intestinal diseases in 
which the presence and/or the amount 
of one or more antibodies which bind 
to ribosomal proteins, in particular P0 
and L5, are determined in the serum, 
plasma, tissue samples and/or stool. 
Biological 
sample 
Antibody  
7,138,2
37 
Diagnosis, prevention and 
treatment of Crohn's 
disease using the OmpC 
antigen  
Cedars-Sinai Medical 
Center  (Los Angeles, 
CA) 
The Regents of the 
University of 
California (Oakland, 
CA)  
** Determining the presence or absence 
of IgA anti-OmpC antibodies in the 
subject, where the presence of the IgA 
anti-OmpC antibodies indicates that 
the subject has Crohn's disease. 
Sample Antibody  
6,777,1
97 
Method and test kit for 
measuring immunoglobulins 
reactive with amylase as 
indication of crohn's disease  
Wakamoto 
Pharmaceutical Co., 
Ltd. (Tokyo, JP) 
** Detection of the presence of 
immunoglobulins reactive with 
amylase. 
Blood Antibody  
7,700,1
06 
Therapeutic agent for 
ulcerative colitis  
 Sato; Nobuhiro  
(Tokyo, JP) 
Wakamoto 
Pharmaceutical Co., 
Ltd. (Tokyo, JP)  
** Preliminarily determining that the 
probability for developing or having 
ulcerative colitis by detecting 
Fusobacterium varium anitbodies in 
patient sera. 
Sera Antibody  
  
PAT. 
NO. 
Title Assignee  Description Type of 
specimen 
used 
Type of 
marker 
 
7,183,0
65 
Diagnosis, prevention and 
treatment of ulcerative 
colitis, and clinical subtypes 
thereof, using microbial UC 
pANCA antigens  
The Regents of the 
University of 
California (Oakland, 
CA) 
** Microbial UC pANCA antigens and 
methods of diagnosing UC and 
methods of inducing tolerance in a 
pANCA-positive patient with UC using 
a histone H1-like antigen. Methods of 
diagnosing UC and methods of 
inducing tolerance in a pANCA-
positive patient with UC using a 
Bacteroides antigen also are provided. 
Biological 
sample 
Antigen  
7,361,7
33 
Compositions and methods 
for the therapy and 
diagnosis of inflammatory 
bowel disease  
Corixa Corporation 
(Seattle, WA) 
** Compositions and methods for the 
therapy and diagnosis of Inflammatory 
Bowel Disease comprising one or 
more bacterial polypeptides, 
immunogenic portions thereof, 
polynucleotides that encode such 
polypeptides, antigen presenting cell 
that expresses such polypeptides, and 
T cells that are specific for cells 
expressing such polypeptides. 
Biological 
sample 
Bacterial 
gene and/or 
polypeptide 
 
6,805,8
52 
Methods of diagnosing 
irritable bowel syndrome 
and other disorders caused 
by small intestinal bacterial 
overgrowth  
Cedars-Sinai Medical 
Center (Los Angeles, 
CA) 
** A method of diagnosing irritable bowel 
syndrome by detecting the presence of 
small intestinal bacterial overgrowth 
(SIBO) by measuring exhaled gas 
mixture after ingesting a controlled 
quantity of a labeled substrate. 
Intestinal 
sampling, 
cellular, fluid, 
fecal, or 
gaseous 
matter 
Gas  
7,419,7
82 
Methods of using a major 
histocompatibility complex 
class III haplotype to 
diagnose Crohn's disease  
Cedars-Sinai Medical 
Center (Los Angeles, 
CA 
** A method of diagnosing or predicting 
susceptibility to an autoimmune 
disease in an individual by determining 
the presence or absence in the 
individual of a 2-2-4 haplotype at the 
Notch4, HSP70-HOM and D6S273 
loci. 
Blood Human gene 
and/or 
polypeptide 
 
6,858,3
91 
Nod2 nucleic acids and 
proteins  
Regents of the 
University of Michigan 
(Ann Arbor, MI) 
** Methods of identifying individuals at 
increased risk of developing CD by 
Nod2 protein and nucleic acid 
detection. 
Sample Human gene 
and/or 
polypeptide 
 
6,762,0
21 
Method for diagnosis of 
crohn's disease  
Mitsubishi Pharma 
Corporation (Osaka, 
JP) 
** Analyzing the level of gene 
expression.  
Colon tissue 
or ileum 
tissue 
Human gene 
and/or 
polypeptide 
 
6,632,6
17 
Tumor-associated antigen  Incyte Corporation 
(Palo Alto, CA) 
** The invention is based on the 
discovery of a tumor-associated 
antigen (TUAN) which is useful in the 
diagnosis and treatment of 
inflammatory and cell proliferative 
disorders, in particular, Crohn's 
disease and colon cancer. 
Biological 
sample 
Human 
protein 
 
6,590,0
89 
RVP-1 variant differentially 
expressed in Crohn's 
disease  
Incyte Genomics, Inc. 
(Palo Alto, CA) 
** Mammalian cDNA which encodes a 
mammalian RVP-1 variant (MAPOP-1) 
useful in the diagnosis and treatment 
of cell proliferative disorders, 
particularly cancers, and autoimmune 
disorders, particularly Crohn's disease. 
Sample Human gene 
and/or 
polypeptide 
 
7,560,2
40 
Method for monitoring 
gastrointestinal 
inflammation in persons 
with inflammatory bowel 
disease(IBD)  
TechLab, Inc. 
(Blacksburg, VA) 
** A method for aiding in differentiating 
irritable bowel syndrome from 
inflammatory bowel disease by 
determining the level of total 
endogenous human lactoferrin in 
clinical specimens 
Feces, 
mucus and 
bile 
Human 
protein 
 
7,192,7
24 
Method for differentiating 
irritable bowel syndrome 
from inflammatory bowel 
disease (IBD) and for 
monitoring persons with IBD 
using total endogenous 
lactoferrin as a marker  
Techlab, Inc. 
(Blacksburg, VA) 
** Method for quantitating the level of 
total endogenous human lactoferrin in 
clinical specimens, such as feces, 
mucus and bile, to monitor 
gastrointestinal inflammation in 
persons having inflammatory bowel 
disease. 
Feces  Human 
protein   
 
6,627,4
58 
Nuclear envelope protein 
recognized by atypical p-
ANCA in patients with 
inflammatory bowel disease 
and autoimmune liver 
diseases  
The Trustees of 
Columbia University 
in the City of New 
York (New York, NY) 
** A method for determining nuclear 
envelope protein of neutrophils and 
myeloid cells capable of binding of a 
typical p-antineutrophil cytoplasmic 
antibodies (p-ANCA) 
Body fluid, 
serum 
Human 
protein and 
cells 
 
  
PAT. 
NO. 
Title Assignee  Description Type of 
specimen 
used 
Type of 
marker 
 
7,375,1
92 
Antibodies that specifically 
bind to chemokine beta-4  
Human Genome 
Sciences, Inc. 
(Rockville, MD) 
* The present invention relates to 
antibodies and related molecules that 
specifically bind to CK-B4. Such 
antibodies have uses, for example, in 
the prevention and treatment of cancer 
as well as immune system diseases 
Biological 
sample 
Antibody  
7,557,1
94 
Antibody materials for an 
IBD-associated polypeptide  
The Regents of the 
University of 
California (Oakland, 
CA 
* Nucleic acid and amino acid sequence 
of I-1 and I-2 polypeptides, which are 
associated with humanIBD. Methods 
of diagnosing and treating IBD using 
the IBD-associated I-1 and I-2 
antigens 
Sample Bacterial 
gene and/or 
polypeptide 
 
7,531,3
10 
Methods of diagnosing 
Crohn's disease by 
measuring expression level 
of RNA encoding human G-
protein coupled receptor, 
HGPRBMY11  
Bristol-Myers Squibb 
Company (Princeton, 
NJ) 
* Methods of diagnosing Crohn's 
disease by measuring expression level 
of RNA encoding human G-protein 
coupled receptor, HGPRBMY11  
Colon test 
sample 
Human gene 
and/or 
polypeptide 
 
7,479,4
79 
CNGH0010 specific 
polynucleotides, 
polypeptides, antibodies, 
compositions, methods and 
uses  
Centocor, Inc. 
(Malvern, PA) 
* Polypeptides (CNGH0010) useful for 
therapeutic and diagnostic 
formulations, administration and 
devices. 
Sample Human gene 
and/or 
polypeptide 
 
7,326,6
87 
CNGH0010 specific 
polynucleotides, 
polypeptides, antibodies, 
compositions, methods and 
uses  
Centocor, Inc. 
(Malvern, PA) 
* CNGH0010 polypeptides, variants, 
and fragments useful for therapeutic 
and diagnostic formulations. 
Sample Human gene 
and/or 
polypeptide 
 
7,151,1
65 
Antibodies immunospecific 
for a novel human G-protein 
coupled receptor family  
Solvay 
Pharmaceutical B.V. 
(Weesp, NL) 
* Polynucleotides, polypeptides more 
particularly G-protein coupled receptor 
(GPCR) and the use and production of 
them. The invention also relates to 
inhibiting or activating the action of 
such polynucleotides and polypeptides 
and a method for screening 
compounds capable to act as an 
agonist or an antagonist of G-protein 
coupled receptor IGS4, and to the 
cognate ligand of IGS4. 
Sample Human gene 
and/or 
polypeptide 
 
7,049,4
22 
Tumor necrosis related 
receptor, TR7  
SmithKline Beecham 
Corporation 
(Philadelphia, PA) 
* TR7 polypeptides and polynucleotides 
and methods for producing such 
polypeptides and diagnostic assays  
Sample Human gene 
and/or 
polypeptide 
 
7,771,9
32 
Method for identification of 
Tr1 lymphocytes regulators 
by the presence and over-
expression of specific 
molecules and application 
thereof  
TxCell (Nice, FR) * A method for identifying Tr1-regulatory 
lymphocytes present in a biological 
sample comprising lymphocytes. A 
method for in vitro prognosis or 
diagnosis of an autoimmune or 
inflammatory disease. 
Biological 
sample 
comprising 
lymphocytes 
Human gene 
and/or 
polypeptide, 
and protein 
 
7,655,4
80 
Method for predicting sepsis 
or an acute infectious 
inflammatory response  
The Board of Regents 
of the University of 
Oklahoma (Norman, 
OK) 
* Early detection marker for chronic or 
acute inflammatory-associated 
diseases. 
Serum, 
plasma, or 
cerebrospinal 
fluid 
Human 
protein and 
cytokines 
 
6,998,2
55 
Human G-protein coupled 
receptor  
Solvay 
Pharmaceuticals B.V. 
(CP Weesp, NL) 
* The invention relates to  
polynucleotides, polypeptides more 
particularly G-protein coupled receptor 
(GPCR)  and the use and production 
of them. The invention also relates to 
inhibiting or activating the action of 
such polynucleotides and polypeptides 
and a method for screening 
compounds capable to act as an 
agonist or an antagonist of G-protein 
coupled receptor IGS4, and to the 
cognate ligand of IGS4. 
Sample Human gene 
and/or 
polypeptide, 
and protein 
 
6,800,4
46 
Therapeutic and diagnostic 
methods for ulcerative 
colitis and associated 
disorders  
University of Medicine 
& Dentistry of New 
Jersey (New 
Brunswick, NJ) 
* Diagnostic method for detecting 
inflammatory bowel disease and 
ulcerative colitis comprising detecting 
CEP-hTM5 complexes with antibodies 
against CEP and hTM5 in a colonic 
Colonic 
tissue 
Human 
protein 
 
  
PAT. 
NO. 
Title Assignee  Description Type of 
specimen 
used 
Type of 
marker 
 
tissue 
7,736,6
22 
Methods of diagnosing 
small intestinal bacterial 
overgrowth (SIBO) and 
SIBO-related conditions  
Cedars-Sinai Medical 
Center (Los Angeles, 
CA) 
* A human subject ingests a controlled 
quantity of an isotope-labeled sugar, 
and  gas mixture exhaled are detected 
and used for diagnosis purpose. 
Gas mixture 
exhaled by 
an human  
Gas  
6,787,3
03 
Identification of a novel 
retrovirus associated with 
primary sclerosing 
cholangitis and autoimmune 
hepatitis  
Alton Ochsner 
Medical Foundation 
(New Orleans, LA) 
* Detecting the presence or absence of 
a Primary Sclerosing Cholangitis, 
PSC, associated retroviral nucleic acid 
molecule to indicate PSC, 
Autoimmune Hepatitis, Crohn's 
disease, and ulcerative colitis.  
Biological 
sample 
Retroviral 
gene 
 
7,138,2
50 
Method of determining 
thiopurine 
methyltransferase activity  
Prometheus 
Laboratories, Inc. 
(San Diego, CA) 
 * Methods for determining thiopurine 
methyltransferase activity in order to 
individualize dosages of 6-
mercaptopurine therapy. 
Sample Human gene 
and/or 
polypeptide 
 
6,576,4
38  
 Method of determining 
thiopurine 
methyltransferase activity 
Prometheus 
Laboratories, Inc. 
(San Diego, CA) 
 * Determining thiopurine 
methyltransferase (TPMT) activity in a 
subject. 
Sample, a 
preferred 
sample is 
whole blood 
Human 
protein 
 
7,048,9
06 
Methods of diagnosing and 
treating small intestinal 
bacterial overgrowth (SIBO) 
and SIBO-related conditions  
Cedars-Sinai Medical 
Center (Los Angeles, 
CA) 
-     
7,585,5
04 
High affinity antibodies 
against HMGB1 and 
methods of use thereof  
MedImmune, LLC 
(Gaithersburg, MD) 
 -     
7,781,1
69 
Diagnosis of gluten 
sensitive enteropathy and 
other autoimmunopathies  
 -   -     
7,740,8
54 
Treatment of macrophage 
mediated disease  
Purdue Research 
Foundation (West 
Lafayette, IN) 
 -     
7,671,0
54 
Reverse-turn mimetics and 
method relating thereto  
Choongwae Pharma 
Corporation (Seoul, 
KR) 
 -     
7,605,2
40 
Methods of treating diarrhea 
and bloating caused by 
small intestinal bacterial 
overgrowth  
CedaraSinai Medical 
Center (Los Angeles, 
CA) 
 -     
7,585,8
62 
Reverse-turn mimetics and 
method relating thereto  
Choongwae Pharma 
Corporation (Seoul, 
KR) 
 -     
7,585,8
38 
Methods of treating 
fibromyalgia caused by 
small intestinal bacterial 
overgrowth  
Cedars-Sinai Medical 
Center (Los Angeles, 
CA) 
 -     
7,576,0
84 
Reverse-turn mimetics and 
method relating thereto  
Choongwae Pharma 
Corporation (Seoul, 
KR) 
 -     
7,566,7
11 
Reverse-turn mimetics and 
method relating thereto  
Choongwae Pharma 
Corporation (Seoul, 
KR) 
 -     
7,482,0
03 
Treatment for asthma with 
.alpha.4-specific antibodies  
Biogen Idec MA Inc. 
(Cambridge, MA) 
 -     
7,452,8
57 
Methods of treating irritable 
bowel syndrome and other 
disorders caused by small 
intestinal bacterial 
overgrowth  
Cedars-Sinai Medical 
Center (Los Angeles, 
CA) 
 -     
  
PAT. 
NO. 
Title Assignee  Description Type of 
specimen 
used 
Type of 
marker 
 
7,232,8
22 
Reverse-turn mimetics and 
method relating thereto  
Choongwae Pharma 
Corporation (Seoul, 
KR) 
 -     
7,157,0
86 
Treatment for inflammatory 
bowel disease with 
.alpha.4-specific antibodies  
Biogen Idec MA Inc. 
(Cambridge, MA) 
 -     
7,122,3
36 
Therapeutic and diagnostic 
methods for ulcerative 
colitis and associated 
disorders  
University of Medicine 
& Dentistry of New 
Jersey (New 
Brunswick, NJ) 
 -     
7,056,6
86 
Method of diagnosing 
fibromyalgia caused by 
small intestinal bacterial 
overgrowth  
Cedars-Sinai Medical 
Center (Los Angeles, 
CA) 
 -     
6,555,5
66  
Methods and materials for 
treating and preventing 
inflammation of mucosal 
tissue 
Mayo Foundation for 
Medical Education 
and Research 
(Rochester, MN) 
 -     
6,399,5
73  
Interleukin-1 receptor 
antagonist beta (IL-1rabeta) 
SmithKline Beecham 
Corporation 
(Philadelphia, PA) 
 -     
Relevance: -less interesting, *relevant, **interesting, ***very interesting 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
